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Abstract 
Functional motor disorder (FMD) is a common cause of disability and distress 
amongst patients seen by neurologists and physiotherapists. Patients present with 
combinations of weakness, tremor, jerks, dystonia and gait disorder. The long term 
prognosis is poor.  
Historically, psychological explanations for FMD have dominated, correspondingly, 
psychological therapy has been considered the treatment modality of choice, 
although evidence for its effectiveness is limited. A more recent understanding of 
FMD, considers symptoms within a broader biopsychosocial framework. This is 
backed by research into biological mechanisms that suggest FMD is associated with 
abnormalities in motor planning and agency, related to illness beliefs/expectations 
and abnormal self-directed attention. This broader conceptual model of FMD 
provides a rationale for physiotherapy treatment. A systematic review of the 
literature found that, while promising, the evidence for physical rehabilitation is 
limited, with a lack of randomised controlled trials.  
This thesis describes a specific 5-day physiotherapy intervention that is based on a 
mechanistic understanding of how functional motor symptoms are generated. The 
intervention was tested in a randomised feasibility study with an embedded 
longitudinal qualitative study. Sixty patients were randomised to either the 
intervention or treatment as usual control. At six months follow up, feasibility was 
demonstrated by high rates of recruitment, retention and intervention 
acceptability. The intervention was associated with a significant improvement 
across a range of physical and quality of life outcome measures, with a moderate to 
large effect size. A health economic analysis showed evidence of likely cost-benefit. 
Findings from the qualitative study suggest that helping the patient develop a 
biopsychosocial understanding of their problem was an important ingredient of the 
intervention.  
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The findings from these studies add to the growing evidence for specialist 
physiotherapy for FMD and support the need for a multicentre randomised 
controlled trial. 
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Thesis Aims, Objectives and Overview 
The research contained in this thesis aims to build on my previous work developing 
physiotherapy treatment for patients with Functional motor Disorder (FMD). This 
work started in July 2012 when, in collaboration with Professor Mark Edwards, I 
developed a specialist treatment programme for FMD, which was part of an NHS 
clinical service at the National Hospital for Neurology and Neurosurgery. The 
programme was assessed and reported in a cohort study of 47 consecutive 
patients.1 The promising results led to an expansion of the clinical service and my 
successful application for a National Institute for Health Research - Clinical Doctoral 
Research Fellowship, to further develop the physiotherapy treatment and evidence 
for its efficacy.  
Thesis Objectives 
The primary aim of this thesis is to determine the feasibility of testing the 5-day 
Physiotherapy Programme in a randomised controlled trial (RCT).  
The specific objectives of my thesis were: 
1. To describe a standardised physiotherapy treatment protocol for FMD: the 5-
day Physiotherapy Programme. 
2. To assess the feasibility of conducting an RCT of the 5-day Physiotherapy 
Programme. 
3. To assess the usefulness of a range of possible outcome measures to evaluate 
the effectiveness of physiotherapy for FMD and determine a primary outcome 
for a future trial (including the collection of data in order to perform a sample 
size calculation for a future RCT). 
4. To assess the feasibility of completing a formal cost effectiveness analysis as 
part of an RCT. 
5. To assess the acceptability of the intervention to patients. 
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6. To explore the lived experience of being diagnosed with FMD using qualitative 
semi-structured interviews. 
7. To explore how participants interacted with the study intervention using 
qualitative semi-structured interviews. 
14 
 
Thesis Overview 
To meet these objectives, I have completed 3 separate projects, (i) a systematic 
review of the literature for physical rehabilitation for FMD; (ii) a large randomised 
controlled feasibility study; and (iii) a longitudinal qualitative study of patients 
undergoing the physiotherapy intervention. This work is described in the following 
chapters: 
Chapter 1 is an introduction to FMD, covering terminology, epidemiology, diagnosis, 
clinical presentations, prognosis and an overview of treatment. 
Chapter 2 is a brief review of the history of FMD. It is argued that to understand the 
current status of FMD in health care settings, it is necessary to consider the 
historical context. 
Chapter 3 is a systematic review of the literature for physical interventions for FMD. 
Chapter 4 presents the theoretical aetiological model for FMD, which underpins the 
study intervention. The intervention protocol is briefly described. 
Chapter 5 describes the methods for the randomised controlled feasibility study. 
Chapter 6 reports the feasibility study results. 
Chapter 7 is a discussion of the feasibility study results.  
Chapter 8 introduces the qualitative study and describes the study methods. 
Chapter 9 presents the qualitative findings from interviews conducted prior to 
treatment. 
Chapter 10 presents the qualitative study findings from interviews conducted 
immediately after treatment.   
Chapter 11 presents the qualitative study findings from interviews conducted at six 
months follow-up. 
Chapter 12: is a discussion of the qualitative study findings. 
Chapter 13 is the final thesis discussion and thesis conclusions. 
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The research plan for this thesis was devised with reference to the Medical 
Research Council’s (MRC) guideline for developing and evaluating complex 
interventions.2 The guideline identifies four key stages, (i) Development, (ii) 
Feasibility/Piloting, (iii) Evaluation and, (iv) Implementation, see Figure 1.1. The 
double headed arrows in the figure indicate that the stages are considered to be 
cyclical, so that interventions evolve over time, with continuous development, 
evaluation and implementation. The cycle starts with the development of an 
intervention, which involves identifying the evidence base and developing the 
theory that underpins the intervention, these are the topics of Chapters 3 and 4 
respectively. 
 
Figure 1.1. Cycle of Development, Evaluation and Implementation of Complex 
Interventions. 
The thesis Feasibility and Qualitative studies (Chapters 5 to 12) aim to determine 
the feasibility of conducting, and inform the design of, an adequately powered, 
pragmatic, RCT of the study intervention. That is, to enable the progression to the 
Evaluation stage of the MRC guideline by conducting a definitive trial. Data from 
this research will also be used to further refine and develop the intervention.
Feasibility/Piloting
1. Testing procedures
2. Estimating recruitement/retention
3. Determining sample size
Evaluation
1. Assessing effectiveness
2. Understanding change process
3. Assessing cost-effectiveness
Implementation
1. Dissemination
2. Surveillance and monitoring
3. Long term follow up
Development
1. Identify the evidence base
2. Identify/develop theory
3. Modelling process and outcomes
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Chapter 1 Introduction to Functional Motor Disorder 
Functional neurological symptoms are broadly defined as genuine neurological 
symptoms that lack internal consistency and are unexplained by a defined disease 
process.3 It is a diagnosis that exists on the boundary between the disciplines of 
neurology and psychiatry. Symptoms are diverse and can include disorders of 
movement, sensation and awareness. This research is concerned with functional 
symptoms affecting movement, which I will collectively refer to as Functional Motor 
Disorder (FMD). Patients with FMD typically present with one or a combination of 
weakness, tremor, jerks, spasms, dystonic postures or an altered gait pattern. Despite 
being amongst the most common diagnoses made in neurology;4 having been 
recognised as a discrete problem for hundreds if not thousands of years;5 and causing 
disability and distress equivalent to neurological disease;6 there is very little awareness 
and understanding of FMD. As a result there are few treatment options available for 
patients.  
1.1 Terminology 
Over the years many different terms have been used to describe patients with FMD, 
including hysteria, psychogenic, conversion disorder, somatization disorder, non-
organic, medically unexplained, etc. Many of these terms remain in current use. While 
there is disagreement over which are most appropriate,7 the term ‘functional’ appears 
to be gaining traction. It was endorsed by the most recent version of the Diagnostic 
Statistical Manual of Mental Disorders (DSM-5) released in 2013, which updated its 
terminology from “Conversion Disorder” to “Conversion Disorder (Functional 
Neurological Symptoms Disorder)”.8 In addition, the beta draft version of the 
International Classification of Disease version 11 (ICD-11), due for release in 2017, has 
also updated its terminology to use functional.9  
The term ‘functional’ is used to imply a change in function of the nervous system 
rather than structure. Its use has a long history in neurology; in the early 19th century, 
conditions that were classified as functional included chorea, migraine, tetanus, 
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epilepsy, as well as hysteria.10 In more recent times, it has come to represent those 
conditions that exist on the boundary between neurology and psychiatry.10,11 
Opponents of the term “functional” have suggested it is ambiguous, that it obfuscates 
the true cause of the problem and can lead to a reluctance or refusal of the patient to 
accept the diagnosis and psychological treatment.7 The counter argument to this is 
that the current data suggests that psychological factors may not be of primary 
relevance to the aetiology and/or treatment in every patient with FMD, therefore 
terms such as psychogenic and conversion disorder are not necessarily appropriate. 
Perhaps more importantly, “functional” is the preferred term of patients and terms 
that imply a psychological aetiology are often considered unacceptable by patients.12 
In this thesis I have opted to use the term “Functional Motor Disorder (FMD)”. This 
term is inclusive of the range of motor phenomenology seen in patients with 
functional neurological symptoms and it excludes functional symptoms that are not 
necessarily amenable to physiotherapy, such as attacks of decreased awareness 
(including nonepileptic/functional seizures), memory loss and confusion. The term 
“functional movement disorder” is often used in the literature, however a classical 
definition of a “movement disorder” excludes weakness, which is one of the most 
common functional motor symptoms.3  
The lack of consensus of agreement of terminology reflects the heterogeneity of the 
patient population, as well the current state of limited understanding and differences 
of opinions in regards to the aetiology. The lack of consistency in terminology is 
confusing for patients and clinicians, but it also inhibits accurate clinical coding of 
these patients, inevitably leading to inadequate provision of health resources. The case 
for widespread adoption of the term functional is strengthened in Table 1-1 below, 
which lists common terminology and the associated problems with each term. 
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Table 1.1. Terminology related to Functional motor disorder 
Terminology Description 
Functional Used to imply a change in function to the nervous system, as opposed to structure. This 
term was shown to be less likely to offend patients, compared to other terms commonly 
used to describe these symptoms.12 However, it has been criticised for being ambiguous.  
Conversion 
Disorder 
Along with “Functional Neurological Symptom Disorder”, Conversion disorder is the term 
used by DSM-5. Some criticise this term for assuming an aetiology (conversion of psychic 
angst into physical symptoms) that is not supported by evidence. It has been described as a 
relic of late 19th centrury Freudian psychoanalytic theory.13  
Dissociative 
Disorder 
Dissociative (motor, sensory or seizure) disorder, is the term used in the ICD-10.14 This term 
implies that symptoms are aetiologically related to the phenomenon of dissociation, where 
there is a subjective perception of a disconnection.15 This term has been criticised for not 
representing all patients, as many do not recognise having dissociative experiences.13 This 
may explain why the the term has not been readily accepted by the medical community, 
rarely appearing in clinical correspondence or the scientific literature.  
Psychogenic In a survery of 519 neurolgists, the term psychogenic was shown to be the preferred term 
for FMD by 83% when talking to collegues, but only 59% used the term when talking to 
patients.16 This suggests issues with patient acceptability of the term.  The term assumes a 
psychological aetiology, which is not necessarily supported by evidence, or may be overly 
simplistic. 
Pseudo-
neurological 
Meaning symptoms are not neurological in origin and implies symptoms are of a nonorganic 
basis. The prefix pseudo may be perceived as pejorative, by insinuating symptoms are not 
real. 
Non-organic Meaning symptoms do not have an organic basis. There is some argument over what 
constitutes an organic basis. In addition, this term and other similar terms such as non-
epileptic are criticised for describing what the problem is not, which can leave the patient 
wondering what the problem is.13 
Psychosomatic Originally meant to imply an interaction between mind and body, but is often used or 
preceived pejoratively.13 
Medically 
Unexplained 
symptoms 
This term is used to describe functional symptoms from mulitple body regions including 
pain, fatigue and gastrointestinal symptoms. It is often criticised for being a “non-diagnosis” 
and may be interpreted by patients as meaning the doctor does not know what is wrong.13 
Hysteria An historical term, entering the English languarge during the early 17th century, a time when 
FMD was presumed to be caused by “the wondering womb”.5 The term encompassed many 
different presentations of functional disorders and remained in use into the 20th century, 
long after uterine theories were dismissed. The meaning of hysteria has evolved to mean 
uncontrolled emotion. 
Briquet’s 
Syndrome 
Named after French physician Pierre Briquet (1796-1881) who completed a large 
epidemolgical study noting that patients with hysteria were often polysymptomatic. 
Briquet’s Syndrome was a term used in the DSM synonymously with Somatisation Disorder 
(see below). It denoted patients with multiple functional symptoms in multiple body 
symptoms. The term was no longer in use by DSM-4. (1994)17 
Somatisation 
Disorder 
A term used in DSM-4, the specific criteria for Somatisation Disorder included the patient 
having at least one “conversion symptom”, four pain symptoms, two gastrointestinal 
symptoms, and one sexual symptom, all before the age of 30. The term has been replaced in 
DSM-5 (the current version) with Somatic Symptom Disorder.18 
Somatic 
Symptom 
Disorder 
In the DSM 5, Somatic Symptom Disorder replaced Somatisation Disorder. The plain English 
description includes “excessive thoughts, feelings, or behaviours related to somatic 
symptoms or associated healthc concerns”. This diagnositic label is widely criticised for 
being overly inclusive and pathologising normal behaviour.18 
Factitioius 
Disorder 
A psychiatric disorder distinct from FMD where symptoms are consciusly fabricated for the 
purpose of receiving medical care.13 
Munchausen 
Syndrome 
Alternative name for factitious disorder. Often described as a more severe form of factitious 
disorder, where patients seek hospital admissions and treatments.13 
Malingering Feigning symptoms for material gain.13 
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1.2 Incidence and Prevalence of Functional Motor Disorder 
The incidence of a disease is the rate at which new cases occur in a population during a 
specified period.19 Functional motor disorder is generally considered to be common, 
but high quality studies of incidence are lacking. Epidemiological study of FMD is 
complicated by problems with definition and case ascertainment.20 Defining FMD is 
complicated because diagnostic categories are often broad and therefore overlap with 
other diagnoses (e.g. psychogenic nonepileptic seizures, functional overlay in 
neurological disease, functional symptoms with organic comorbidity, and other 
functional or psychological syndromes such as chronic fatigue/myalgic 
encephalomyelitis). Case ascertainment is problematic as diagnosis often requires 
expert neurological assessment, which may not have been performed in studies 
conducted in primary care. Also, studies in tertiary care (where most studies of FMD 
are conducted) may miss patients who are managed in secondary or primary care.20 
Additionally, as previously discussed, many diagnostic labels are used for patients with 
FMD, preventing accurate coding of cases. Despite the obstacles in examining 
incidence, results from studies are relatively consistent, ranging from 4 to 12 per 
100,000 population per year.21 To put this into context, the incidence of multiple 
sclerosis is estimated to be 4 to 6 per 100,000 in northern parts of North America and 
Europe22 and estimates of the incidence of Parkinson’s disease range from 8-18 per 
100,000.23  
Stone et al (2010)3 estimated a minimum incidence of functional weakness in adults of 
3.9 per 100,000 population per year. This figure was based on 116 cases from a referral 
population of 1,261,191 in 28 months. While this study included all NHS neurologists in 
the referral population for South East Scotland, the authors note it may have missed 
patients who were not referred to the study or who were referred to other medical 
specialties (e.g. rheumatology). This figure was therefore considered a minimum 
incidence. Also the study only included functional weakness, therefore the incidence of 
all functional motor symptoms in South East Scotland can be presumed to be higher 
than 3.9 per 100,000.  
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A study of “disability due to motor conversion disorder” in Sweden found an incidence 
of 4.6 per 100,000 and 5.0 per 100,000 in two different Swedish district hospitals in 
1997.24 
The proportion of the population that have the diagnosis at any one time point is 
referred to as the prevalence.19 Estimates of the prevalence of “conversion disorder” 
(inclusive of cases with non-motor functional neurological symptoms such as non-
epileptic attacks) start from 50 per 100,000.25  
Functional symptoms are extremely common in clinical neurology settings. The 
Scottish Neurological Symptoms Study recruited 36 out of 38 neurologists working in 
the Scottish NHS and asked them to rate all new referrals over a 15 month period 
according to the degree to which the patient’s symptoms could be explained by 
disease. They found that 30% had neurological symptoms that were either ‘not at all’ 
or only ‘somewhat’ explained by neurological disease. Functional neurological disorder 
was the second most common diagnosis made, comprising 16% of patients and second 
only to headache (19%).4 
1.3  The Cost of Functional Motor Disorder 
Corresponding to the high incidence, FMD is widely considered to be associated with a 
substantial economic burden, though specific data is limited. The most commonly cited 
study to support this assertion is one that estimated the economic burden of medically 
unexplained symptoms in England, which included neurological symptoms as well as 
other functional symptoms such as gastrointestinal problems, fatigue and pain. The 
estimated annual total cost was estimated to be £18 billion for the period 2008-2009. 
This figure took into account healthcare use, quality of life effects and output losses. 
The cost of additional healthcare was estimated to be £3 billion per year, representing 
10% of total NHS expenditure on healthcare services for the working age population.26  
Additional data that support the high costs of FMD, is found in a cohort of 1144 cases 
of functional symptoms from the Scottish Neurological Symptoms Study. Twenty-six 
percent were found to be unemployed due to ill health and 27% were in receipt of 
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disability benefits.6 In general these values were equivalent to patients with organic 
neurological disease, however patients with functional symptoms are usually more 
likely to be of working age.  
1.4 Aetiology 
Functional motor disorder is often primarily defined by an absence of disease, which 
does little to help understanding and treatment. When it comes to defining the actual 
mechanisms explaining symptoms, much remains unknown and there is disagreement 
over the relative importance of psychopathology. 
It has been well established that psychological problems are more common in patients 
with FMD compared to the general population and patients with organic neurological 
disease. Kranick et al (2011)27 compared 64 patients with “psychogenic movement 
disorder” (FMD), with 39 patients with organic focal hand dystonia, and 38 healthy 
volunteers, using a battery of psychological assessments. They found that patients 
with FMD scored higher in questionnaires assessing childhood trauma (specifically 
emotional abuse and physical neglect), as well as self-rated depression and anxiety. 
However, no difference was found between the groups across a large range of 
variables including the frequency of sexual abuse, frequency of physical abuse, a 
measure of the tendency to dissociate, and a self-reported measure of recent life 
events. There was also no difference between FMD and focal dystonia patients in the 
presence of interviewer-rated psychiatric disorders of major depression (lifetime), 
generalised anxiety disorder, phobia and panic disorder. This study and others have 
shown an inconsistent relationship between functional neurological disorders and 
psychological factors, for instance, childhood trauma appears to be more common in 
FMD, but the majority of patients are unaffected.28 Also, average self-reported anxiety 
scores are higher in groups of patients with FMD compared to other diagnoses, but 
many patients with FMD still score within the normal (subclinical) range. These data 
suggest a pure psychological model is insufficient to understand FMD. 
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Factors other than psychological have become increasingly recognised as an important 
part of the aetiology. There are several studies that demonstrate a relationship 
between FMD and physical precipitating events, including pain, injury and neurological 
disease. In a systematic review, physical injury prior to symptom onset was found in 
37% of 869 patients with functional sensory and motor symptoms.29 In a study of 50 
consecutive patients with FMD at the National Hospital for Neurology and 
Neurosurgery, 80% reported a physical event shortly before the onset of their motor 
symptoms.30 The events included physical injury, infections, drug reactions and 
episodes of acute or exacerbated chronic pain.  
Research into the neurobiological basis for FMD has become a topic of increasing 
interest. Modern functional imaging techniques hold promise as a method of studying 
the aetiology of FMD, however, this field of science is still in its infancy. To date, there 
have been over 20 functional imaging studies of FMD.31 While these studies are limited 
by small subject numbers and differing paradigms, a number of interesting findings 
have been reported. Patients with FMD appear distinct from those feigning 
neurological symptoms;32 they  have shown abnormal recruitment of limbic areas, an 
abnormal functional connectivity between the amygdala and the supplementary motor 
area (a region involved in motor planning)33 and finally, activity in areas associated 
with a normal sense of self-agency appear to be different in patients with FMD versus 
controls, which may be related to the patients’ reported experience that symptoms 
feel involuntary.33  
An interesting finding from neurophysiological studies, that may be related to the lack 
of sense of agency, is that patients with FMD have been found to have impaired 
sensory attenuation.34,35 Sensory attenuation is where there is a difference in 
perception of identical sensory input depending on whether the input was self- 
generated or externally generated. Sensory feedback from self-generated movement is 
associated with a reduction in the perceived intensity (sensory attenuation), and this is 
believed to be how the brain labels a movement as self-generated rather than 
externally generated.35 It has been demonstrated in repeated experiments that 
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patients with FMD lack normal sensory attenuation, which may explain why they 
experience symptoms such as a functional tremor as externally generated.34,35  
Other novel findings in some patients with FMD are impaired interoception 
(perception of sensations related to the physiological state of the body),36 and higher 
rates of alexithymia (an inability to correctly interpret emotions).37 These findings 
suggest that patients with FMD may show reduced awareness of internal body signals, 
which may lead to their misinterpretation.  
A neurobiological aetiological model for FMD, incorporating the above findings, has 
been described by Edwards et al (2012).38 The model highlights two key mechanisms 
that account for functional symptoms, which are (i) an abnormal attentional focus, and 
(ii) erroneous illness beliefs and expectations. The role of attention can be easily 
demonstrated, as functional motor symptoms require attention to manifest. When the 
patient’s attention is distracted away from their symptoms, there is a reduction or 
disappearance of the movement disorder.39 Expectation as a symptom mechanism 
relates to the patient’s expectation or belief that their movement will be abnormal. 
The role of belief and expectation can be seen with commonly reported instant 
“curative” responses to placebo treatment, for example an instant response to 
botulinum toxin injections for fixed functional dystonia.40 The mechanism by which 
belief and expectation may result in functional symptoms has been described in 
regards to the theory of active inference of brain function.38 In brief, active inference 
refers to how the brain operates using predictive models rather than attempting to 
process the potentially infinite amount of afferent and efferent information available 
when performing functions such as controlling movement. Peoples’ predictive models 
are based on prior experiences of interacting with the world. In the context of FMD, 
experiences may lead to a particular illness belief (e.g. of paralysis) and an associated 
expectation of abnormal movement. It is thought that the expectation of abnormal 
movement influences motor output at a preconscious level. The way in which 
expectations influence and shape motor output is thought to be related to the process 
by which the brain uses predictive “pre-programmed” models to generate or control 
movement. This concept can be likened to the experience of picking up an object that 
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you expected to be heavy but turns out to be light. The expectation is inaccurate 
resulting in overshooting the movement. 
An alternative, biopsychosocial aetiological representation of FMD, considers the 
problem in terms of predisposing, precipitating and perpetuating factors. Each of these 
can be considered in biological, psychological and social categories. This 
biopsychosocial framework is helpful to understand the broader context of a patient’s 
problem and to formulate the relevant issues within a clinical treatment context. See 
Table 1.2 below. 
Table 1.2. Biopsychosocial aetiological representation of FMD41 
Factors Biological Psychological Social 
Factors 
acting at all 
stages 
"Organic" Disease 
(including underlying 
neurological disease) 
 
Emotional disorder 
Personality disorder 
Socio-economic/ 
deprivation 
Life events and difficulties 
 
History of previous functional symptoms 
Predisposing 
Vulnerabilities 
Genetic factors affecting 
personality 
Biological vulnerabilities 
in the nervous system 
Persistent Pain 
Fatigue 
Perception of childhood 
experience as adverse  
Personality traits 
Poor attachment  / coping 
style 
Childhood neglect / 
abuse 
Poor family functioning  
Symptom modeling of 
others 
Precipitating 
Mechanisms 
Abnormal physiological 
event or state (e.g., drug 
side effect 
hyperventilation, sleep 
deprivation, sleep 
paralysis) 
Physical injury / pain 
Perception of life event 
as negative, unexpected   
Acute dissociative 
episode /panic attack. 
 
Perpetuating 
Factors 
Plasticity in CNS motor 
and sensory (including 
pain) pathways leading to 
habitual abnormal 
movement 
Deconditioning 
Neuroendocrine and 
immunological 
abnormalities similar to 
those seen in depression 
and anxiety 
Pain and Fatigue 
Illness beliefs (patient 
and family) 
Perception of symptoms 
as being irreversible 
Not feeling believed 
Perception that 
movement causes 
damage  
Avoidance of symptom 
provocation  
Fear of falling 
 
Social benefits of being ill 
Availability of legal 
compensation 
Ongoing medical 
investigations and 
uncertainty 
Employment and financial 
issues 
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1.5 Diagnosis 
In the past, FMD has been described as a diagnosis of exclusion but in recent times 
there has been a move towards making a ‘positive’ diagnosis. A positive diagnosis is 
generally based on clinical signs, incongruity with recognised neurological disease or 
internal inconsistency during the physical examination.11. A number of clinical signs 
have been described to positively identify FMD. Perhaps the most clinically useful is 
Hoover’s sign for functional lower limb weakness, which has been shown to have high 
specificity (99%) and sensitivity (94%).42 Other clinical signs of FMD are described in 
Table 1.3 below.  Examples of incongruity with recognised clinical disease include 
midline splitting of sensory disturbance, global pattern of limb weakness and a tubular 
visual field.15 An example of internal consistency is when the patient is unable to 
actively plantarflex their ankle against resistance but is able to stand on their toes. 
Table 1.3 Clinical Signs of Functional Motor Disorder 43 
Clinical Sign Description 
Hoover’s sign Hip extension weakness that returns to normal when the 
contralateral hip if flexed against resistance. 
Give-way weakness / collapsing 
weakness 
Muscle power is initially generated on testing which quickly 
gives way or collapses. 
Hip Abductor sign Hip abduction power is tested bilaterally with the patient 
supine. Power in both limbs is generated in a positive test. 
Dragging leg gait  Gait pattern characterised by dragging a weak leg behind. 
Clear signs of inconsistency For example, weak ankle plantarflexion on testing but the 
patient is able to walk on their toes. 
Hemifacial muscle over activity 
presenting with unilateral limb 
symptoms 
Over-activity of orbicularis oculus, orbicularis oris and/or 
platysma giving the appearance of a facial droop. 
Sternomastoid test Weakness of head turning to affected arm and leg in functional 
hemiparesis. 
Drift without pronation test During a 'pronator drift' test, the forearm may not pronate in a 
functional hemiparesis. 
Global pattern of weakness Flexors and Extensors equally affected - e.g. wrist flexion and 
wrist extension. 
Tremor entrainment or 
distractability 
A distraction task, when tapping an unaffected limb at a set 
frequency, the affected limb entrains to the set frequency of 
tapping or the tremor stops.11 
Dragging monoplegic gait The leg is dragged at the hip behind the body.42 
Walking on ice gait Exaggerated postural responses, pivoting at the wait with a 
narrow base of support.11 
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In addition to clinical signs, key features of the history may support the diagnosis. This 
can include a history of other functional symptoms, rapid onset to peak disability and 
physical precipitating factors (such as a viral illness or minor injury).44 Psychological 
problems such anxiety, depression and recent stress are generally more common in 
functional disorder than other neurological diagnoses, but they are not universal and 
therefore are an unreliable basis for the diagnosis.44 It is also generally recommended 
that specific and targeted investigations should be conducted to rule out other 
potential causes for symptoms, this may include MRI and nerve conduction testing.11 
Criteria for degrees of diagnostic certainty were proposed by Fahn and Willams 
(1988)45, and were updated by Lang and Gupta (2009)46, see Table 1.4 below. These 
criteria are useful for defining patient eligibility criteria for clinical trials.  
Table 1.4. Classification of diagnostic certainty for functional movement disorders 
(Gupta and Lang, 2008) 
1. Documented 
 Remittance with suggestion, physiotherapy, psychotehrapy, placebos, “while 
unobserved” 
2a. Clinically established plus other features 
 Inconsistent over time/incongruent with clinical condition + other manifestations: 
other “false” signs, multiple somatizations, obvious psychiatric distrubance 
2b. Clinically established minus other features 
 Unequivocal clinical features incompatible with organic disease with no features 
suggesting another underlying neurological or psychiatric problem 
1 + 2a + 2b = Clinically definite 
 
3. Laboratory-supported definite 
 Electrophysiological evidence proving a psychogenic [functional] movement disorder 
(primarily incases of psychogenic [functional] tremor and psychogenic [functional] 
myoclonus 
 
It is often recommended that making the diagnosis of FMD should be the responsibility 
of a neurologist.47 This is because of the potential complexity of ruling out rare 
neurological conditions that may mimic FMD, such as the alien hand phenomenon of 
corticobasal degeneration, and the variability seen in stiff person’s syndrome.44 In 
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addition, on rare occasions, FMD may exist as a prodromal state for neurological 
disease. For example a functional gait disturbance and psychiatric symptoms may 
occur prior to the onset of firm signs of motor neurone disease, multiple system 
atrophy or Parkinson’s disease.44 More importantly, functional symptoms are often co-
morbid with neurological (and other) disease, up to 15% of patients with an “organic” 
neurological disease diagnosis additionally have functional symptoms.48 Despite these 
complexities, the diagnosis appears to be stable when made in neurological practice. A 
systematic review found that the rate of misdiagnosis is approximately 4%, which is in 
line with misdiagnosis rates of other neurological disagnoses.49   
1.6 Malingering and Factitious Disorders 
Clinicians commonly report concerns that patients with FMD are feigning their 
symptoms.50 The term malingering is used to describe the situation where symptoms 
are feigned for material gain and factitious disorders are when symptoms are feigned 
as part of a psychiatric disorder, for the purpose of receiving medical care.13 Many 
convincing arguments have been made to support the suggestion that FMD is distinct 
from feigning, this includes evidence from fMRI and laboratory studies.35,51 Some 
clinicians may interpret symptom variability or exaggeration of symptoms as evidence 
of malingering. Symptom variability can also be explained by the amount of attention 
invested in a movement or action. It may be true that some patients with FMD 
exaggerate symptoms to convince others of the need to be taken seriously, but this is 
different from exaggeration to deceive.13  
1.7 Clinical Presentations  
Functional neurological symptoms rarely occur in isolation. Functional motor, sensory 
and cognitive symptoms commonly coexist together with subjective reports of fatigue 
and persistent pain. When taking a history, the patient may focus on one particular 
problem, such as limb weakness, but on closer questioning, multiple symptoms are 
usually uncovered.  
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A number of specific presentations of FMD have been described. The most common 
are discussed below. 
1.7.1 Functional Weakness 
Functional weakness most commonly presents as weakness or paralysis of the limbs. It 
may occur in any combination including monoparesis, hemiparesis, paraparesis, and 
tetraparesis.52 The weakness is characterised by internal inconsistency, which 
differentiates it from weakness due to neurological disease. Examples of inconsistency 
include an inability to move a lower limb on testing but the patient is still able to stand. 
Clinical signs of functional weakens are described in Table 1.3. 
Patients presenting with sudden onset of functional weakness are often mistakenly 
directed through emergency stroke treatment pathways. In this context patients are 
referred to as stroke mimics (other conditions that can also mimic stroke include 
migraine and brain tumours). Within specialist stroke services functional stroke mimics 
represent a reported range of 1.4 to 8.4% of all admissions53–57 and 0.5 to 5% of all 
patients who receive intravenous thrombolysis for presumed stroke58–60. 
1.7.2 Functional Tremor 
Functional tremor as a dominant functional symptom is one of the more common 
presentations seen in tertiary specialist Movement Disorder clinics, accounting for up 
to 55% of patients with functional movement disorders.61,62 Functional tremor most 
commonly affects upper limbs, but can also affect the lower limbs, head and neck, and 
even the palate.11 Functional tremor is characterised by distractibility and 
entrainability (see Table 1.3). It  may occur at rest or with movement (action tremor). 
The tremor may be generated by alternating contraction of agonist-antagonist muscles 
or by co-contraction.11  
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1.7.3 Functional Jerks (Myoclonus) 
Functional jerks are intermittent jerking movements that can affect any part of the 
body, though jerks affecting the trunk are probably the most common (axial jerks).63  
They have been estimated to make up approximately 15% of patients with functional 
symptoms in specialist Movement Disorder clinics. As functional jerks are intermittent 
and have variable frequency, it is difficult to assess the effect of distraction, which 
makes diagnosis complex. A clinical diagnostic test has been devised for functional 
myoclonus which involves EEG-EMG back averaging to assess for cortical activity 
before movement. In patients with functional myoclonus and in normal voluntary 
movement, there is a pre-movement potential (also known as a Bereitschafts 
potential) arising approximately 1.5 seconds before activity.11 This test is not suitable 
for all cases as it requires at least 30 recorded measurements and may not be possible 
when jerks occur at a greater frequency than 3-5 per second.11 
Many patients with functional jerks were previously diagnosed with myoclonus that 
was presumed to originate from the spinal cord, often called Propriospinal Myoclonus. 
The develop of EEG-EMG back averaging to assess for pre-movement potentials has 
resulted in many patients being re-diagnosed with  FMD, and the existence of organic 
Propriospinal Myoclonus has been questioned.64 
1.7.4 Functional Dystonia 
Functional dystonia presents as “dystonic” postures and movement that can affect 
virtually any body part, including the limbs, facial muscles, head, neck and the tongue. 
Functional dystonia commonly presents with other functional symptoms such as 
tremor, weakness and altered sensation.  
1.7.5 Fixed Functional Dystonia 
Fixed functional dystonia typically presents as a fixed (locked) abnormal joint posture 
(commonly ankle plantarflexion and inversion), accompanied by significant pain. It 
often overlaps with the diagnosis of complex regional pain syndrome.65 Evaluation 
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under sedation relaxes the muscle tension and may reveal a soft tissue contracture, 
but often joint range of motion is unexpectedly preserved. Fixed dystonia commonly 
develops rapidly after a relatively minor injury, such as an ankle sprain.66 Another 
common presentation of fixed dystonia is fourth and fifth finger flexion at the 
metacarpophalangeal and interphalangeal joints.66 There is some disagreement over 
the aetiology of fixed dystonia and whether or not it is best characterised as a 
functional disorder.65,66 The debate draws on the cross over with complex regional 
pain syndrome and the inconsistent relationship of fixed dystonia with psychological 
factors. 
1.7.6 Functional Gait Disorder 
A functional gait disorder can present as part of a mixed functional movement disorder 
picture (due to functional weakness, dystonia, tremor, altered sensation, pain, etc) or 
as an isolated problem.67 Common patterns of functional gait disorder have been 
described including a dragging leg gait, walking on ice gait (exaggerated trunk-sway 
postural adjustments without falling), astasia-abasia (inability to stand or walk despite 
normal power when tested on the bed), excessive slowness, non-economic postures, 
knee buckling and scissoring-leg gait.42,67 
1.7.7 Other Categories 
Other categories of FMD have been described in the literature and used in clinical 
descriptions for research cohorts. Mixed Movement Disorder is often used to describe 
a mixture of motor symptoms including dystonia, weakness and tremor. Functional 
motor disorder can mimic Parkinson’s disease and several case series of functional 
Parkinson’s disease have been described. Patients exhibit a functional tremor (usually 
at rest and during action), slow effortful movement, abnormal response to postural 
stability testing and resistance to passive movement.68  
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1.7.8 Non-epileptic Seizures and Other Common Symptoms 
Non-epileptic seizures (NES) (also called dissociative/psychogenic/functional seizures) 
are a specific presentation of functional neurological disorder characterised by 
episodes of decreased awareness often associated with movement resembling tonic-
clonic epileptic seizures.69 Non-epileptic seizures are not considered part of the 
spectrum of functional movement disorders, due to the predominant characteristic of 
reduced awareness. However, symptom cross over is common and many patients with 
a primary complaint of NES will also experience functional motor symptoms and vice 
versa. In general, patients with a predominant problem of NES differ from those with 
FMD in in a number of ways. They are more likely to be younger, more likely to report 
childhood abuse and more likely to report adverse life events prior to the onset of 
their symptoms.69 
It is also common for patients with functional neurological disorders (motor and non-
motor) to experience functional symptoms in other body systems. Among the most 
commonly reported are gastrointestinal symptoms (many are diagnosed with irritable 
bowel syndrome), bladder retention and chronic fatigue. Many patients will also have 
other medical conditions and complaints that may need separate diagnosis and 
treatment in addition to their FMD. These conditions may act as one of several risk 
factors for the individual for developing FMD.  Common comorbidities in FMD include 
migraine and Ehlers Danlos syndrome. In this context anxiety, depression and other 
psychiatric diagnoses may also be considered as separate comorbidities. 
1.8 Prognosis 
The prognosis of FMD is generally considered to be poor; a systematic review of 
prognosis found that approximately 40% of patients were the same or worse at long 
term follow up of 7 years and it would appear that the majority of patients remain 
symptomatic.70 This data is based on a broad cross section of patients with FMD, 
including those with chronic symptoms at baseline assessment. There is limited data 
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on the prognosis of first episode acute onset FMD, a group that may have a higher rate 
of symptom resolution.  
A number of prognostic indicators have been identified. Longer duration of symptoms 
prior to diagnosis and the presence of a personality disorder are among the most 
powerful predictors of poor outcome, while high satisfaction with care has been 
shown to predict positive outcome.70 
1.9 Treatment 
There is limited evidence for the treatment of FMD. Multidisciplinary treatment is 
generally considered the gold standard, which may involve neurology, psychiatry, 
physical therapists (physiotherapy, occupational therapy and speech and language 
therapy) and psychology (or similar therapists); with the general practitioner at the 
centre of the team. Additionally, clinical nurses have an important role in inpatient 
treatment programmes. 
1.9.1 Neurology 
As described above (section 1.5 Diagnosis), neurologists are usually the clinician 
responsible for making the diagnosis of FMD. Several authors have presented 
arguments suggesting that neurologists have a key role in the management of patients 
with FMD and that this starts with the first step of treatment, which is effective 
communication and explanation of the diagnosis.11,15 Other roles of the neurologist 
may include treating comorbidity such as migraine and chronic pain; rationalising 
medications; referral to other medical specialities for assessment of comorbidity that 
has not previously been addressed (e.g. sleep apnoea);  referral for psychiatric 
assessment and management if appropriate; and referral for  multidisciplinary 
rehabilitation.  
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1.9.2 Psychiatry 
The role of psychiatry will differ between patients and in the NHS may be dependent 
on the provision and commissioning of local services. The key role of a psychiatrist is to 
assess and treat psychiatric comorbidity. Psychiatrists may also oversee rehabilitation; 
the two specialist inpatient multidisciplinary rehabilitation programmes in the UK are 
led by psychiatrists within the psychiatry departments of tertiary hospitals.71,72  
1.9.3 Physical Therapists 
The role of physical therapies is increasingly being recognised. In the UK, specialist 
services for FMD involve physiotherapy, occupational therapy and speech and 
language therapy.71,72 Specialist treatment programmes abroad include other 
clinicians, such as exercise therapists.73 The evidence for physiotherapy treatment is 
reviewed in Chapter 3. The evidence for Occupational Therapy is limited to cohort 
studies of multidisciplinary inpatient rehabilitation programmes,71,72,74,75 which report 
promising outcomes. For Speech and Language Therapy, in addition to their 
involvement in multidisciplinary cohort studies,37,72 there are several cohort studies 
showing promising treatment outcomes, in particular for functional stuttering.76 
1.9.4 Psychological Therapies 
Psychological therapies can be an important part of treatment for patients who 
consider that psychological factors are relevant to their problem. A randomised 
controlled trial of a CBT-based, guided self-help intervention for patients with a wide 
range of functional neurological symptoms, including motor symptoms, showed 
benefits in subjective health at 3 months and the physical function domains of the 
SF36 questionnaire at 3 and 6 months. The number needed to treat was 8.77 There is 
some evidence for psychodynamic interpersonal therapy combined with neurological 
consultation,78,79 though these studies have low numbers and other limitations due to 
pragmatic experimental designs. There is better evidence for psychological treatment 
of the specific functional presentation of NES.80 
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1.9.5 Other Treatments 
A range of other treatments have been described for FMD. This includes transcranial 
magnetic stimulation,81 therapeutic sedation and abreaction,82 and hypnosis.83 
Controlled evidence for these treatments is currently lacking, however they may prove 
to be useful treatment adjuncts in some patients.  
Alternative therapies such as reflexology are popular amongst some patients and often 
patients turn to alternative therapies when they have been unable to find support in 
the NHS. Alternative therapies can be a contentious issue, particularly in a cohort of 
patients that are vulnerable to iatrogenic harm and financial exploitation by 
unscrupulous providers. 
1.10 Summary 
 Functional motor disorder is a common cause of disability for which there are few 
evidence based treatment options currently available. The aetiology is multifactorial, 
but historically it has been considered a problem predominantly of psychogenic origin. 
In the past 10-15 years however, neurobiological mechanisms for functional motor 
symptoms have been described and supported by clinical and laboratory evidence. 
This has led to a biopsychosocial understanding of FMD and opened the door to the 
development of physical as well as psychological treatments.
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Chapter 2 A Brief History of Hysteria 
Functional motor disorders have a long and colourful history, full of charismatic 
characters, many of whom have been remembered as the early pioneers of 
neurology and psychiatry. Below I will review significant milestones that have led to 
the current day understanding and status of FMD within the health care system.  
It is often reported that the first descriptions of symptoms now recognised to be 
FMD come from ancient Egyptian papyrus, dating from 1900 BC.5,17,84 The 
symptoms included choking, mutism and paralysis, and were attributed to 
spontaneous movement of the uterus within the body.5 FMD was also described in 
ancient Greek and Roman texts. It was believed that the symptoms were caused by 
a lack of normal sexual contact, which resulted in the uterus migrating upwards 
causing multiple bodily symptoms. This is recorded in Plato’s Timaeus (360 BC):  
“… the matrix or womb, as it is called, which is an indwelling creature 
desirous of child-bearing, remains without fruit long beyond the due season, 
it is vexed and takes ill; and by straying all ways through the body and 
blocking up the passages of breath and preventing respiration it cases the 
body into the uttermost distress, and causes, moreover all kinds of maladies; 
until the desire and love of the two sexes unite them.”85,86 
The association between FMD and the uterus was commonly accepted until well 
into the 19th century. This obviously confined the diagnosis to women and gave rise 
to the label hysteria, derived from the Greek and Latin words for uterus. The term 
hysteria came into usage in the English language around 1615 but was used in 
French literature around 1568.5 
During the Middle Ages (5th to 15th century) and the early Modern Period (16th to 
19th century), beliefs about the uterus were replaced by beliefs of demonic 
possession and witchcraft. “Hysterical” women were subjected to exorcisms in an 
attempt to cure them or punish them for sorcery.84 Often confessions were 
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obtained under torture, before the victim was put to death. With the Renaissance 
and emergence of scientific thinking, the uterus once more became the focus of 
descriptions of hysteria. However, examples of accusations and belief in demonic 
possession continued to appear, perhaps most famously in the witch trials of Salem 
Massachusetts in 1692.84 Cultural and religious beliefs remain influential in how 
some cultures treat people with FMD today. 
Edward Jordan an English physician and chemist (1569-1633) produced what is 
regarded as the first English work on hysteria in “The Suffocation of the Mother” 
(1603).10 He argued that hysteria was a natural disease, within the scope of medical 
study, rather than a theological issue. He suggested the uterus was the source of 
the problem, which in turn could affect organs such as the brain, heart and liver.10,87 
Uterine theories of hysteria remained  dominant until the 17th century, when the 
influential English physicians Thomas Willis (1621-1675) and Thomas Sydenham 
(1624-1689), promoted the brain and nervous system as “the seat of hysteria”, thus 
controversially suggesting that men could also be affected.87,88 Sydenham used the 
phrases “nervous distemper” and “animal spirits” when postulating on the 
mechanism of hysteria. 
The naming of the brain and nervous system as the seat of hysteria led to the 
concept of nervous disorders.5 George Cheyne (1671-1743) a physician, 
mathematician and philosopher who was born in Scotland and practiced medicine 
in Bath wrote the influential “English Malady or a Treatise on Nervous Diseases of 
all kinds, as Spleen, Vapours, Lowness of Spirits, Hypochondriacal and Hysterical 
Distempers” in 1733.89  Cheyne suggested that nervous symptoms arose from the 
moist climate, rich food and nervous culture of wealthy English society.5 It is 
considered that this suggestion may have provided a basis for a fashionable nervous 
culture, where fainting, swooning and attacks of the vapours became a fashionable 
way to behave,5 an interesting contrast to the stigma attached to mental illness in 
the present day. It was widely considered that hysteria only affected the upper 
classes, the lower classes were considered to be insufficiently impressionable and of 
too coarse  a sensibility to fall victim to the disorder. In contrast, one hundred years 
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later the French neurologist Charcot and his contemporaries considered hysteria to 
be a disorder of the lower classes.5 
The 19th century is often described as the heyday of Hysteria, when great interest 
and time was devoted to the subject by the pioneers of neurology and psychiatry. 
The French neurologists were particularly influential and much of the research 
occurred at the Parisian hospital La Salpêtrière. A comprehensive historical 
catalogue of French psychiatric dissertations written during the 19th century 
indicates that 20 percent were devoted to hysteria, and this was more than any 
other subject in psychiatry at the time.90  
Pierre Briquet (1796-1881) was also a neurologist and early pioneer of functional 
neurological symptoms. He became the chief physician at Charité hospital in Paris 
and reportedly undertook a study of hysteria as a matter of duty, on account of the 
frequency of cases.91 His published work “Traité clinique et thérapeutique de 
l’hystérie” (Clinical and Therapeutic Treatise on Hysteria) of 1859 was an 
epidemiological study of 430 patients with hysteria over  a 10 year period.92 He 
noted that the patients were often poly-symptomatic and he  believed that their 
symptoms were caused by the brain and related to nervousness caused by the 
emotional part of the brain.85 He considered predisposing factors to be  female sex, 
affective and impressionable temperament, family history, low social class, and 
situational difficulties.5 His work remained influential and he lent his name to the 
DSM diagnostic label “Briquet’s Syndrome”, characterised by multiple medically 
unexplained physical complaints in multiple body systems. This term remained in 
use until the release of version four of the DSM in 1994,93 when it was replaced 
with Somatization Disorder, which has since been replaced with Somatic Symptom 
Disorder in version five of the DSM, released in 2013.17 
Perhaps the next influential figure in the history of hysteria is Englishman John 
Russell Reynolds (1828-1896), a much respected early neurologist and professor of 
medicine at University College London.85 Reynolds wrote a paper that was 
published in the British Medical Journal in 1869 titled “Remarks on paralysis, and 
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other disorders of motion and sensation, dependent on idea”.94 In this paper he 
describes disorders of movement and sensation that would appear to be caused by 
disease of the brain or spinal cord, but instead “may depend upon a morbid 
condition of emotion, of idea and emotion, or of idea alone”. This paper presents an 
aetiological understanding that is strikingly similar to current biopsychosocial 
models for FMD.11,39 Similarities include highlighting the importance of belief as part 
of the symptom mechanism; that symptoms are often associated with biological 
events (e.g. physical precipitating factors) but are distinct from definite diseases of 
the nervous system; suggesting that psychopathology is common but not a 
necessary part of the aetiology; that symptoms are distinct from malingering; and 
that a positive diagnosis can be made based on characteristics of the motor 
symptoms. Reynolds suggested that treatment should be “A real, earnest dealing 
with the case, as one of grave character”. The doctor should give a confident 
expression of hope and positive reinforcement, facilitate early weight bearing “with 
support on each side, the amount of support [should] be gradually diminished day 
by day”. He also suggested the use of electrotherapy “partly as a moral and mental 
agent”, friction and passive movements. Reynolds’ summary of this condition, 
which he considered was neither neurological disease nor hysteria, insanity or 
malingering is outlined in his words in the table below. Reynolds’ paper was cited as 
an important influence by the French neurologist Jean-Martin Charcot.85  
Table 2.1. Reynolds description of functional neurological symptoms94 
1. That some of the most serious disorders of the nervous system, such as paralysis, 
spasm, pain, and otherwise altered sensations, may depend upon a morbid condition of 
emotion, of idea and emotion, or of idea alone;  
2. That such symptoms often exist for a long time, appearing as complicated disease of 
the brain or spinal cord;  
3. That they resist many different kinds of treatment [such as pain not responding to 
morphine as one would expect]…, but that they disappear entirely upon the removal of 
the erroneous idea;  
4. That they occur independently of anything that could be called either insanity of mind, 
hysteria, hypochondriasis, or malingering;  
5. That they are often, but not constantly, associated with some bodily weakness or 
general debility;  
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6. That they sometimes associated themselves with distinct and definite disease of the 
nervous centres, so that it becomes very important to know how much of a given case is 
due to organic lesion, and how much to morbid ideation;  
7. That it is possible to make a diagnosis with regard to them in many instances; and,  
8. That the principles upon which their treatment should be conducted are simple, and 
their application marvellously successful.” (Reynolds 1869). 
 
Jean-Martin Charcot (1825-1893) was an extremely influential figure in the history 
of FMD and has also been described as the premier clinical neurologist of the 19th 
century.95 He spent his career at the Salpêtrière Hospital in Paris, where he built a 
much respected centre of neurological research. People came from around the 
world to hear his famous lectures and study with him. Among his students and 
collaborators were Georges Gilles de la Tourette, Pierre Janet, Joseph Babinski and 
Sigmund Freud, who all went on to make their own mark on the field of neurology 
and hysteria.95–97 During the 19th century, hysteria was a specific and defined 
neurological diagnosis largely due to the work of Charcot.95 Outside of FMD, 
Charcot pioneered the classification of neurological symptoms according to 
anatomical lesions, based on post mortem studies, and he also established a 
category of neurological disorders, the “névroses” (neuroses) which were  
neurological conditions that were clinically characterised but still had no identifiable 
physical lesions, and  included epilepsy, migraine and hysteria.98  
Charcot believed that a neurological basis for hysteria would eventually be found. 
He developed the concept of a dynamic lesion to explain paroxysmal symptoms,97 a 
concept that some authors have likened to the findings from fMRI studies of 
abnormal neural circuitry.95 He believed that suggestibility and susceptibility to 
hypnotism were pathognomonic of hysteria, although the pathology, in his opinion, 
remained grounded in neuroanatomy.95 He used hypnosis to induce hysterical 
attacks during lectures and demonstrations as well as for treatment. Charcot had 
his detractors, including the British neurologist William Gowers, who practiced at 
Queen Square, and  suggested that the displays of Charcot’s patients in his famous 
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lectures had been nothing to do with mental disorders, but were displays initiated 
by suggestion or feigned by the patient to please Charcot and his students.97 
After Charcot’s death, his student the French neurologist Joseph Babinski (1857-
1932) distanced himself from some of Charcot’s work, in particular that there was a 
neuroanatomical basis for hysteria. He considered hysteria to be a psychological 
problem in which suggestion was important.99 His views were influenced by his 
involvement in the treatment of soldiers suffering shell shock from the Battle of the 
Somme.99 Babinski’s contribution to hysteria included describing methods to 
differentiate hysteria from neurological disease.96 Pierre Janet (1859-1947), another 
neurologist and student of Charcot’s, emphasised the importance of psychological 
factors in hysteria and introduced the concept of dissociation as part of the 
explanatory mechanism.97,99 With the growing conceptualisation of hysteria as a 
psychological disorder, and the emergence of Sigmund Freud and psychoanalysis, 
hysteria started to move towards the field of psychiatry and became excluded from 
neurology.85 
The neurologist and founder of psychoanalysis Sigmund Freud (1856-1939) may be 
the most famous early clinician in the field of hysteria. Charcot is often credited 
with sparking Freud’s interest in the area, after he spent time studying with him at 
the Salpêtrière in 1885.17 Despite being a neurologist by training, Freud’s work 
made hysteria a psychiatric illness and his psychoanalytical paradigm dominated 
psychiatry’s thinking for over 50 years.100 Freud’s ideas centred on repression of a 
traumatic idea and its conversion into physical symptoms. He highlighted the role of 
the unconscious to differentiate symptoms from feigning and initially considered 
sexual abuse to be an important trigger, although this became less prominent in his 
later work.100 Together with the Austrian physician Josef Breuer (1842-1925), he 
published his famous manuscript “Studien über Hysterie” (Studies on Hysteria) in 
1895, which included 5 case studies, including Breuer’s famous case of Anna O. This 
work was seminal for the development of psychoanalysis and the “talking cure”.101 
Freudian theories about hysteria remained part of the DSM diagnostic criteria for 
conversion disorder until the most recent iteration in 2013.100 In a recent textbook 
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chapter, psychiatrist Richard Kanaan (2016) suggests that with the removal of 
Freudian criteria, no obviously psychiatric features remain, once again hysteria is 
returning to the field of neurology where it had sat under the influence of 
Charcot.100  
The onset of World War I in 1914 saw an epidemic of functional neurological 
symptoms, with what became known as ‘shell shock’. Soldiers presented with a 
variety of physical and psychological symptoms, including gait disorders, tremors, 
nightmares and panic attacks, that were the consequence of trench warfare.99 Shell 
shock renewed the debate over whether hysterical/functional symptoms were 
conscious (malingering) or subconscious.100 Treatments were influenced by the 
need to send soldiers back to the front, and often involved painful electrotherapy 
(Faradic currents). It is widely reported that the treatment was often delivered 
abusively, and that treatment often became to be considered as a form of 
punishment.17 The National Hospital for Neurology and Neurosurgery (at the time 
known as the National Hospital for the Paralysed and Epileptic) took in many 
patients with shell shock, with up to one third of the hospital allocated to military 
casualties.102 Lewis Yealland (1884-1954) a Canadian-born physician treated a large 
proportion of these patients. He described his treatment regimen as including 
walking exercises, re-education, suggestion, complete rest, isolation and strong 
faradic currents.102 This electrical therapy was often extremely painful and some 
historians have judged Yealland as having dealt out cruel punishing therapies. 
However, more recently  Linden et al (2013)102, suggest that Yealland has been 
unfairly singled out, arguing that paternalistic and often painful treatment was 
standard practice for the time. Yealland played on soldiers’ fear of being accused of 
malingering, by explaining to patients that, if you recovery quickly, then it is due to 
disease, if you recover slowly, … then I shall decide that your condition is due to 
malingering.102 Interestingly, a similar deceptive approach to rehabilitation was 
described as current practice in a paper from Canada, published in 2004.103  
Following World War I, there was a common perception that hysteria had 
disappeared from medicine. It was argued that the florid symptoms described by 
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Freud and Charcot were a product of the repressed Victorian era and had since 
been replaced with more elusive symptoms such as fatigue.104 However, Stone et al 
(2008)104 noted that, although there is limited data on the incidence of FMD over 
time, the best evidence suggests that the proportion of patients presenting with 
FMD in neurology has remained strikingly similar over time, but that these patients 
became effectively invisible. Stone suggested a number of factors which might have 
contributed  to the disappearance of FMD/hysteria from medical history, including 
the divergence of neurology and psychiatry leaving patients in a virtual ‘no-man’s 
land’; both neurologists and psychiatrists being  notoriously uninterested in seeing 
patients with FMD;104 and also  the reported findings of the British psychiatrist Eliot 
Slater.  
Eliot Slater (1904-1983) was a Psychiatrist at the National Hospital for Neurology 
and Neurosurgery.105 Shortly before retiring, he  gave a lecture, the transcript of 
which was published in the BMJ in 1965,106 which described a follow up study of 
112 patients diagnosed with hysteria over nine years. He reported that over half of 
the patients diagnosed with “hysteria” developed an alternative clear neurological 
or psychiatric diagnosis at follow up. Slater concluded, “The diagnosis of hysteria is 
a disguise for ignorance and a fertile source of clinical error.” The paper has since 
been widely criticised for numerous flaws and poor methods of data 
collection.105,107 Unfortunately Slater’s  study was  very influential and it has been 
suggested that it contributed to the almost complete disappearance of the concept 
of functional neurological symptoms from neurological curricula and text books.99 
The “disappearance” of functional neurological symptoms from scientific interest 
appeared to last until around the mid 1990’s, when a resurgence of the topic can be 
seen in the scientific literature.99 Modern imaging techniques, such as fMRI, have 
helped to develop an understanding of FMD to include theoretical and empirically 
testable neurobiological models, allowing for a biopsychosocial explanation for 
symptoms with no apparent organic basis.  
There is however ongoing debate in the scientific literature about the classification 
of some symptoms as either functional or organic. Until the early 1980’s, focal and 
45 
 
task specific dystonias were often considered psychogenic in origin. The British 
neurologist David Marsden (1938-1998) is credited with firmly establishing these as 
organic neurological conditions.108 The syndrome of fixed (functional) dystonia has 
only relatively recently been widely recognised as a functional symptom,65,108 
although many still consider this an ‘organic’ problem due to the diagnostic cross 
over  with complex regional pain syndrome and the absence of a clear link to 
psychopathology. The development of modern neurophysiological assessments, has 
led to the condition known as propriospinal myoclonus, characterised by repetitive 
abdominal jerks, being considered  a functional movement disorder in most 
cases.109  
In summary, the history of FMD dates back to the earliest medical records, yet 
these patients have never found a ‘secure home’ in medicine. In the late 19th 
century patients were embraced by neurology, before being moved towards 
psychiatry, where they sat uncomfortably, until recently when the pendulum has 
started to swing back towards neurology. This uncertain territory, where patients 
have found themselves, has no-doubt influenced the lack of awareness, 
understanding and status of FMD. Things, however, appear to be changing with the 
recently increased interest in FMD as a topic of research and with collaborations 
between neurology, psychiatry and rehabilitation specialists.
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Chapter 3 Literature Review 
A Review of the Literature of Physical Rehabilitation for Functional Motor 
Disorder 
This review builds on my previously published systematic review of physiotherapy 
for FMD.110 Since publication, several new studies have been reported and the 
literature has been reviewed in light of this new evidence.  
The research was reviewed in respect to the questions: (i) what is the evidence for 
physical rehabilitation of FMD? and (ii) what are the important ingredients of 
physical rehabilitation, as described in the published literature?  
3.1 Methods 
A systematic search of the literature was conducted. The search strategy from the 
earlier literature review (1950 to 5 September 2012) was extended to include the 
period of September 2012 to 15 March 2015. Condition terms were combined in an 
“AND” search with treatment terms. Output was limited to English language papers 
and studies of paediatric subjects were excluded due to potential differences in 
aetiology and corresponding treatment. The search was executed on databases: 
Medline (OVID and Pubmed), Embase and CINAHL. See Table 3.1 for search 
strategy. Additional searches were conducted using Google Scholar and the 
reference lists of published papers. 
Table 3.1. Literature Search Strategy 
Database Results Search Strategy (01/09/2012 – 15/03/2015) 
Medline (OVID) 83 Condition terms: Exploded MeSH terms: “Conversion 
Disorder”, “Somatoform Disorder”, “Dissociative Disorder”. 
Keywords: “psychogenic”, “medically unexplained”, 
“hysteri*”  
Treatment terms: Exploded MeSH terms: “Physical  Therapy 
Modalities”, “Rehabilitation”, “Physial and Rehabilitation 
Medicine”. Keywords: “physiotherapy”, “physical therapy”, 
“exercise” 
Medline (Pubmed) 88 
Embase 507 
CINAHL 44 Condition specific terms: Exploded MeSH terms: 
“somatoform disorders”, “dissociative disorders”.  
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Keywords: “psychogenic”, “medically unexplained” and 
“hysteri*”.  
Treatment terms: Exploded MeSH terms “physical therapy”, 
“rehabilitation”. Keywords: “physiotherapy”, “physical 
therapy” and “exercise”. 
 
Being aware of limitations in the number and methodological quality of published 
studies on this topic, the inclusion criteria were kept deliberately broad. Studies 
were included if they described physiotherapy or physical rehabilitation of patients 
with an established diagnosis of FMD. Peripheral electrical stimulation aimed at 
improving movement was included in the definition of physical rehabilitation. 
Studies of multidisciplinary treatment inclusive of physiotherapy were also 
included. Studies were not excluded on the basis of low methodological quality. The 
abstracts (or full text when unclear) of all studies returned from the search were 
reviewed for inclusion. The original paper was retrieved for all studies fitting the 
inclusion criteria. 
The following data were extracted from each study: (i) study type/methodology; (ii) 
treatment type; (iii) sample size; (iv) demographic characteristics of subjects (sex 
and age); (v) clinical characteristics of subjects (symptom phenotype, symptom 
duration and measures of disability); (vi) treatment parameters (setting, duration 
and frequency; (vii) treatment outcome; (viii) follow up duration; (ix) treatment 
ingredients; and (x) use of outcome measures. As part of the literature review 
process, a quality appraisal checklist designed for case series was applied to studies 
with subject numbers of 10 or more. It was felt that the appraisal criteria were not 
consistently applicable to small case series and case studies. This checklist and the 
scoring of studies with 10 subjects or more is given in Appendix 1 (page 217). 
3.2 Results 
The search criteria returned 722 hits including duplicates, from which 5 new studies 
were included in this review. An additional study, published after the search date 
was identified and included. Combined with the previous search, a total of 35 
studies describing physical interventions for FMD were identified, published from 
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1970 to 2016, these are presented in Table 3.2. These studies represent a pooled 
population of 564 subjects. The majority of studies took place in an inpatient 
setting, with only 4 studies set in outpatients. There was only one RCT, which was a 
cross over design.73 There was one cohort study with a historical control group,75 
the remaining studies were case series (n=25) and single case studies (n=8). Meta-
analysis was not considered possible due to limitations in the reporting of the 
studies and the inconsistent use of outcome measures. A narrative analysis was 
therefore conducted. Studies with subject numbers greater than 10 (n=12 studies) 
are described in more detail.
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Table 3.2. Studies describing physical rehabilitation of FMD, listed in order of sample size 
Reference Type Symptoms Treatment n Setting Symptom 
Duration 
Treatment 
duration 
Outcomes Follow 
up 
Demartini et 
al 201471 
Prospective 
cohort study 
 
Mixed 
movement 
disorder 
including 
weakness 
4 week inpatient 
multidisciplinary 
rehabilitation involving 
physiotherapists, 
occupational therapists, 
cognitive behavioural 
therapists and nursing 
overseen by psychiatry with 
input from neurology. 
66 IP 4.8 years 4 weeks Two-thirds of patients rated 
their general health as better or 
much better on a 5 point CGI at 
discharge, which was 
maintained at 12 month follow 
up. 45% of patients were lost to 
follow up. 
12 
months 
Jordbru et al 
201473 
Randomised 
cross over trial 
G (100%) 3 week inpatient 
rehabilitation described as 
adapted physical activity 
within a cognitive behavioural 
frame work. Intervention 
carried out by physicians, 
physiotherapists, 
occupational therapists, 
nurses and an educator in 
adapted physical activity. 
60 IP 9.5 
months 
(12.1 SD) 
3 weeks Treatment resulted in 
significant improvement in 
physical function (FMS and FIM) 
and quality of life (SF12). 
Improvements were sustained 
at 1 month and 1 year follow 
up, except for the mental 
health domains of the SF12. 
12 
months 
Czarnecki et 
al  201275 
Retrospective 
cohort study 
with historical 
control group 
  
G (40%) 
MD(43%) 
W (10%) 
Physical therapy and 
occupational therapy with a 
motor reprogramming 
approach. 
60 
 
OP 17 month 
median 
(range 1-
276) 
5 days  68.8% markedly improved or 
nearly normal at end of 
treatment, 60.4% at follow up 
(self rated). This group was 
compared to a historical control 
group of 60 patients who did 
not receive treatment. 21.9% of 
this group were markedly 
improved at follow up. 
25 
month 
median  
(range 
10 -64) 
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Nielsen et al 
20151 
Prospective 
cohort study 
G (34%) 
D (25%) 
T (19%) 
W (9%) 
MD (13%) 
 
5-day specialist physiotherapy 
based programme consisting 
of education and movement 
retraining with a self-
management focus. 
47 IP 5.5 years 
(SD 6.7) 
5 days 65% rated their symptoms as 
“very much improved” or 
“much improved” on a 7 point 
CGI scale at the end of 
treatment. This reduced to 55% 
at 3 month follow up. This 
corresponded with significant 
improvement physical scales 
and self-reported outcome 
measures. 
3 
months 
Moene et al 
200283 
2 arms of a 
randomised 
controlled trial 
(considered here 
as an 
uncontrolled 
cohort) 
W (84%) 
G (56%) 
MD (42%) 
T (16%) 
D (18%) 
* 
Hypnosis and MDT 
rehabilitation compared with 
MDT rehabilitation alone.  
45 IP 2 months-
22 years 
(Mean 3.9 
years) 
12 weeks Both groups improved 
significantly, the addition of 
hypnosis did not affect 
outcome. 65% of patients were 
substantially to very much 
improved post-treatment and 
83.7% at follow up. 
6 
months 
Shapiro and 
Teasell 
2004111 
Prospective 
cohort study 
W (72%) 
G (31%) 
* 
Behavioural intervention 
including physiotherapy. A 
standard programme is 
compared to a strategic 
double bind where patients 
are told that recovery 
constituted proof of an 
organic aetiology and failure 
to recover was proof of 
psychiatric aetiology. 
Outcomes were reported as 
recovery, significant 
improvement or no 
improvement. 
39 IP 9 Acute 
(less than 
2 months) 
28 
Chronic 
(more 
than 6 
months) 
Not stated Standard Programme was 
effective for acute patients only 
– recovery was seen in 8 of 9 
acute patients and 1/28 
chronic. 
Patients who did not improve 
with the standard programme 
transferred to the strategic 
protocol. 
14/22 recovered. 2 patients 
who had the strategic protocol 
only recovered. 
 
Nil 
Matthews et 
al 2016112 
Prospective 
cohort study 
G & W Inpatient physiotherapy that 
included an explanation of 
35 IP 2 week 
median 
Mean 
length of 
Patients had a mean of 11.2 
physiotherapy sessions (range 
Nil 
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the diagnosis, demonstration 
of reversibility of symptoms 
and movement retraining. 
Half the patients also had 
intervention from a 
neuropsychologist or liaison 
psychiatrist.  
(range 1 
day-10 
years) 
stay 18 
days 
(range 2-
62 days) 
2-43). The mean MRMI went 
from 20 to 37 post-treatment 
(max score 40). 
Heruti et al 
2002113 
Retrospective 
cohort of 
consecutive 
patients 
W (100%) MDT rehabilitation 34 IP Not 
stated  
Not stated 26% complete recovery, 
29% partial recovery, 
44% unchanged, 5 patients 
were re-diagnosed as 
malingering. 
Nil  
McCormack 
et al 201372 
Retrospective 
cohort of 
consecutive 
patients 
Motor 
conversion 
disorder 
Multidisciplinary 
rehabilitation on a specialist 
neuropsychiatric unit, median 
length of stay was 101 days. 
The core treatment was from 
neuropsychiatrists, 
psychologists, 
physiotherapists, 
occupational therapists and 
speech therapists if needed. 
33 IP 48 
months 
medium 
(IQR 19–
72) 
Median 
length of 
stay 101 
days 
Significant improvement in 
Modified Rankin Scale. There 
was also an increase in the 
proportion of patients 
mobilising unaided and an 
increase in proportion of 
patients independent in 
personal activities of living.  
Nil 
Saifee et al 
201274 
 
Retrospective 
cohort of 
consecutive 
patients 
MD (68%) 
W (16%) 
MDT rehabilitation 26 IP 68% had  
symptoms 
for more 
than 36 
months 
Mean 24 
days 
At long term follow-up 58% of 
patients reported that the 
programme had been helpful or 
very helpful. 
Mean 7 
years 
Ferrara et al 
2011114 
 
Prospective 
cohort study 
 
T (68%) 
D (63%) 
G (37%) 
* 
Daily TENS to produce a 
tingling sensation without 
muscle twitch or pain. 
19 OP Mean 46 
months, 
66 (SD)  
Not stated Statistically significant 
improvement in the PMDRS 
after an average of 6.9 months 
(SD 4.7) of treatment. Symptom 
resolution occurred in 
approximately 25% of subjects. 
Nil 
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Dallocchio et 
al 2010115 
Prospective 
cohort study 
MD (75%) 
T (25%) 
Group walking exercise 
programme, 3 times/week. 
16 OP 3-44 
months 
(median 
13) 
12 weeks Marked improvement in 62% of 
patients. 
Nil 
Espay et al 
2014116 
Proof of 
concept, 
prospective 
cohort study 
T (100%) Tremor “retrainment” using 
visual biofeedback  
10 OP 4.3 years 
(2.9 SD) 
range 0.8-
10 years 
Training 
sessions 
over 1-3 
days, 
equating 
to 2-6 
hours 
Resolution of tremor in 3 
subjects which remained at 
follow up of 4-5 months. Two 
subjects remained improved at 
4-6 months. The remaining 5 
patients relapsed.  
3-6 
months 
Speed 
1996117 
Retrospective 
cohort study of 
consecutive 
patients 
W (100%) MDT rehabilitation 10 IP 0.5-112 
weeks 
4-22 days 
(mean 12) 
All had Improved FIM-gait score 
post-treatment. 7 out of 9 
patients maintained 
improvement at follow up. 
7-36 
months 
(mean=2
9) 
Moene et al 
1998118 
Retrospective 
cohort study of 
consecutive 
patients 
W (50%) 
D (25%) 
G (12.5%) 
D (12.5%) 
MDT rehabilitation including 
hypnosis. 
8 IP & 
OP 
1.5-19 
years 
(Mean 9 
years) 
4 weeks-6 
months IP, 
OP 
sessions 2-
66 
One patient dropped out, the 
remaining 7 had good recovery. 
3 had relapsed on follow up, 2 
of these resolved with 
outpatient hypnosis. 
7-0.5 
years 
(mean 
2.6 
years) 
Weiser 
1976119 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) Persuasion, suggestion, 
general rhythmic exercises 
and emotional support 
provided by a physiatrist. 
7 OP 1 week-1 
year 
1-3 
sessions 
over 2 
weeks 
Symptom removal in 5 of 7 
patients. 
1 
month-7 
years 
Delargy et al 
1986120 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) Physiotherapy focused 
rehabilitation. 
6 IP 1-24 yrs 2-10 
weeks 
All improved and were 
independent in activities of 
daily living at follow up. 
8-14 
months 
Withrington 
and Wynn 
Parry 
1985121 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) MDT rehabilitation 5 IP 1-6 yrs 1-6 
months 
Improved 6 
months-
3 years 
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Cardenas et 
al 1986122 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) MDT rehabilitation with 
behavioural shaping. 
4 IP & 
OP 
1-4 years Unclear in 
each case. 
Subject 1, 
12 weeks. 
Improvement but not 
resolution of symptoms. 
2-5 
months 
Fishbain et 
al 1988123 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) EMG Biofeedback with MDT 
rehabilitation. 
4 IP 3.5-13 
years 
2 weeks-
3.5 
months 
Functional improvements and 
relinquished assistive devices 
for walking. 
4 
months-
4 years 
Silver 
1996124 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (50%) 
MD (25%) 
 
MDT rehabilitation 4 IP Acute to 3 
months 
Not stated Improved Nil 
Watanabe et 
al 1998125 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) MDT rehabilitation 4 IP Acute  Mean 11 
days 
All improved. Nil 
Teasell and 
Shapiro 
1994103 
Retrospective 
cohort study of 
non-consecutive 
patients 
W 1 
MD 2 
MDT rehabilitation with 
“double bind”. 
3 IP 2.5-10+ 
years  
5 weeks-4 
months 
Some improvement, one 
“completely well”. 
2 
months-
2 years 
Behr 1996126 Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) MDT rehabilitation 3 IP 2-4 yrs 2-4 
months 
All improved Nil  
Ness 2007127 Retrospective 
cohort study of 
non-consecutive 
patients 
MD 2 
W 1 
MDT rehabilitation 3 IP 1 day-2 
months 
6-9 days 
 
All patients improved.  3 
months 
Trieschmann 
1970128 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) MDT rehabilitation 3 IP 18 
months-6 
years 
4-6 weeks Improved, 2 patients had 
relapses that resolved with 
treatment. 
2 years 
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Abbreviations: W=Weakness/Paralysis; MD= Movement Disorder (mixed); T=Tremor; D=Dystonia; G=Gait; IP=Inpatient; OP=Outpatient; FMS=Functional Mobility Scale; 
MRMI=Modified Rivermead Mobility Index; FIM=Functional Independence Measure; SF12=Short Form 12; CGI=Clinical Global Impression; PMDRS=Psychogenic Movement 
Disorders Rating Scale; MDT=Multidisciplinary Team; TENS=Transcutaneous Electrical Nerve Stimulation; EMG=Electromyography. * Unable to classify the primary motor 
disorder as frequency of symptoms were listed.
Vatine et al 
1996129 
Retrospective 
cohort study of 
non-consecutive 
patients 
W (100%) MDT rehabilitation 2 IP 6 weeks-6 
months 
4-6 weeks Subject 1 mild residual 
weakness and symptom free at 
follow up; Subject 2 symptom 
free. 
4 weeks-
6 
months 
Glennon 
2011130 
Retrospective 
case study 
T Physiotherapy with a focus on 
gait re-education. 
1 IP 4 weeks Not stated Ongoing improvement Nil 
Atan et al 
2007131 
Retrospective 
case study 
W Physiotherapy with TENS and 
faradic stimulation 
1 IP Approxim
ately 6 
weeks 
7 days Complete resolution, 
maintained at follow up. 
1 month 
Oh et al 
2005132 
Retrospective 
case study 
G Physiotherapy with a focus of 
functional training. 
1 IP Not 
stated 
5 weeks Improved  Nil 
Sullivan and 
Buchanan 
1989133 
Retrospective 
case study 
W MDT rehabilitation 1 IP 23 years 4 weeks Improved mobility and 
independence in ADL. 
Dysphonia did not respond to 
treatment. Sustained at follow 
up. 
1 year 
Khalil et al 
1988134 
Retrospective 
case study 
W Functional electrical 
stimulation and MDT 
rehabilitation. 
1 IP 4 years 2 weeks (3 
sessions a 
week) 
 
Resolution of symptoms, 
sustained at follow up. 
3 years 
Findlater  
1986135 
Retrospective 
case study 
W MDT physical and behavioural 
treatment programme. 
1 IP 2 years of 
physical 
symptoms 
35 weeks Independent in mobility 
without aids and all activities of 
daily living. 
7 
months 
Klein et al 
1985136 
Retrospective 
case study 
G MDT rehabilitation 1 IP 16 years 11 weeks Attained all goals including 
normal gait pattern. 
2.5 years 
MacKinnon 
1984137 
Retrospective 
case study 
W Physiotherapy with 
psychiatric treatment 
1 IP 1 week 6 weeks Return to walking Nil 
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3.2.1 Randomised Controlled Trial of Physical Rehabilitation 
Jordbru et al 2014 
Jordbru et al73 conducted the only randomised trial reported in the literature. In this 
study they tested a 3-week inpatient rehabilitation programme on 60 patients with a 
functional gait disorder. Patients were randomised to receive either the treatment or a 
4-week waiting list control. After the 4 weeks, the controls crossed over into the 
intervention group. The exclusion criteria were: age over 69 years, symptom duration 
greater than 5 years, presence of a comorbid medical condition and if the patient did 
not want to take part in active rehabilitation. Patients were also excluded if they 
“needed inpatient psychiatric treatment”, a criterion that was not operationalised. The 
intervention was described as adapted physical activity with an educational and 
cognitive behavioural frame of reference. The treatment team consisted of a 
physician, physiotherapist, occupational therapist, nurses and an educator in adapted 
physical activity. Treatment included sporting activity such as bicycling, canoeing and 
indoor rock climbing. The authors describe using a behavioural approach in treatment, 
where improvement and desired behaviours were positively reinforced and positive 
reinforcement was withheld where no improvements were made. 
Of the 60 randomised patients, 46 were followed up at one month and 40 at one year. 
Eighty percent were women, 20% were in receipt of a disability pension, 64% 
employed and the mean symptom duration was 9.5 months (SD 12.1). Subjects were 
assessed using the Functional Mobility Scale, the Functional Independence Measure 
(FIM) and the Short Form 12 (SF12). Data were collected at baseline, admission, 
discharge, 1 month and 1 year. Data were analysed using a covariance matrix model, 
to determine a treatment effect (the difference between treatment and no treatment 
within subjects, as each patient was exposed to a period of treatment and no 
treatment) and a carry over effect (treatment effect at one year follow up). The 
Functional Mobility Scale gives a score between 3-18, based on assistive device 
required to walk over 5, 50 and 500 metres, with a higher score indicating better 
function. The mean difference between treatment and no treatment was 6.9 
Functional Mobility Scale units (95% CI 5.5, 8.3) and the carry over effect was 8.1 units 
56 
 
(95% CI 5.9, 10.3). The FIM is an 18-item scale of physical and cognitive disability, 
scored according to the level of assistance required to complete various activities of 
daily living. Each item is scored from 1-7, giving a score range of 18-126, with higher 
scores equating to more independence. The treatment effect for the FIM was 8.4 units 
(95% CI 5.2, 11.7) and the carry over effect was 9.2 (95% CI 5.4, 13.1). The SF12 is a 
condensed version of the Short Form 36, a health related quality of life questionnaire. 
The questionnaire yields a physical health and a mental health composite score, each 
out of 100. For the physical health score, there was a significant treatment effect (11.7 
units, 95% CI 7.2, 16.1) and carry over effect (14.1 units CI 5.9, 22.2). The mental 
health score had a more modest treatment effect of 6.9 units (95% CI 2.1, 11.8) and 
the carry over score was not significant.  
This study provides the first controlled evidence of physical rehabilitation for FMD. 
Specifically, this study suggests that multidisciplinary treatment with a physical focus, 
combined with a symptom explanation and positive reinforcement can provide 
improvement lasting at least 4 weeks in functional gait disorders of less than 5 years 
duration, in patients without significant psychopathology. The cross over design limits 
the control-intervention comparison to 4 week follow up only. This invites criticism 
over the necessity of treatment, in that both groups may have improved 
spontaneously over the follow up period without intervention. The counterpoint to 
this argument is the large body of evidence that patients with FMD tend to remain 
symptomatic without treatment,70 while in this study benefit from treatment was 
maintained at one year. Another limitation is that a third of participants were lost to 
follow up (23% at one month and 33% by one year). The authors conducted a 
complete case analysis, meaning that subjects with missing data were excluded from 
analysis, potentially biasing the results. The authors justify this approach with a 
comparison to an observed data analysis, which suggested the dropouts did not result 
in a significant selection bias. An additional limitation was that the assessor was not 
blinded to patient group. 
3.2.2 Cohort Studies of Physical Rehabilitation n>10 
Czarnecki et al 2012 
57 
 
Czarnecki and colleagues75 retrospectively report the outcome of 60 consecutive 
patients following an outpatient 5-day physical rehabilitation programme, consisting 
mostly of physiotherapy and occupational therapy, for functional movement disorders. 
To be considered for treatment, patients had to have a clinically established diagnosis 
and to have completed diagnostic testing. The functional movement disorders 
included gait disturbance, tremor, hyperkinetic movements and paresis. An important 
part of the treatment was the initial counselling of the patient. The important 
elements of this were: expressing confidence in the likelihood of success of treatment, 
a symptom explanation that was described as “a disconnect between brain and body” 
and an explanation of therapy as re-establishing this connection. The treatment 
consisted of 5 consecutive days of twice daily physiotherapy and occupational therapy. 
Treatment was described as motor reprogramming by establishing elementary 
movements and building on those. This included distracting motor tasks such as 
tapping to extinguish abnormal movements. Repetition was described as important to 
reinforce gains and a behavioural component included positive reinforcement of 
desired behaviour and ignoring abnormal movements. A psychological or psychiatric 
evaluation was completed prior to treatment. The aim of the evaluation was to 
identify possible contributory factors and psychological issues that might interfere with 
the programme and recovery, but this did not form part of the intervention. 
Outcome was assessed using a patient rated 5-point ordinal scale at the end of 
treatment and by mail or telephone at follow up of median 25 months. The scale range 
was: no improvement or worse (25% improvement), mild improvement (26-50% 
improvement), moderate improvement (51-75% improvement), marked improvement 
(76-95% improvement), almost completely normal/in remission (>95% improvement). 
Based on these ratings, a good outcome was defined as a marked improvement or 
better. At the end of treatment, 69% of patients rated themselves as having had a 
good outcome. Eighty percent of patients were followed up at a median of 25 months, 
of these 60% continued to have a good outcome and 25% were considered treatment 
failures, being no better than mildly improved.  It was reported that 87.5% of patients 
continued to have some degree of abnormal movements. The cohort were mostly 
chronically affected, the median symptom duration was 17 months (range 1-276) and 
30% were “work disabled”. Forty-three percent had a history of depression and 41% 
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had a psychiatric diagnosis such as anxiety or personality disorder. It was reported that 
21 cases were excluded from this analysis due to departure from the treatment 
protocol, no further information was given. The authors compared this treatment 
group to a historical control group who did not undergo the treatment for reasons 
such as lack of insurance, logistical reasons such as work, travel or family issues, the 
treatment had not yet commenced or non-acceptance of the diagnosis. The treatment 
group had significantly better outcomes. Arguably the control group is not a 
comparable group as it is likely to be affected by selection bias towards a worse 
outcome, especially due to the inclusion of subjects not accepting the diagnosis. 
Disregarding the historical control group and allowing for the limitations of this study, 
it provides uncontrolled evidence that physical rehabilitation can provide 
improvement lasting up to one year in selected patients. 
 
Nielsen et al 2015 
This paper presents the outcomes of our (Mark Edwards and Glenn Nielsen) 5-day 
physiotherapy programme for FMD in a prospective cohort of 47 consecutive 
patients.1 The patients were admitted to the day hospital and those who did not live a 
commutable distance from the hospital stayed in a nearby hotel. The treatment was 
based on a symptom explanatory model for FMD highlighting self-focussed attention 
and expectations about movements as key aetiological mechanisms. Education using 
the symptom model formed the basis of the treatment and physical retraining aimed 
to normalise movement by progressive task retraining with redirected attention. The 
cohort was comparable to those in other studies in that 66% were women, the mean 
age was 44 and the mean symptom duration was 5.5 years (SD 6.7, range 2 months-40 
years). 
 
Outcome was assessed using a number of assessments. We used a 7-point clinical 
global impression scale to assess the patient’s perception of change. The scale ranged 
from very much worse to very much improved. Based on this scale, 65% of patients 
were judged to have had a good outcome with treatment (a self rating of much 
improved or very much improved). This was reduced to 55% at 3-month follow up. In 
the SF36 there was a statistically significant improvement in the physical function and 
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physical role domains only (physical function: 26.1 SD 25.6 baseline, 35.0 SD 27.1 
follow-up, p=0.001; physical role: 12.8 SD 26.5 baseline, 27.7 SD 31.4 follow-up, p= 
0.001). There was also a corresponding change in the (observer rated) physical 
assessments the Berg Balance Scale and 10 metre timed walk. This study provides 
further uncontrolled evidence of the effectiveness of physical rehabilitation, and 
uncontrolled evidence for treatment delivered by a physiotherapist. In addition it 
quantifies a treatment effect in the form of improved scores on the SF36 physical 
domains, Berg Balance Scale and 10 metre timed walk. 
Moene et al 2002 
Moene et al 200283 report the results of a randomised controlled trial of the addition 
of hypnosis to a 12 week inpatient multidisciplinary treatment for motor conversion 
disorder (which included paresis, gait disturbance, tremor and jerks). No additional 
effect was found for hypnosis and for the purposes of this review, the study is being 
counted as uncontrolled evidence for multidisciplinary treatment. The rehabilitation 
team consisted of a nurse, group therapist, creative therapist, sports therapist and 
physiotherapist. The group therapy consisted of psychological therapies (such as group 
psychotherapy and social skills training), creative therapy and sports. The 
physiotherapy was individual to the patient and described as step by step training of 
the lost function. When symptoms affected gait, patients were restricted to a 
wheelchair to prevent reinforcement of abnormal movement. Physiotherapy lasted 
one hour, 3 times a week during the first 6 weeks and 2 hours a week during the last 6 
weeks. Patients were given homework and practiced their exercises 5 times a week. 
The patients were 77% female, with a mean symptom duration of 47 months (SD 4.5 
months, range 2 months to 22 years). The primary outcome measure was a video 
rating scale designed for the study, the Video Rating Scale for Motor Conversion 
Symptoms (VRMC). The scale rates symptoms during standardised movement on a 7-
point Likert scale ranging from 1: unchanged to 7: very much improved. Based on this 
scale, 65% were judged to be “substantially to very much improved” at the end of 
treatment. This number increased to 84% at 6 month follow up.  
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Dallocchio et al 2010 
The study by Dallocchio et al 2010115 stands out as one of only a handful conducted in 
an outpatient setting. The intervention was low to medium intensity progressive 
exercise in the form of outdoor walking in groups, conducted 3 times a week over 12 
weeks. Participants (n=16) were required to be habitually sedentary at baseline and 
have functional movement disorders of mild to moderate severity. The primary 
outcome measure was the Psychogenic Movement Disorders Rating Scale (PMDRS), a 
standardised assessment of symptom severity scored blindly by video. There was a 
marked improvement in the PMDRS in 10 patients (62%), 2 of these patients 
experienced complete symptom resolution. In addition there was a statistically 
significant improvement in self-reported measures of anxiety and depression, 
improved VO2 max (maximal oxygen uptake) and body mass index. There was no 
follow up. As with the other studies described here, these results are interpreted with 
caution due to the relatively small sample size and lack of control. The cohort had 
characteristics that may be associated with a good prognosis, such as relatively short 
symptom duration (mean 15.5 months) and mild to moderate symptom severity. 
Taking into account these limitations, this study suggests that simple interventions 
such as nonspecific exercise and/or exercising in groups may be helpful for patients 
with mild to moderate symptoms who are habitually sedentary. 
Shapiro & Teasell 2004 
Shapiro & Teasell 2004111 retrospectively reported outcomes of 39 consecutive 
patients who completed a rehabilitation protocol for “non-organic motor disorder”. 
Patients were initially entered into a standard rehabilitation programme where they 
were told that regardless of the origin of their disorder, their current symptoms were 
maintained by abnormal muscle patterns that had developed over time and that full 
recovery was possible with intensive inpatient rehabilitation. Treatment consisted of 
daily physiotherapy combined with positive reinforcement. If after 4 weeks there was 
no progress with this treatment, a strategic protocol was implemented, which involved 
telling patients that full recovery constituted proof of a physical aetiology and failure 
to recover constituted evidence of a psychiatric aetiology. It was explained to the 
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patient that their slower than expected progress was due to either the presence of a 
psychiatric problem called conversion disorder, or there was an aspect of their 
treatment programme that required modification, and once made, progress would be 
rapid and recovery complete.  This change to treatment was “a minor and 
inconsequential change in physiotherapy”. There were 9 patients with acute 
symptoms (less than 2 months duration) and 30 patients with chronic symptoms 
(greater than 6 months). The standard protocol was effective for 8 of the 9 acute 
patients and only 1 of 28 chronic patients. Twenty-two patients went on to the 
strategic protocol (one acute, 21 chronic). The strategic protocol was reported as 
effective for 17 of 24 patients (71%) (some patients started in the strategic protocol). 
Of the 21 chronic patients who did not improve with the standard protocol and went 
on to the strategic protocol, 13 (62%) were completely or almost completely symptom 
free at discharge. This study did not use any standard assessment measures, outcome 
was subjectively judged by the authors as complete/near complete improvement, 
significant improvement, or minimal/no improvement and there was no follow up. It is 
therefore difficult to draw any conclusions or lessons from this study. The strategic 
protocol could be considered as deceptive, in that the clinicians were not upfront with 
the patients. 
Matthews et al 2016 
Matthews et al 2016112 present a prospective case series of 35 consecutive patients 
with functional gait disorder and functional weakness who were referred to 
physiotherapy in an acute neurology ward over a 23 month period. On the whole, the 
cohort had a relatively acute presentation, with a median symptom duration of 2 
weeks (range 1 day to 10 years) and 60% had had symptoms for less than one month. 
The mean number of physiotherapy sessions was 11.2 (range 2-43) and the mean 
length of stay was 18 days (range 2-62). Treatment included an explanation of the 
diagnosis, demonstration of reversibility of symptoms and movement retraining with 
distraction. The Modified Rivermead Mobility Index (MRMI) was recorded at baseline 
and discharge, there was no follow up. Half the patients also received intervention 
from a neuropsychologist or liaison psychiatrist, it was not stated how it was 
determined who received this additional treatment. The mean MRMI increased from 
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20 to 37 points, out of a possible 40. A ceiling effect was evident with this measure. 
Those with symptom durations greater than one month made less gains on average 
than the patients with more acute symptoms, but both groups made a statistically 
significant improvement. The addition of psychological intervention in this cohort did 
not have a statistically significant effect on outcome, as measured by the MRMI. This 
study demonstrates a large improvement in mobility score and differs from most of 
those reported here in that treatment was conducted on an acute hospital ward. This 
setting allows early treatment which may be advantageous given that long symptom 
duration has been associated with poor prognosis.70 Follow up and control data from 
further studies is needed in order to be able to comment on the benefits of early 
intervention.  
Heruti et al 2002 
Heruti et al 2002113 report the results of 34 consecutive patients admitted to one of 
two rehabilitation centres in Israel, over a 27 year period, with suspected spinal cord 
injury, but later found to have no organic basis for their symptoms. The diagnosis of 
conversion disorder was made after rehabilitation had commenced and four patients 
were re-diagnosed as malingering. The spinal rehabilitation setting and perhaps other 
social and political factors may account for the higher percentage of male patients 
(74%). Treatment was provided by a multidisciplinary team consisting of physiatrists 
(rehabilitation physician), nurses, physiotherapists, occupational therapists, social 
workers and psychologists, with consultation from psychiatry. Outcomes were 
reported in terms of complete recovery, partial recovery and unchanged. Standardised 
outcome measures were not reported. Excluding the malingerers, 8 patients had 
complete recovery (27%), 8 had partial recovery (27%) and 14 patients did not improve 
(46%). There was no additional detail on treatment approach nor length of stay.  
Specialist Multidisciplinary Treatment Programmes 
Outcomes from two NHS specialist treatment programmes have been reported. These 
programmes comprise treatment from a multidisciplinary team, usually involving 
psychiatry, psychology (or psychological therapy from specialist cognitive behavioural 
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therapists), occupational therapy and physiotherapy. Some have additional input from 
neurology and speech and language therapy. These specialist programmes tend to 
accept patients with more significant comorbidity, such as higher physical disability 
and psychopathology that are excluded from some of the studies described above.  
Demartini et al 201471 report results from the 4 week inpatient treatment programme 
at Queen Square, London, in a prospective cohort of 66 consecutive patients. At one 
year follow up, there was a significant improvement with large effect size in the Health 
of the Nation Score (HoNOS), a clinician rated scale of outcome used in mental illness. 
In a patient reported clinical global impression scale at 12 months, 67% rated their 
general health as better or much better (points 5 and 4 on a 5-point Likert scale) and 
64% rated their main symptoms as better or much better. There was also 
improvement in other self-report assessments. Only 55% of the 66 patients were 
followed up. In a separate cohort from the same treatment programme, a long term 
follow up assessment (median 7 years, IQR 4.5-8.5) was conducted via questionnaire.26 
Fifty-eight percent reported that the programme had been helpful or very. There was 
no change in employment status.  
McCormack et al 201372 report the results from the inpatient rehabilitation 
programme for conversion disorder at the Lishman Neuropsychiatry Unit, The 
Maudsley Hospital, London. In this retrospective review, 33 consecutive patients, were 
assessed pre and post-treatment using the Modified Rankin Scale, a 6-point scale 
ranging from 0=no symptoms to 5=severe disability, bedridden, incontinent and 
requiring constant nursing care and attention. There was a statistically significant 
improvement in mean scores from 3.64 (SD 0.86, range 2-5) to 2.83 (SD 0.85, range 2-
5). There were also improvements in mobility and independence with activities of daily 
living. There was no follow up. This programme did not have a predetermined duration 
of treatment, the median length of stay was 101 days (IQR 84-130). 
3.2.3 Patient Characteristics 
Gender, Age and Symptom Duration  
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The published research on physical interventions for FMD includes 564 subjects, across 
35 studies, of which 79% were women. The mean age and symptom duration at start 
of treatment was calculated where data was available. The mean age from 429 pooled 
subjects was 36 and the mean symptom duration from 336 pooled subjects was 36.5 
months.  
Disability 
Level of disability or symptom severity at baseline may impact on prognosis and 
potential benefit gained from rehabilitation. This is difficult to quantify due to varying 
biological, psychological and social influences on disability amongst individuals. It is 
therefore often poorly described in studies. Baseline SF12/36 physical function scores 
may be a useful indicator of disability. This was reported in Jordbru et al (2014)73, 
giving a value of 26.9 and Nielsen et al (2015)1 with a value of 26.1. To provide some 
context to these values, normative data for a similar age range (35-44 years) is 89.4 
(SD 16.1) for women and 91.9 (SD 14.5) for men.138 Mobility aid use is reported in 
some studies as a measure of disability, usage rates ranged from 63%73 to  85%.72 
Employment status can be used as a surrogate measure of physical disability and 
mental health, though this will also reflect other factors such as comorbidity, 
chronicity, age and the social and welfare climate in the host country. A number of 
studies reported the percentage of patients not working due to ill health. These 
numbers are Jordbru et al (2014)73 20%, Czarnecki et al (2012)75 30% and Nielsen et al 
(2015) 64%. This data is presented in Table 3.3. 
Table 3.3. Comparison of measures of disability at baseline 
 SF 12/36 
Physical 
Function 
Score 
Wheelchair 
dependency 
Mobility aid 
use including 
wheelchairs 
Not working 
due to ill 
health 
Jordbru et al 201473 26.9 25% 63% 20% 
Nielsen et al 20151 26.1 - - 64% 
Czarnecki et al 201275 - - - 30% 
Moene et al 200283 - - 82% - 
McCormack et al 201372 - 61% 85% 88%* 
* This figure did not differentiate unemployment due to ill-health from alternative reasons. 
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3.2.4 Symptom Phenomenology 
In the literature, motor symptom phenomenology was usually broken down into the 
following categories: functional gait disorder, tremor, weakness/paralysis, dystonia or 
mixed movement disorder. The RCT by Jorbru et al (2014)73 exclusively looked at 
functional gait disorders. The remainder of the studies with subject numbers greater 
than 10 had cohorts of mixed symptom phenomenology, except for Heruti et al 
(2002)113, which included symptoms due to suspected spinal injury only (and later 
found to have no organic basis). There is insufficient data to comment on whether one 
type of symptom responds more positively to physical rehabilitation or whether 
phenomenology may affect prognosis. There is however better evidence for the 
physical treatment of functional gait disorders based on the controlled study design by 
Jordbru et al (2014).73 
Classification of FMD phenomenology is not standardised and there is some cross over 
between categories. For example, a functional gait disorder may be comprised of 
functional tremor, weakness and/or dystonia. Classification may be unimportant if 
symptoms have a similar pathophysiological basis and respond similarly to treatment. 
However, there are reasons to suggest that this may not be the case, in particular for 
the specific symptom of fixed-functional dystonia. This symptom is often considered 
separately from other FMD for a number of reasons. Firstly, there is some 
disagreement over whether it fits more with an organic or functional aetiology. Also 
because it commonly crosses over with the diagnosis of complex regional pain 
syndrome.65 No rehabilitation study has specifically looked at fixed-functional dystonia 
and it is unclear if studies have included patients with fixed-functional dystonia but 
classified them under labels such as dystonia or mixed movement disorder.  
3.2.5 Treatment Parameters: Setting, Duration & Frequency 
The majority of the 35 studies were conducted in an inpatient setting, with only 5 
accounts of outpatient treatment,75,114–116,119 although some older studies described 
outpatient follow up after inpatient treatment.83,122 There were 2 studies of intensive 
treatment set over 5 consecutive days in either an outpatient75 or day hospital1 
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setting, with patients staying in a nearby hotel. This may be considered an 
intermediate step between inpatient and outpatient treatment. It is unclear if setting 
influences outcome, but an inpatient setting may enable higher intensity treatment 
regimens. 
There were 6 purpose designed rehabilitation programmes for FMD, in all but one, 
length of stay was dictated by protocol. These were 12 weeks,83 4 weeks,71 3 weeks,73 
and 5 days in length.1,75 One multidisciplinary inpatient programme had an open 
ended admission, the median length of stay was 101 days (IQR 84-130 days).72 
Treatment provided outside of specialist programmes reported length of stays ranging 
from 4 days117 to 8 months.135 It is therefore not possible to accurately define and 
compare the intensity of treatments based on the available data.  
Outpatient treatments included; 5 consecutive days of physiotherapy and occupational 
therapy,75 a group walking programme, which took place 3 times a week over 12 
weeks, 115 a tremor retraining with biofeedback study in which subjects attended 1 to 
3 days of training equating to 2-6 hours116 and a study of transcutaneous electrical 
nerve stimulation (TENS), in which patients were set up with a device and instructed to 
use it daily for 30 minutes over 4 months.114  
3.2.6 Composition of treatment 
Explaining the Diagnosis and Education 
The method of discussing the diagnosis with patients was considered an important 
part of treatment in several studies. In a previous literature review110 we categorised 
this approach into 3 groups. The first and most common was a direct approach that 
seeks to explain symptoms. Some explanations emphasised the importance of 
psychological factors, while others were skewed towards biological factors, such as “a 
disconnect between body and mind”75 or the role of self-focussed attention in 
disrupting movement.1 Most studies used a direct approach. The second approach was 
called a deceptive approach. In this, a diagnosis of FMD/conversion disorder was 
made, but deliberately withheld from the patient. Instead patients were presented 
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with a double bind, where they were told that if they recovered with rehabilitation it 
constituted evidence of a physical aetiology. Conversely, non-recovery was evidence of 
a psychological cause for their symptoms, requiring long term psychiatric treatment. 
Only 2 studies (from the same authors) were clearly deceptive.103,111 The third 
approach was described as a constrained approach, where no attempt was made to 
explain the origin of their symptoms and a structural disease process was not ruled 
out. Six studies followed this approach.113,120,124,133,135,137 These tended to be older 
studies and they were not part of treatment programmes set up specifically for FMD. 
Two studies described symptom education as being central to the intervention.1,112 
Overarching Principles of Treatment 
Most studies described the importance of following broad principles that underpinned 
the treatment. See Table 3.4 for a list of commonly described treatment principles. 
One of the most prominent principles described in the literature is the behavioural 
approach to treatment, where positive behaviours and asymptomatic movement are 
praised and reinforced with attention, whilst undesirable behaviours and symptomatic 
movement are ignored.75,83,103,111,117,120–122,124–130,132,133,135,136 Shapiro and Teasell (2004) 
described how in their initial treatment protocol, deep rest was prescribed for patients 
who failed to meet their goals111. This was considered an operant intervention, where 
all reinforcement for failure to progress was withdrawn by confining the patient to 
their bed without stimulation such as television, visitors or telephone contact. After a 
trial with 3 patients, they concluded that deep rest was unnecessary and removed it 
from their protocol. In some studies, behaviour modification was a dominant part of 
the intervention,127 while in other it was supplemental to the other components of 
treatment.73,75 
The influential early paper by Trieschmann et al (1970), devised a treatment protocol 
for functional gait disorder which involved confining patients to a wheelchair outside 
of therapy sessions while their gait remained symptomatic.128 This was designed to 
prevent reinforcement of symptomatic movement. As the patient progressed they 
were rewarded with walking privileges. This approached was instituted in several other 
studies.83,117,122,127,132,135,136 
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Table 3.4. Commonly described overarching treatment principles 
Principles of Treatment  
Provide an explanation for symptoms1,73,75,83,115,117,121 
Follow a behavioural approach with positive reinforcement75,83,103,111,117,120–122,124–130 
Limit reinforcement of maladaptive movement patterns & behaviours83,117,122,127,128,132,135,136 
Project confidence in the treatment1,75,120 
Clear communication with patient and treating team1,75,113,127,129,130 
Goal focussed rehabilitation83,103,120,122,126–128,130,132,135,137 
Graded progression of exercise difficulty to reshape movement patterns75,128,135,136 
Use of outcome measures to quantify and motivate1,121,126,135,136 
Agree on a treatment contract/agreement at the beginning83,113,120,133,136 
Involve the patient’s family in rehabilitation83,111,124,127,128,130,136 
Allow for face saving83,111,113,126,127 
 
Physical Treatment Strategies 
Physical rehabilitation most commonly followed a motor relearning 
approach.1,75,83,111,112,117,122,127,128,130,132,136 This usually involved introducing elementary 
symptom free movements and gradually progressing the movements in stages, so that 
each stage progressively approximates normal movement. In their influential study, 
Trieschmann et al (1970) delivered this type of progressive motor learning approach in 
a very structured format.128 Several stages of movement were prescribed in advance, 
the final stage being normal walking. The patient worked their way through these 
stages, but was not allowed to progress to the next stage until the previous stages had 
been mastered and they continued to be symptom free.  
Some studies describe following treatment protocols of analogous organic conditions, 
for example stroke or spinal cord injury pathways,111,117,127,129 while others are 
structured specifically towards the diagnosis of FMD.1,71,73,75,83 Some studies described 
using distracting techniques to assist movement retraining, this included tapping or 
bouncing a balloon.1,75,126 Another treatment strategy described was positioning the 
patient on an unstable surface (such as a therapy ball) to elicit automatic postural 
responses.120,126,139 
There are few studies describing treatment strategies for functional tremor. Espay et al 
(2014), tested entrainment as a treatment approach using visual biofeedback in a 
small proof of concept study.116 The aim was to help the patient to develop volitional 
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control over the movement and bring it to a stop. This small study of 10 patients 
demonstrated improvements in tremor after three, 2-hour retraining sessions. Six 
patients reported lasting improvement at 6 months. Nielsen et al (2015) described 
retraining tremulous movement by imposing competing movements on top of the 
tremor and readjusting postures to change the frequency of the tremor.1  A mirror was 
used for visual feedback. 
Electrotherapies have a long history in the treatment of FMD and were initially used as 
aversive therapy.17 More recent descriptions of electrotherapies include TENS for 
sensory stimulus,114 electrical simulation for muscle activation and function1,131,134 and 
EMG biofeedback to retrain movement.140 Electrotherapy was described as a discrete 
intervention in only one study.114 In this study, a cohort of 19 patients with FMD were 
given a trial of TENS to elicit a sensory stimulation but not a muscle twitch. Fifteen 
patients continued to use the TENS, prescribed for 30 minutes daily for 4 months. One-
third of these demonstrated a significant improvement in their symptoms (greater 
than 50% on a symptom scale) after a single trial. At 7 months follow up there was a 
statistically significant improvement in the PMDRS, and a quarter of patients had 
complete symptom resolution. This appears to be an unusually high success rate when 
compared to other studies with a similar cohort. 
Nonspecific exercise is described as an important part of some of the interventions. It 
was central to the treatment for patients with mild to moderate FMD described by 
Dallocchio et al (2010), in the form of a group walking programme.115 In this study 62% 
of 16 patients were reported to have had a marked improvement in their symptoms 
immediately after treatment. Two studies included specialist instructors in physical 
activity,73,83 one of these included activities such as indoor rock climbing and canoeing 
as part of the intervention.73 Some studies describe using specific strengthening 
exercises.111,127,132 Different therapeutic equipment described in the literature included 
a treadmill,1 mirror,1,132 hydrotherapy,120,135 tilt table,120 parallel bars,128,130,132 
throwing and catching a ball or balloon,75,130 and a therapy ball.120 
Concurrent psychological treatment 
70 
 
Successful treatment has been described both with concurrent psychological 
therapy71,72,83,130 and without.1,75,112,115 Studies that do not include concurrent 
psychological therapy tend to exclude patients judged to have significant 
psychopathology, although it is difficult to determine exactly how the cohorts may 
differ in this regard. This is due to inconsistent use of standard psychological 
assessments and their inherent limitations. One possible comparison is the Hospital 
Anxiety and Depression Scale (HADS) scores on admission for a multidisciplinary 
treatment 15.8 (SD 8.5)71 and a physiotherapy delivered intervention 13.1 (SD 7.3).1  
3.2.7 Use of Outcome Measures 
A variety of different outcome measures have been used in the literature, these are 
listed in Table 3-5 below. Many studies did not use any standardised assessment 
measures and described outcome subjectively in terms of recovery, partial recovery or 
non-recovery, rated by the clinician.111,113 
Table 3.5: Outcome measures used in the literature 
Physical Outcome Measures 
 Functional Independence Measure (FIM) 73,117,125,127,141 
 Berg Balance Scale 1,130 
 10 metre Walk Time 1,130 
 Functional Mobility Scale 73 
 Modified Rivermead Mobility Index 112 
 Psychogenic Movement Disorders Rating Scale 114,115 
 Video Rating Scale for Motor Conversion Symptoms 83 
 Gait Abnormality Rating Scale 132 
 Measures of physical fitness (BMI, HR, VO2max) 115 
 Dynamometry 122,134,140 
 Modified Rankin Scale 72 
   
Patient Reported Outcome Measures (excluding explicit psychological measures) 
 Clinical Global Impression Scale 1,71,75 
 Short Form 36, Short Form 12 1,73 
 Work and Social Adjustment Scale 1 
 EQ-5D-5L 1 
 International Classification of Impairment Disability & Handicap 83 
 Canadian Occupational Performance Measure (COPM) 71 
 Patient Health Questionnaire (PHQ-15) 71 
 Multidimensional Health Locus of Control Form C (MHLC) 114 
 Symptom Checklist 90 83 
 Revised Illness Perception Questionnaire (IPQ) 71 
 The Common Neurological Symptoms Questionnaire (CNSQ) 71 
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Measures of Anxiety, Depression and Other Psychological Assessments 
 Hospital Anxiety and Depression Scale 1,71 
 Beck Anxiety Inventory 114,115 
 Beck Depression Scale 114 
 Hamilton Depression Scale 115 
 Health of the Nation Outcome Scale (HoNOS) 71 
 Dissociative Experiences Scale 114 
 Posttraumatic Stress Disorder Checklist (PCL) 114 
 Dissociative Experiences Scale 114 
 Fear Questionnaire 71 
   
 
3.2.8 Outcome of Treatment 
All the included studies (n=35) reported an overall positive effect of treatment in 
patients selected for rehabilitation. Some studies reported the proportion of patients 
that were judged to have had a good outcome with treatment. This was generally 
determined by a clinical global impression scale or a threshold score on a particular 
assessment. This data is presented in Table 3.6 below. 
Table 3.6. Proportion of patients judged to have had a “good outcome” with 
treatment. 
Study How Outcome was 
Assessed 
End of 
Treatment 
Follow up 
Czarnecki et al 201275 Patient rated scale 69%  60%  12 months 
Demartini et al 201471 Patient rated 5 point 
Likert scale 
72.2%  66.6%  12 months 
Moene et al 200283 VRMC by blind video 
rating 
65% 83.7%  6 months 
Nielsen et al 20151 Patient rated 5 point 
Likert scale 
64% 55%  3 months 
Dallocchio et al 
2010115 
PMDRS by blind video 
rating 
62% -  
Heruti et al 2002113 Subjective clinician 
rating of partial or full 
recovery 
55% -  
Key: VRMC=Video Rating Scale for Motor Conversion; PMDRS=Psychogenic Movement 
Disorders Rating Scale. 
 
In the randomised controlled study of 3-weeks inpatient treatment versus waiting list 
control (Jordbru et al 2014),73 there was a statistically significant improvement in  the 
assessments of support required for activities of daily living (FIM) and physical function 
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(physical domains of the SF12) in the intervention group.73  The question remains as to 
whether these were clinically important changes. The minimum clinically important 
difference (MCID) for the SF12 or SF36 has not been well established. A number of 
studies have reported values but these tend to vary considerably across 
populations.142 The change reported by Jordbru et al in the SF12 physical domain 
(11.7, CI 7.2-16.1) was considerably greater than the MCID calculated in a study of 
total knee replacement surgery (4.3, CI 3.8-4.8).143 The MCID for the FIM has only been 
studied in a stroke population, this value was 22 FIM points.144 The difference with 
treatment in Jordbru et al (2014)73 was considerably less than this MCID at 8.4.  
A number of prospective studies reported follow-up after the end of  treatment; time 
scales ranged from 3 months1 to 2 years.75 In general on-going benefit from the 
treatment was reported. Jordbru et al (2014) found that treatment effects were 
maintained at 1-year follow up, though the cross over design of this study does not 
allow comparison with a control group. Some studies reported a reduction in gains 
made with treatment over time,1,71,75 but in general the majority of patients sustained 
at least some longer-term benefit.  One study reported further improvement at follow 
up,83 this being an MDT inpatient treatment delivered over 12 weeks. Saifee et al 
(2012) reported 7 year follow up from a 4 week inpatient multidisciplinary 
rehabilitation and found that 58% of patients reported continued benefit compared to 
their recall of symptom severity prior to admission.74  
Three studies included assessments of participants’ mental health before and after 
treatment.1,71,73 Demartini et al (2014)71, evaluating a multidisciplinary treatment 
including psychiatry and cognitive behavioural therapy, reported significant 
improvements in the HADS and HoNOS. However, the physically based interventions 
studied by Jorbru et al (2014)73 and Nielsen et al (2015)1 reported no significant change 
in the mental health domains of the SF12 or SF36 respectively nor change in the HADS. 
These differences may reflect the absence of psychological therapy or other factors 
such as differences in mental health at baseline. 
Only one study has considered the cost effectiveness of rehabilitation. Nielsen et al 
(2015)1 converted the EQ-5D-5L change scores into quality adjusted life years (QALY) 
73 
 
and found a gain of 0.1 over 3 months1. If this gain was maintained at 12 months, the 
comparatively low cost intervention would most likely be considered cost effective by 
the National Institute of Clinical Excellence. This calculation was considered a 
precursory estimate of cost effectiveness only. 
3.3 Discussion 
In this systematic review, 35 studies describing physical rehabilitation for FMD were 
identified.  The overall quality of the evidence is low. There was only one randomised 
controlled trial and 10 cohort studies with subject numbers greater than 10, of these 
four were reported retrospectively. The relatively small number of studies seems to be 
at odds with the reported size of the problem in terms of cost and prognosis, as well as 
the high level of utilisation of physiotherapy/physical rehabilitation for FMD.16,145 
Despite low numbers and methodological limitations, the results from treatment 
reported in the literature are encouraging. There is controlled evidence from one 
study that physical based rehabilitation can provide at least short term improvement 
for patients with functional gait disorder without significant psychopathology and a 
symptom duration of less than 5 years.73 There is also uncontrolled evidence from 6 
relatively large (n>10) cohort studies that treatment for mixed FMD involving physical 
rehabilitation is beneficial for the majority (55-72%) of patients.1,71,75,83,113,115 This is 
supported by positive results from an additional 28 smaller cohort and single case 
studies. The effect size of physical rehabilitation on patient reported measures of 
quality of life tends to be small to medium.1,73 It appears that the majority of patients 
remain to some extent symptomatic after treatment75 and that very few patients with 
chronic symptoms return to work.74 There were no reports of significant adverse 
effects of physical rehabilitation for FMD, although this may reflect the fact that many 
studies were set within specialist services with experienced staff.  
At least some of the improvements made with physical rehabilitation appear to be 
maintained at follow up of 1 to 2 years71,73,75 and patients have continued to report 
some benefit at 7 years following multidisciplinary treatment.74 The evidence to 
support sustained improvement at follow up is uncontrolled.  
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The most appropriate outcome measures to use in physical rehabilitation of FMD 
remains unknown. The modest effect size seen with treatment may be related to a 
lack of sensitivity of standardised measures such as the SF36 in this population. 
Problems may also be encountered with ceiling effects, as was seen with the Modified 
Rivermead Index.112 Snapshot measures of physical performance and symptom 
severity, such as the Berg Balance Scale, arguably have validity and reliability issues 
due to fluctuations in symptom severity inherent within the diagnosis. Clinical global 
impression scales of perceived change have been used most regularly in the more 
recent studies. These have the advantage of being valid, quick, free to use and 
sensitive to change. However these scales are unable to quantify the impact of 
treatment, for example change to disability, and are vulnerable to confounding factors. 
There are no formal studies of the cost effectiveness of rehabilitation for FMD, but 
there is some suggestion that this may be favourable.1  
The current evidence for the benefit of physical rehabilitation may not be 
generalisable to the FMD population as a whole. Cohorts tend to be highly selected 
and patients with non-acceptance of the diagnosis, significant psychopathology, pain, 
fatigue and other comorbidities (which are commonly seen in this population) are 
often excluded from studies.1,73,75,115 It is sometimes stated that certain patients are 
not suited to physical rehabilitation for these reasons1,75 and that it is difficult to 
determine suitability for rehabilitation.71 It is also not clear if different symptom 
presentations respond differently to treatment.  
There is insufficient data to recommend one treatment approach over another, 
however what is done during the treatment does seem to matter. Two studies report 
improvement with specialised treatment following failed attempts at more generic 
physical rehabilitation.1,75 The interventions described in the literature are 
multifaceted, making it impossible to determine which are the most important 
ingredients in a treatment programme. There are however many useful ideas from 
which to design and empirically test a treatment. Explanation of the diagnosis and 
education about the disorder is likely to be important, and it forms a common part of 
the better-designed studies.1,73,75 It appears that physical rehabilitation that aims to 
retrain movement patterns in graded steps is useful and arguably more appropriate 
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than following treatment protocols for analogous neurological conditions. In addition, 
it is likely that there are important overarching principles that can support treatment, 
such as positive reinforcement, goal setting, family involvement and clear 
communication. The evidence is insufficient to determine the most appropriate 
treatment parameters in terms of setting, duration and intensity. The dominance of 
inpatient treatment studies may simply reflect research-resource distribution. 
Alternatively, there may be therapeutic benefits to inpatient treatment, such as a 
higher intensity with treatment delivered over consecutive days, as was considered 
important in some studies,1,75 but this requires further evaluation. 
It is acknowledged that there are historical accounts of treatment of FMD in the 
literature that predate database indexing and the emergence of physiotherapy as a 
defined profession. Researching historical treatment was considered outside the scope 
of this work, but its omission is a limitation of this literature review. It is also 
acknowledged that there may be mechanisms of change following physical 
rehabilitation not discussed in this paper; including placebo, face-saving opportunities 
to “relinquish” symptoms and the psychological impact of physical rehabilitation.  
3.4 Conclusions 
This systematic review found 34 cohort studies of physical rehabilitation and 1 
randomised (delayed start) controlled trial. This limited evidence base supports the 
use of physical rehabilitation for FMD. The best evidence is for inpatient rehabilitation 
for functional gait disorders and treatment within a specialist programme (as opposed 
to a generic treatment service). In view of the promising results reported in the 
literature more research is warranted. The many unanswered questions that future 
research should address include: what are the important therapeutic elements of 
treatment; what is the likely effect size of treatment; which are the most appropriate 
measures to assess outcome; who is most suitable for physically based treatment; how 
might symptom phenomenology and comorbidity affect treatment; what are the 
optimal treatment parameters in terms of setting, duration and intensity; can 
symptom relapse be prevented or minimised; and finally what is the economic benefit 
of physical rehabilitation of patients with FMD.
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Chapter 4 Development of the Study Intervention 
4.1 Introduction 
Physiotherapy is generally considered an important part of treatment for patients with 
functional motor disorder (FMD).16 Physiotherapists specialised in neurology report 
seeing these patients frequently,145 and physiotherapy forms a key part of specialist 
multidisciplinary inpatient rehabilitation, which is usually considered the gold standard 
treatment.71,72 High utilisation of physiotherapy for FMD has continued despite limited 
evidence for effectiveness and an absence of guidelines and formal descriptions of 
what physiotherapist should actually do to help such patients.110  
Lack of progress in the development of physiotherapy treatment over the years may in 
part be explained by the uncertain territory occupied by FMD. It is diagnosed by 
neurologists, but treatment has been considered the responsibility of psychiatrists and 
psychologists. This is due to the dominance of aetiological theories that consider FMD 
as a manifestation of psychopathology triggered by adverse life events. In this 
situation the role of physiotherapy is unclear, there are no obvious symptom-
mechanisms to address and physiotherapy may be considered as a placebo treatment 
or a “face saving” reason for recovery, allowing the stigma of mental ill-health to be 
side-stepped.111 Additionally, in the past, some have suggested that physiotherapy 
treatment could be harmful when physical symptoms are a manifestation of mental 
illness.146 Arguably these factors have steered the physical rehabilitation community 
away from interest in and ownership of patients with FMD.  
It is increasingly recognised that pure psychological explanations for FMD do not apply 
to a sizeable proportion of patients with FMD and that broader biopsychosocial 
aetiological models are more relevant.28 This change in perspective is reflected in the 
most recent version of the Diagnostic Statistical Manual for Mental Disorders (DSM-
5),8 where the requirement for the presence of a psychological stressor preceding 
symptom onset has been downgraded from an essential to a supportive criterion. 
However, progress towards a unified biopsychosocial understanding of FMD has been 
limited by the “black-box” of the biological sphere, which has only recently become a 
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topic of interest in the scientific literature. The past 10 years has seen important 
developments in understanding how symptoms are produced and experienced as 
involuntary.38 These “neurobiological” mechanisms provide a rationale for 
physiotherapy treatment, paving the way for a specific physically-based intervention 
targeting symptom mechanisms. 
4.2 Developing and Evaluating a Complex Intervention 
The MRC guidelines for developing and evaluating complex interventions informed the 
development of the physiotherapy intervention in this study.2 A complex intervention 
in this context is one where there are several interacting components. For example, 
and in relation to physiotherapy for FMD, the intervention depends on behaviours 
required by those delivering and receiving the intervention; the intervention has 
several targets (i.e. biological, psychological and social domains); the intervention 
requires flexibility in how it is administered; and the intervention may have a variety of 
different outcomes measured across different domains (e.g. physical disability, social 
functioning and mental health). The MRC state that development of a complex 
intervention should start with identifying an appropriate theory that underpins the 
treatment approach. 
4.3 A Theoretical Aetiological Model for Functional Motor Disorder  
The theoretical underpinning of the study intervention is described in this section. The 
theory is based on a novel neurobiological explanatory model for FMD that has 
recently been described and supported by clinical evidence and laboratory 
experiments.38,39 The model emphasises the role of attention and expectation as the 
key mechanisms that drive functional symptoms. These “neurobiological” mechanisms 
are considered alongside other evidence-based aetiological factors, including physical 
precipitating events, psychological factors, social factors, neuroplasticity, pain and 
fatigue, to produce a physically based aetiological model for FMD that is amenable to 
physiotherapy treatment. 
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4.3.1 The Role of Attention in Functional Motor Symptoms 
FMDs require attention in order to manifest. When the patient’s attention is directed 
away from their abnormal movement, the symptom resolves or reduces. This is the 
basis for many clinical signs used to make a positive diagnosis of FMD.11 For example, 
distractibility is a positive sign used to diagnose functional tremor and can be 
demonstrated by finger tapping tasks in the contralateral limb,147 see Figure 4.1. The 
tapping frequency is directed by the clinician, the patient is required to copy this and 
in order to do so they must shift their attention away from their tremor and focus on 
the tapping task. This shift in attention leads to resolution of the tremor or 
entrainment of the tremor to the frequency of the tapping task. If the patient is unable 
to shift attention from the tremor they will be unable to perform the tapping task 
(poor task performance). Tremor entrainment, tremor resolution and poor task 
performance are positive signs for functional tremor.11  
 
Figure 4.1 Tremor distraction and entrainment 
 
The role of attention has been explored in laboratory experiments. One experimental 
paradigm showed that when movement is highly predictable, patients with functional 
tremor perform worse than normal controls. Conversely when movement is 
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unpredictable, patients perform normally.148 The implication is that when movement is 
predictable, there is opportunity for attention to be focused on movement, which 
disrupts the movement. Conversely, when movement is unpredictable, there is no 
opportunity for self-focused attention to disrupt movement. 
A potential clinical implication for physiotherapy for FMD is that unpredictable 
movements may be useful to elicit symptom free movement.  
The disruptive effect of self-focussed attention on movement is a normal 
phenomenon. It has been described and studied in sports science, colloquially termed 
“choking under pressure” in competitive situations. It is thought that the pressure to 
do well heightens self-focus (self-consciousness), resulting in conscious attention to 
the step-by-step process of movement, with the end result of impaired task 
performance.149 Research aimed at improving the resistance of sports performance to 
such ‘choking under pressure’ has provided encouraging results for promoting implicit 
learning over explicit learning.150 Implicit learning refers to learning by exposure or 
repetition and does not necessarily involve awareness of how the task is performed. In 
contrast, explicit learning refers to accumulation of knowledge or rules of how to 
perform a task, which can be verbally expressed. Implicit learning may be more 
appropriate in the rehabilitation of people with FMD, as it requires less awareness of 
(and attention towards) the processes of movement. Implicit motor learning 
paradigms have been applied to neurorehabilitaiton in subjects with Parkinson’s 
disease and stroke.151,152 Though they should be interpreted with caution due to small 
numbers (n=27 and 22 respectively), these studies suggest that skills acquired through 
implicit learning are more resistant to interference from dual tasking than explicit 
learning paradigms. Paradigms for implicit learning attempt to create learning without 
errors in order to reduce the accumulation of explicit rules of how to perform the task, 
whereas explicit learning paradigms encourage trial and error learning and the 
generation of rules for performing the task.  
In relation to the rehabilitation of FMD, an implicit learning approach could 
limit errorful movement, avoid accumulation of verbal rules and discourage 
awareness of and attention to step-by-step components of a movement.  
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4.3.2 The Role of Expectation and Belief in Functional Motor Symptoms 
Functional motor symptoms are associated with an expectation or belief that 
movement will be abnormal. Perhaps the clearest illustration of the role of expectation 
in FMD is the potential for curative responses to placebo treatment.11 For example, 
botulinum toxin takes at least 72 hours to exert a neuromuscular blocking action, but 
when administered to patients with fixed functional dystonia together with the 
suggestion that the effect will be immediate, some patients have a dramatic instant 
(placebo) response.40 Here expectation can be considered a mechanism driving the 
symptom and symptom-resolution.  
Theoretical models of how the brain functions in a predictive manner have been used 
to explain the role of expectation in driving FMD.38 In the model, expectation 
represents more than just a consciously reportable thought. Expectation also 
represents neurally encoded predictions of how the body will interact with the 
environment, based on an internal model of the world. It is proposed that, in a 
hierarchical brain system, expectations are conveyed via top down processing to 
influence sensory perception and motor output at a preconscious level.38 An example 
of how an expectation can cause aberrant movement is the experience of lifting an 
object that is expected to be heavy, but in actuality is very light. The lifting action of 
the upper limb and the anticipatory postural adjustments are based on an expectation 
that is wrong (i.e. that the object is heavy), the selected motor actions are therefore 
inappropriate and overshoot what is necessary. The movement goes wrong in a way 
that feels involuntary and outside the control of the individual.  
Belief and expectation appear to be important in the prognosis of patients with FMD. 
In a study of 716 neurology outpatients whose symptoms were “unexplained by 
disease”, poor outcome at one year (based on a patient reported clinical global 
impression scale) was predicted by patients’ expectation of non-recovery and patients’ 
belief that their symptoms were not attributable to psychological factors.153   
In a study comparing 107 patients with functional weakness (FMD) to 46 patients with 
organic neurological causes for weakness, many of those with FMD reported ongoing 
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beliefs about the presence of an underlying disease.3 The subjects with FMD were 
more likely to endorse the statements, “my illness is a mystery” and “my illness is 
permanent”. The authors note that it is hardly surprising that patients with FMD were 
mystified, given that many doctors also report poor understanding of the diagnosis. 
This mystery however may be implicated in the detrimental beliefs and expectations 
that form part of the symptom mechanism.  
A clinical implication for FMD is that interventions that seek to help the patient 
understand their symptoms and positively influence their beliefs about the 
potential for recovery and the influence of psychological factors may improve 
prognosis.  
Expectations of abnormal movement can be directly addressed in physiotherapy by 
demonstrating to the patient that their movement can be normal, by using distraction 
and clinical signs that demonstrate symptom reversibility.154 Presenting the patient 
with evidence of normal movement may reduce the certainty with which they hold 
problematic illness beliefs and expectations. This demonstration may take the form of 
experiencing normal symptom-free movement during therapy sessions and watching 
their movement in a mirror or on video. Unhelpful expectations and beliefs may also 
be addressed by education. 
Physiotherapy may address detrimental illness beliefs by demonstrating to the 
patient that their movement can be normal and through education on the role 
of attention and expectation in driving FMD. 
4.3.3 Symptom Precipitating Events, Attention and Expectation  
Functional motor disorders are commonly preceded by physical events that appear to 
trigger the onset of symptoms.29,30 Typical events include minor injury, surgical 
procedures, adverse reactions to medication, or the somatic consequences of panic 
(i.e. tremor, palpitations, hyperventilation, etc.).  
Triggering events, together with self-focussed attention and expectation can be 
formulated together into a simplified aetiological model for FMD.38 The triggering 
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event, for example a fall from a height, leads to an erroneous illness belief, such as, “I 
can’t move my leg, I must have a spinal injury”, and an expectation of paralysis or 
abnormal movement. The leg becomes the source of focussed attention, which 
interferes with the execution of normal movement. Somatic sensations are amplified 
under the attentional focus and interpreted as symptoms of disease or injury. Beliefs 
may be reinforced by social interactions, such as admission to hospital and being 
subjected to multiple medical investigations. Certain personality traits, such as health 
anxiety and obsessionality, may reinforce this process and make an individual more 
vulnerable to developing FMD. 
In summary, the precipitating factor leads to high levels of attention directed towards 
the body and an expectation of abnormal movement, resulting in involuntary 
abnormal movement.  
4.3.4 Psychological Factors 
The above explanation for FMD plays down the role of psychological factors. They are 
clearly relevant, in that patients with FMD tend to report higher rates of anxiety and 
depression than the general population and neurological disease controls.6,27 In 
addition, panic attacks are common at the initial onset of FMD, particularly for those 
with rapid progression of their condition.155 However, the evidence on adverse life 
events is inconclusive; a proportion of individuals exposed to early life stressors do not 
develop FMD and not all patients with FMD have a history of adverse life events.27 This 
supports the view that psychological factors are not on their own explanatory, but 
important risk factors and that a biopsychosocial framework is necessary to 
understand FMD.  
4.3.5 Social Factors 
Social and societal factors are a recognised component of the illness experience in all 
health conditions. The “sick role” is described in sociology theory as a medically 
sanctioned societal role where illness exempts a person from his or her normal social 
responsibilities for a period of time. Sociologist Talcott Parsons described how the sick 
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role comes with potential secondary gains, and therefore patients can be 
unconsciously motivated to secure this role.156 The importance of acquiring access to 
the sick role may be behind the commonly reported need of patients with FMD for a 
legitimising diagnostic label.156 Legitimisation may not be found in diagnostic 
explanations that emphasise psychological factors or that are perceived to trivialise 
symptoms. Arguably, accessing the sick role may be a necessary, transient first step in 
rehabilitation and recovery. If this is the case, patients who feel they have been denied 
a legitimate diagnosis may be denied access to the sick role and therefore the path to 
recovery. 
A potential clinical implication is that the patient with FMD may need a 
diagnosis that legitimises their illness experience in order to engage with 
rehabilitation. Stone and Edwards (2012)154 describe a method of delivering the 
diagnosis of FMD to patients, where it is emphasised that “symptoms are 
genuine and not ‘made up’ or ‘crazy’.” 
4.3.6 Habitual Movement, Neuroplasticity and Secondary Changes 
Functional motor symptoms are associated with chronic long term disability and 
worsening symptoms over time.70 Chronic disability and deteriorating symptoms can, 
at least to some extent, be explained by abnormal movement patterns becoming 
habitual. Symptomatic habitual movement may be associated with neuroplastic 
changes in the central nervous system. Neuroimaging and neurophysiological studies 
have suggested that FMD is associated with abnormal neural circuitry, changes in 
cortical thickness, and reduced volumes of specific structures, although these findings 
are based on studies with small numbers and should be interpreted with caution.157 
Additionally, it is possible that some of these findings may be pre-existing conditions 
that make individuals more prone to developing FMD. 
In addition to the role of problematic self-focused attention, abnormal movement may 
be an adaptive behaviour that serves some purpose, for example reducing the weight 
through a painful ankle or “unloading” (taking weight off) a leg that is at risk (or 
perceived risk) of giving-way and causing a fall. The end result is an altered gait 
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pattern. Illness behaviours may also be important for demonstrating distress to others, 
for example with anatalgic movement patterns.  
Maladaptive behaviours may occur secondary to FMD and contribute to chronic 
disability. Examples include sedentary behaviour due to functional weakness (e.g. 
wheelchair use), leading to physical deconditioning; avoidant behaviour leading to 
sensitisation of pain; avoidant behaviour leading to heighted anxiety on exposure; and 
boom-bust activity patterns exacerbating chronic pain and fatigue. 
4.3.7 Chronic Pan and Fatigue 
Chronic pain and fatigue are common in patients with FMD. In our previous cohort 
study of 47 patients with FMD selected for physiotherapy treatment, 77% reported 
persistent pain and 60% regular fatigue.1 Pain and fatigue may act as risk factors for 
developing FMD, or as symptom precipitating factors and/or symptom maintaining 
factors. Chronic pain and fatigue is sometimes considered part of the same syndrome 
as FMD.155 Whichever perspective one takes, when present, management of pain and 
fatigue is probably a necessary part of treatment of FMD. 
4.3.8 Physical Biased Symptom Explanatory Model 
Bringing these factors together we can produce a symptom explanatory aetiological 
model for FMD that highlights mechanisms and issues that can be addressed in 
physiotherapy treatment.1 This physically based model is presented in Figure 4.2 
below. It is acknowledged that this model is a simplistic and incomplete representation 
of FMD, the role of psychological factors and other comorbidity may be 
underrepresented and it may not be generalisable to every patient.  
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Figure 4.2. Symptom explanatory model 
 
This model depicts that FMD are (commonly) triggered by an event, typically a physical 
event such as a fall, within the context of a stressful situation that for some patients 
may result in panic (or a panic attack). Panic may be more easily understood and 
acceptable to patients when described more biologically as a “fight or flight response”.  
The precipitating event (e.g. a fall) results in sensory and motor information (e.g. pain 
with give-way weakness), which due to the context of the triggering event is 
interpreted as a significant threat. This leads to increased attention directed towards 
the body (self-focus) and an expectation of abnormal movement or an illness belief 
(e.g. the expectation is “I am unable to walk”, the illness belief is “I have damaged my 
spine”). This illness belief is reinforced by the “evidence” of altered movement. Self-
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focused attention and expectation drive functional motor symptoms and lead to 
secondary changes which in turn result in increasing disability. The model also 
acknowledges the role of social factors, which might include employment issues, 
family dynamics and societal pressures. 
4.3.9 Rationale for Physiotherapy 
Physiotherapy can address the mechanisms and other specific issues highlighted in this 
symptom model. Movement can be retrained by redirecting the focus of motor 
attention away from the body. Expectation and illness belief can be addressed through 
education, by demonstrating to the patient that they are able to move normally and 
teaching them how to initiate normal movement. Addressing secondary changes such 
as physical deconditioning, fatigue and central sensitisation of pain are accepted and 
well described roles of physiotherapy.158,159 Physiotherapy may also address social 
factors. This may be directly, for example as part of vocational rehabilitation, or 
teaching family members how to support rehabilitation, or indirectly via other 
rehabilitation goals.  
This intervention treatment model can be used to help explain the diagnosis of FMD 
and the rationale of physiotherapy treatment to patients. This was described in 
previously published work, with a cohort of 47 patients.1 The model was used as a 
framework to formulate an individualised explanation to account for how each person 
had developed FMD.  
In summary, a rationale for physiotherapy is that FMD can be conceived of as learnt 
patterns of movement that are outside the patient’s control. Physiotherapy seeks to 
retrain movement with redirection of the focus of motor attention and to change 
unhelpful illness beliefs. 
4.4 The Physiotherapy Treatment Protocol 
The theoretical aetiological model for FMD described above was used to inform the 
design of the 5-day specialist physiotherapy treatment protocol. The protocol was 
influenced by my previous clinical experience in the rehabilitation of patients with 
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FMD, as well as experience in neurorehabilitation and chronic pain management. The 
overall approach of education and activity is based on established practices of 
physiotherapy for chronic back pain.160,161 
The treatment protocol can be broken down into four main components: Assessment, 
Education, Movement Retraining, and Self-Management. The treatment protocol is 
presented in Appendix 2 (page 218) , and has been described in recent 
publications.1,162 
4.5 Testing the Intervention: A Prospective Cohort Study  
The 5-day physiotherapy intervention was previously tested in a prospective cohort of 
47 consecutive patients with FMD, during the period from August 2012 to March 2014 
at the National Hospital for Neurology and Neurosurgery.1 Participants were admitted 
to the day hospital for five consecutive days and received eight physiotherapy sessions 
lasting up to 90 minutes each. Prior to treatment, the patient had attended a 
consultation with the neurologist, where the diagnosis was made and explained in 
detail to them, according to a structured format.154 All patients were followed up at 
three months.  
Immediately after treatment, 96% of patients rated their symptoms as improved on a 
7-point Likert scale, this reduced to 85% at 3 months. We defined a good outcome as a 
self-rating of “very much improved” or “much improved” (points 7 and 6 on the scale); 
64% had a good outcome after treatment and 55% at three months. This corresponded 
to a significant improvement with moderate effect size in more objective outcomes at 
three months. These included the SF36-Physical Function, SF36-Physical Role, Berg 
Balance Scale, 10 metre timed walk, and Work and Social Adjustment Scale. Measures 
that were not significantly different at follow-up were the remaining 6 domains of the 
SF36 and the Hospital Anxiety and Depression Scale. Quality adjusted life years (QALY) 
were calculated from the EQ-5D-5L, a generic health questionnaire commonly used for 
this purpose. A projected mean QALY gain of 0.1 per patient at 1 year was calculated 
for an approximate cost of £2000 per patient. The resulting incremental cost 
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effectiveness ratio of £20,000 per QALY suggests a high probability that the 
intervention is cost effective.  
4.6 The next stage in the MRC Guidelines for Developing Complex Interventions 
In this chapter I have presented a theoretical basis for the use of physiotherapy for 
FMD. The theory is derived from empirical clinical and laboratory evidence on the 
nature of functional motor symptoms, focusing on the importance of attention and 
expectation as mechanisms driving FMD. A specific physiotherapy treatment approach 
is described which is designed to address these theoretical symptom mechanisms. The 
treatment has been tested in a cohort of 47 patients with FMD. The results were 
promising, providing preliminary evidence for efficacy. The next stage of research, as 
described in the MRC guidelines was to gather information and evidence of feasibility, 
in order to inform the design of a pragmatic randomised controlled trial. This is the 
topic of the following chapters.
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Chapter 5 Feasibility Study Methods 
The work presented in Chapters 5 to 7 has been published in the form of a research 
paper: Nielsen G, Buszewicz M, Stevenson F, Hunter R, Holt K, Dudziec M, Ricciardi L, 
Marsden J, Joyce E, Edwards MJ. Randomised Feasibility Study of Physiotherapy for 
Patients with Functional Motor Symptoms. J Neurol Neurosurg Psychiatry. Published 
Online First: 30 September 2016. doi: 10.1136/jnnp-2016-314408 
5.1 Introduction 
It has been established that FMD is a common cause of disability and distress, with 
limited evidence for the few treatment options that are available. Physiotherapy has 
shown promise as a potentially effective treatment, although controlled evidence is 
lacking. A randomised feasibility study was conducted to determine the feasibility of 
conducting a pragmatic RCT of specialist physiotherapy for FMD and to obtain the 
necessary data to inform the design of such a trial.  
In this chapter, I report the methods of: A randomised controlled feasibility study of 
specialist physiotherapy for functional motor disorder. 
5.2 Study Design and Setting 
The study design was a two parallel arm, randomised feasibility study of a specialist 
physiotherapy-led intervention conducted over five consecutive days versus a 
treatment-as-usual control, for patients with FMD. This study took place at the 
National Hospital for Neurology and Neurosurgery, London, UK (NHNN). 
5.3 Ethics Approval 
Approval was obtained from the National Research Ethics Service Committee London – 
City Road & Hampstead (14/LO/0572). A trial steering committee oversaw the conduct 
of the trial. The trial was registered at ClinicalTrials.gov (NCT02275000). 
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5.4 Participants 
Sixty participants were recruited from new patients attending an outpatient neurology 
clinic specialising in movement disorders and FMD.   
Inclusion criteria were:  
1. A clinically established diagnosis of FMD according to Fahn-Williams criteria45  
2. Age 18 years or older 
3. Completed diagnostic investigations 
4. Acceptance of the diagnosis on the balance of probability (i.e., we did not 
exclude patients who continued to express some doubt over the diagnosis). 
5. FMD duration of at least six months 
6. Symptoms severe enough to cause distress (subjectively described by the 
patient) or impairment in social or occupational functioning 
Exclusion criteria were:  
1. Unable to understand English 
2. Pain or fatigue that were judged to be the primary cause of the patient’s 
disability 
3. Prominent dissociative seizures which the patient required assistance to 
manage 
4. Clinically evident anxiety or depression that we felt required assessment before 
starting physiotherapy treatment 
5. High level of disability that prevented participation in an outpatient/day 
hospital environment 
6. Unable to attend five consecutive days of treatment 
Prior to enrolment, all participants attended a consultation with the study neurologist 
(Mark Edwards) where the diagnosis of FMD was made. Each patient received a 
standard comprehensive explanation of the diagnosis. The components of the 
diagnostic explanation have been described in detail elsewhere.154 In brief, this 
involved showing patients their positive signs of FMD and emphasising the role of self 
directed attention in driving symptoms. The patient was also referred to online 
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sources of information (www.neurosymptoms.org and www.FNDHope.org). Patients 
meeting the selection criteria were provided with written information about the trial 
(see Appendix 3: Patient Information Sheet, page 227) and invited to return for 
consent and baseline assessment. All participants gave written informed consent (See 
Appendix 4: Consent Form, page 230), which was obtained by the study lead 
physiotherapist Glenn Nielsen or independent research physiotherapist Magdalena 
Dudziec. Baseline assessment was conducted within 4 weeks of the initial neurology 
consultation.  
5.5 Randomisation and masking 
Eligible consenting participants were randomly allocated with a 1:1 ratio to the 
intervention or control group using a secure online randomisation application (Sealed 
Envelope, London, UK). The randomisation procedure was completed after baseline 
assessment by Glenn Nielsen or Magdalena Dudziec. Participants were immediately 
informed of their treatment allocation. Both participants and clinicians were unmasked 
to treatment allocation. 
5.6 Intervention Group  
The intervention was a protocolised physiotherapy-based programme, delivered over 
five consecutive days by a neurophysiotherapist (Kate Holt), who had undertaken 
additional specific training (from Glenn Nielsen). An expanded description of the study 
intervention can be found in Appendix 2 (page 218). Participants were admitted to the 
day hospital at the NHNN for five consecutive days within four weeks of baseline 
assessment. As part of the day hospital admission, patients who did not live within a 
commutable distance of the hospital (defined as outside the M25 motorway) were 
provided with hotel accommodation.  
The first treatment session was a joint consultation with the study neurologist and 
physiotherapist where information from the initial neurology consultation was 
reviewed and the aims of the programme discussed. The aims were explained as 
retraining movement and learning how to manage symptoms in the longer term. The 
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initial consultation aimed to give an expectation of improvement as a result of taking 
part in the intervention while being realistic about prognosis. The programme 
consisted of eight sessions of physiotherapy conducted over five consecutive days, 
each lasting between 45-90 minutes. Each session included a combination of 
education, movement retraining, and development of a management plan. Education 
was centred on a physical biased aetiological model for FMD, see Figure 5.1. The 
physiotherapist and participant collaboratively devised a formulation to describe how 
the patient had developed the movement problem. This took into account triggering 
events, comorbidity, psychological factors (such as panic at onset), self-focussed 
attention disrupting normal movement, and unhelpful reinforcement of symptomatic 
movement patterns. Movement retraining aimed to restore normal movement during 
problematic activities (such as standing from a chair, transferring, walking, and upper 
limb tasks) by redirecting the focus of motor attention. Specific physiotherapy 
treatment strategies are listed in Appendix 2 (page 218), and are described in a recent 
publication.41 Over the five days, the participant and physiotherapist made notes in a 
workbook, documenting the individualised symptom formulation, information about 
FMD, specific symptom management strategies, daily reflections, a personal self-
management plan and what to do in case of symptom exacerbation or relapse. Family 
members were encouraged to attend the initial consultation and some (but not all) of 
the treatment sessions.  
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Figure 5.1 Symptom explanatory model used in the study intervention 
 
5.7 Control Group 
The control condition was treatment as usual. Following randomisation, a referral was 
made to the control participant’s local neurophysiotherapy service. The referral letter 
contained information about the diagnosis, specific treatment goals, and welcomed 
contact being made by the relevant local team to the specialist centre for further 
information regarding the diagnosis or treatment advice. No attempt was made to 
standardise treatment as usual. Input received was recorded, based on patient report.  
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5.8 Assessment 
All participants were assessed at baseline (prior to randomisation), four weeks (at the 
end of treatment in the intervention arm), and six months. Baseline assessments were 
completed by the study lead physiotherapist or the independent research 
physiotherapist. Four week and six months assessments were completed by the 
independent research physiotherapist only. For the intervention group, the four-week 
assessment coincided with the final day of treatment. Patients’ travel costs associated 
with assessment were reimbursed. 
5.9 Outcome Measures 
We collected measures of feasibility and clinical outcome. Measures of feasibility 
were: recruitment rate, retention, intervention fidelity and acceptability of the 
intervention. Fidelity of the intervention was assessed by attendance, completion of 
intervention workbook and participant feedback questionnaire. Acceptability was 
assessed by participant feedback questionnaire. Safety was assessed by recording 
participant reported adverse events related to receiving the intervention or control 
conditions.  
We did not specify a primary clinical outcome measure as the primary aim of this study 
related to feasibility. Clinical outcome measures collected are listed in Table 5-1. These 
included patient reported questionnaires relating to quality of life, anxiety, depression, 
and physical function; administered physical assessments; and assessments of the 
economic impact of symptoms. Participants in the intervention group were also asked 
to complete a short feedback form to assess acceptability of the intervention.  
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Table 5.1. Clinical outcome measures. Measures were collected at baseline, four 
week assessment and six month follow up (unless otherwise stated). 
Outcome Measure Measurmenet 
Domain 
Description 
Patient reported questionnaires 
Short Form 36 
(SF36)163 
Health-related 
quality of life 
36 items 
10 minutes or 
less 
A commonly used generic health-related quality 
of life measure, producing 8 separate domain 
scores, a physical and mental health composite 
score and a total score. It has been demonstrated 
to be both valid and reliable.164   
The SF36 was administered at baseline and six 
month follow up only (as the questionnaire has a 
four week recall period).  
Work and Social 
Adjustment Scale 
(WSAS)165 
Work and social 
function 
5 items 
2 minutes or less 
A measure of psychosocial function and ability to 
work. Has acceptable reliability and validity. 
Hospital Anxiety 
and Depression 
Scale (HADS)166 
Anxiety and  
depression 
14 items 
5 minutes or less 
A psychological screening tool that has shown to 
be a valid and reliable measure of anxiety and 
depression in and out of the hospital 
environment.166 
Brief Illness 
Perception 
Questionnaire (B-
IPQ)167 
Illness beliefs 
9 items 
5 minutes or less 
A quantitative measure of illness beliefs, shown 
to be valid and reliable. Produces 8 dimensions 
that can be analysed separately or as a total 
score.167 
Clinical Global 
Impression Scale 
(CGI)77,168 
Patient 
perception of 
change 
1 item 
1 minute or less 
Patient rated perception of improvement on a 5 
point Likert scale. It has been used in previous 
treatment studies of FMD.77,80  
Administered at 4 week assessment and 6 month 
follow up only.  
Disabilities of the 
Arm Shoulder and 
Hand (DASH)169 
Upper limb 
disability 
30 items 
5 minutes or less 
A measure of upper limb function that is not 
disease specific. It has good reliability and validity 
and is responsive to change.170 Participants 
without upper limb symptoms did not complete 
this assessment. 
Functional Mobility 
Scale171 
Mobility related 
disability 
3 items 
1 minute or less 
Very brief scale that quantifies functional mobility 
by determining assistance required when walking 
5, 50 and 500 metres. The scale has been shown 
to have good validity and reliability in children 
with cerebral palsy.171 It was used in a previous 
study of rehabilitation for FMD and therefore 
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useful for comparison.73 Participants whose 
symptoms did not affect their gait did not 
complete this assessment. 
Administered physical assessments 
10 metre timed 
walk172 
Walking speed 
1 activity 
5 minutes 
A quick and reliable test of gait speed and step 
length over 10 metres.172 Participants whose 
symptoms did not affect gait or balance did not 
complete this assessment. 
Berg Balance 
Scale173 
Balance  
14 activities 
10-15 minutes 
A widely used measure of balance shown to have 
good reliability and validity.174 Participants whose 
symptoms did not affect gait or balance did not 
complete this measure.  
The Simplified 
Functional 
Movement 
Disorders Rating 
Scale (S-FMDRS)175 
Movement 
impairment 
12 activities 
10 minutes or 
less 
 
A standardised rating scale to assess and score 
FMD via video. It was developed by the thesis’ 
author (GN), based on an existing scale 
(Psychogenic Movement Disorders Rating 
Scale).98 The new scale was developed to address 
problems with the original scale, which are 
described in detail elsewhere.175 We tested the 
inter-rater reliability, validity and sensitivity of the 
S-FMDRS and found the scale performed 
satisfactorily and was comparable to the original 
scale. Participants were videoed completing a 
standardised set of movements and postures. The 
videos were scored using the S-FMDRS by a blind 
assessor (neurologist, Lucia Ricciardi). 
Health Economic Analysis 
EQ-5D-5L176 Health-related 
quality of life 
6 items 
5 minutes or less 
A simple quality of life measure that is the 
preferred instrument of the National Institute for 
Health and Clinical Excellence (NICE) for 
generating quality adjusted life years 
(QALYs).176,177 
Client Services 
Receipt Inventory 
(CSRI)178 
Health service 
utilisation and 
related costs 
10 items 
20 minutes 
A standardised, yet adaptable assessment of 
health service utilisation (such as GP or hospital 
attendance), informal care, lost work time, and 
social benefits.178 The CSRI is commonly used in 
health economic analysis. A version of the CSRI 
was developed for the study (see Appendix 5, 
page 231) and administered at baseline and six 
months follow up only. This questionnaire is 
completed by the participant and asks about 
service receipt retrospectively over the previous 
three months. The data collected will be used to 
inform the design of a version of the CSRI suitable 
for a large trial. 
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5.10 Statistical Analysis 
A power calculation was not performed as the primary aim of this study was to assess 
feasibility. The sample size of 60 was predetermined and considered sufficient to meet 
the objectives of collecting data on outcome measure variation, recruitment and 
retention.  
All data were initially entered into a Microsoft Excel spread sheet (version 2013), by 
Magdalena Dudziec. Data were double entered (by Magdalena Dudziec and Glenn 
Nielsen) to detect and correct data entry errors. Statistical analysis was conducted 
using SPSS version 22. Summary statistics were calculated for each clinical outcome 
measure. For continuous measures, the difference between groups was assessed using 
a linear regression model, adjusting for the baseline scores of the measure. Treatment 
effect was calculated using Cohen’s d to allow comparisons between outcome 
measures.179 Incomplete cases due to drop out were excluded from analysis. The 
Clinical Global Impression scale (CGI) was collapsed into two groups for subgroup 
analysis: good outcome (ratings of much improved and improved) and poor outcome 
(ratings of no change, worse or much worse). For the B-IPQ, a total composite score 
was calculated by combining the sub scores, reversing scores for items 3, 4 and 7.  
Health Economist, Rachael Hunter, completed all health economic analyses, using 
STATA version 12. The EQ-5D-5L utility scores180 were converted to Quality Adjusted 
Life Years (QALYs) by calculating the area under the curve adjusting for baseline 
differences181. Physiotherapist and neurologist salaries and overheads were obtained 
from the Personal Social Services Research Unit,182 and multiplied by the average 
contact time per patient. Other costs were obtained from trial costings 
documentation. The estimated mean cost per patient of the intervention minus the 
mean cost of the control neurophysiotherapy was divided by the difference in QALYs 
gained between groups to calculate the incremental cost-effectiveness ratio (ICER).  
Data from the CSRI was collated using software Microsoft Excel (by Glenn Nielsen) and 
analysed using software STATA version 12 (by Rachael Hunter). Service use was 
reported with descriptive statistics. Service costs were estimated using data obtained 
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from the Personal Social Services Research Unit.182 Costs were categorised as 
community care costs and acute care costs. Community care costs were services 
provided in the community; this included seeing the GP, practice nurse, community 
physiotherapist and community occupational therapist. Acute care costs were services 
provided within a hospital setting; this included hospital outpatient appointments, day 
procedures, elective and non-elective admissions and seeing physiotherapists etc. 
while in hospital. Further statistical analyses were not reported due to the low 
participant numbers in this feasibility study.  
The number of prescribed medications was reported with descriptive statistics. Work 
days lost through sickness were reported for participants who were in paid 
employment. Questions with missing data and areas of high service utilisation or high 
costs were noted to inform a future version of the CSRI. 
5.11 Exploration of the Data 
In an exploratory analysis, the relationship between the presence of anxiety or 
depression at baseline and intervention outcome was explored. This was an exercise in 
hypothesis generation, in recognition that the data was not specifically powered for 
subgroup analysis. Outcome (Good vs Poor) was based on collapsed CGI scores. Cases 
of anxiety and depression were determined by a cut off score of 10 and above in the 
HADS anxiety and depression subscales. This cut off score is thought to exclude false 
positive cases166. This data was presented in a 2x2 contingency table and analysed with 
a Chi-square test.
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Chapter 6 Feasibility Study Results 
Measures relating to feasibility are presented, followed by clinical outcomes. 
6.1 Recruitment 
The trial profile and flow of participant through the study is shown in Figure 6.1. 
Recruitment began 8 September 2014 and was completed by 4 June 2015. During 
these nine months, 210 patients were screened for inclusion and 143 were 
excluded. The most common reasons for exclusion were dominant pain (n=57, 27% 
of screened patients), clinically evident anxiety or depression requiring assessment 
(n=50, 24% of screened patients) and dominant fatigue (n=22, 10% of screened 
patients). Seven patients declined to participate and the remaining 60 were 
recruited and randomly assigned to the intervention (n=30) and control (n=30) 
groups. The percentage of screened patients meeting the selection criteria was 
31.9% (95% CI 25.6, 38.2), 90% of eligible patients consented to participate.  
6.2 Retention and Dropouts 
The number assessed at the primary endpoint was 29 for the intervention group (1 
dropout) and 28 for the control group (2 dropouts). The overall dropout rate was 
5% (95% CI 0.0, 10.5%). The participant that dropped out from the intervention 
group did so prior to commencing treatment. Only one participant gave a reason for 
dropping out, which was a new, separate health condition that was under 
investigation. We suspect the other two participants dropped out due to anxiety 
(which we underestimated on initial assessment) and distance required to travel to 
the hospital. 
One participant from the intervention group was unable to attend the final 
assessment, they completed questionnaires by post and their final physical 
assessment measures (Berg Balance Scale, 10 metre walk time and S-FMDRS) were 
missing from the final analysis. Three participants from the control group did not 
attend the interim four-week assessment, but did attend the final assessment. The 
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most common reason for nonattendance was the distance or difficulty with travel 
to the hospital. 
 
Figure 6.1. Trial Profile 
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6.3 Fidelity 
Participants in the intervention group attended all five days of treatment, except for 
one participant who missed two days due to sickness. All components of the 
workbook were covered for each participant and the majority of participants 
endorsed the following statements in post-treatment feedback (strongly agree on a 
5-point Likert scale): The programme helped me understand my symptoms (93%); 
The programme helped me gain more control over my symptoms (83%); The 
programme has helped me to create a plan to improve my symptoms (90%); and 
The programme included information about thoughts, feelings and psychological 
influences on my symptoms  (86%). The participant feedback questionnaire and 
results are presented in Appendix 6 (page 236). 
6.4 Acceptability of the Intervention 
In the post-treatment feedback questionnaire, all participants in the intervention 
group reported they were either completely satisfied (86%) or satisfied (14%) with 
their treatment and they would be extremely likely (93%) or likely (7%) to 
recommend the programme to family and friends if they required similar 
treatment. The intensity of treatment was considered about right (38%) or very 
intense but manageable (48%). Two participants (7%) found the treatment too 
intense, and two (7%) felt the treatment was not intense enough. See Appendix 6 
(page 236) for feedback questionnaire and results. 
6.5 Follow Up Assessment Timeframes 
The average time from recruitment into the trial to four-week assessment was 5.4 
(SD 2.4) weeks for the intervention group and 5.4 (SD 1.8) weeks for the control 
group. The average time from recruitment to six-month follow up was 6.5 (SD 0.8) 
months for the intervention group and 6.4 (SD 0.8) months for the control group. 
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6.6 Safety 
No serious adverse incidents were reported during the study period.  Some 
participants from the intervention group reported exacerbation of chronic pain or 
fatigue during and the week following the intervention. This resolved without the 
need for new intervention and was usually attributed to being more physically 
active around sessions, such as walking to and from the physiotherapy gym, rather 
than the treatment itself. One participant from the intervention group reported 
having had a fall in the months after treatment, sustaining a wrist fracture, which 
required surgery. This participant had reported falling regularly at baseline.    
6.7 Treatment Received by Control Group 
Self-report data regarding details of physiotherapy treatment was available from 28 
of 30 control participants. Only one participant did not see a physiotherapist in the 
period from baseline to six month follow up. A referral was made but they had not 
been contacted for an appointment.  Three participants opted for private 
physiotherapy treatment (one had private treatment in addition to NHS treatment) 
and they received between 6 and 9 sessions (6, 6, 9). Twenty-five participants saw 
an NHS physiotherapist. The number of sessions ranged from 1 to 17, the median 
number was 5 (IQR 3 – 7.5).  
The content of physiotherapy sessions included gait retraining, stair practice, 
balance work, general cardiovascular exercise, specific strengthening exercises, and 
stretching. Four participants were provided with a walking aid or splint. One 
participant had fatigue management education and one participant was given 
strategies to practice to control a functional tremor.  
Contact from physiotherapists providing treatment as usual (control) physiotherapy 
for advice was received for 5 participants. In each case a published paper describing 
recommendations for physiotherapy for patients with FMD41 was emailed to the 
physiotherapist.  
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6.8 Baseline Characteristics of Participants 
Baseline demographic and clinical characteristics of all the participants are show in 
Table 6.1 and Table 6.2. The mean age was 43 years, 72% were women and 48% 
were not working due to ill health. The mean symptom duration was 5.8 years (SD 
7.3) and the mean age of symptom onset was 37 (SD 12·0). The most common 
predominant symptom at presentation was a mixed movement disorder (40%), 
followed by gait disturbance (27%), weakness (12%) and upper limb tremor (10%). 
The category of mixed movement disorder represented patients with symptoms 
that included dystonic-type movement, tremor and weakness. Sensory symptoms 
were common, these included pins and needles (63%), numbness (55%), dizziness 
(48%) and visual disturbance (38%). Other common comorbid symptoms were 
general weakness (72%), headache (60%), speech disturbance (48%) and bladder 
problems (33%). Half the participants rated their daily levels of pain and fatigue as 
severe to extreme at baseline and only a small minority did not experience regular 
pain (12%) or fatigue (5%). Forty-eight per cent of participants reported having falls 
since their symptoms started. Most had previously seen a physiotherapist (77%), 
and 32% had had psychological therapy.  The control and intervention groups were 
evenly matched for baseline demographic and clinical characteristics. 
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Table 6.1 Baseline demographic characteristics 
Demographic Data Intervention 
group n=30 
Control  
group n=30 
Combined 
N=60 
Age, mean (SD) 44 (13.1) 41 (13.1) 43 (13.1) 
Female Gender  22 (73%) 21 (70%) 43 (72%) 
Marital status    
 Married/partner 19 (63%) 18 (60%) 37 (62%) 
 Single 9 (30%) 11 (37%) 20 (33%) 
 Widowed 0 0 0 
 Divorced/separated 2 (7%) 1 (3%) 3 (5%)     
Employment status    
 Full time work 7 (23%) 7 (23%) 14 (23%) 
 Part time work 6 (20%) 5 (17%) 11 (18%) 
 Retired / not working  2 (7%) 3 (10%) 5 (8%) 
 Volunteer work 0 0 0 
 Current sickness 2 (7%) 0 2 (3%) 
 Not working due to health 11 (37%) 15 (50%) 26 (43%) 
 Medically retired 1 (3%) 0 1 (2%) 
 Student 1 (3%) 0 1 (2%) 
Employment status summary    
 In paid work or full time study 14 (48%) 12 (40%) 26 (43%) 
 Not working due to ill health 14 (45%) 15 (50%) 29 (48%) 
 Other 2 (7%) 3 (10%) 5 (8%) 
In receipt of state benefits 20 (67%) 17 (57%) 37 (62%) 
Education level    
 Less than 16 years 2 (7%) 1 (3%) 3 (5%) 
 Up to 16 years 8 (27%) 13 (43%) 21 (35%) 
 Up to 18 years 4 (13%) 6 (20%) 10 (17%) 
 Degree level qualification 13 (43%) 9 (30%) 22 (37%) 
 Post graduate qualification 3 (10%) 1 (3%) 4 (7%) 
Current litigation 0 0 0 
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Table 6.2. Baseline clinical characteristics 
Clinical data 
 
Intervention 
group n=30 
Control 
group n=30 
Combined 
n=60 
Symptom duration, years, mean (SD) 5.9 (8.3) 5.6 (6.2) 5.8 (7.3) 
Age at symptom onset, mean (SD) 38 (12.9) 36 (11.2) 37 (12) 
Primary Symptom, frequency:    
 Weakness 3 (10%) 4 (13%) 7 (12%) 
 Gait disturbance 7 (23%) 7 (23%) 14 (23%) 
 Upper limb tremor 3 (10%) 3 (10%) 6 (10%) 
 Lower limb tremor 2 (7%) 0 2 (3%) 
 Head tremor 2 (7%) 1 (3%) 3 (5%) 
 Fixed dystonia 0 1 (3%) 1 (2%) 
 Jerks 2 (7%) 1 (3%) 3 (5%) 
 Mixed movement disorder 11 (37%) 13 (43%) 24 (40%) 
Sensory Symptoms, frequency    
 Visual disturbance 11 (37%) 12 (40%) 23 (38%) 
 Hearing difficulties 8 (27%) 6 (20%) 14 (24%) 
 Pins and needles 15 (50%) 23 (77%) 38 (63%) 
 Numbness 14 (47%) 20 (67%) 34 (55%) 
 Dizziness 15 (50%) 14 (47%) 29 (48%) 
Other Symptoms / Complaints:    
 Weakness 20 (67%) 23 (77%) 43 (72%) 
 Headache  14 (47%) 22 (73%) 36 (60%) 
 Sleep disturbance 18 (62%) 20 (67%) 38 (63%) 
 Gastrointestinal complaints 9 (30%) 6 (20%) 15 (25%) 
 Bladder problems 9 (31%) 11 (37%) 20 (33%) 
 Speech disturbance 13 (43%) 16 (53%) 29 (48%) 
 Concentration or attention problems 23 (77%) 22 (73%) 45 (75%) 
 Dissociative attacks/seizures  6 (20%) 3 (10%) 9 (15%) 
Pain, self-rating: None 6 (20%) 1 (3%) 7 (12%) 
 Slight to moderate 10 (34%) 14 (47%) 24 (40%) 
 Severe to extreme 13 (45%) 15 (50%) 28 (47%) 
Fatigue, self-rating: None 2 (7%) 1 (3%) 3 (5%) 
 Slight to moderate 13 (43%) 14 (47%) 27 (45%) 
 Severe to extreme 15 (50%) 15 (50%) 30 (50%) 
Patients who report falling 10 (33%) 19 (63%) 29 (48%) 
Previous physiotherapy 23 (79%) 23 (77%) 46 (77%) 
Previous psychology 9 (31%) 10 (33%) 19 (32%) 
Botulinum toxin injections 6 (20%) 4 (13%) 10 (17%) 
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6.9 Continuous Clinical Outcomes 
Clinical outcomes are presented in Table 6.3, Table 6.4 and Figures 6.2 to 6.10. 
Inspection of baseline data suggests that the control group had generally worse 
scores than the intervention group, which were accounted for in the analysis. 
The assumptions of the regression model were met. After adjusting for baseline 
scores, at six months the intervention group had superior scores (representing 
better health) in three domains of the SF36 (Physical Function, Physical Role, and 
Social Function, see Table 6.3);  the Berg Balance Scale, the 10 metre walk time, the 
Functional Mobility Scale, the DASH, and the composite B-IPQ score (Table 6.4). 
Two outliers skewed the results of the 10 metre walk time, inflating the treatment 
effect. After removing these outliers, the mean difference remained significant. 
Effect sizes were medium to large, ranging from d=0.46 to 0.79, with the greatest 
effect seen in the Functional Mobility Scale and Simplified-PMDRS. Outcomes that 
were not significantly different between groups were the remaining five domains of 
the SF36 (Bodily Pain, General Health, Vitality, Role Emotional, and Mental Health), 
the HADS anxiety and depression scores, and the WSAS.  
We excluded cases with incomplete data due to dropout from the analysis. When 
data were analysed by carrying forward baseline scores of incomplete cases in a 
sensitivity analysis, there was overall little difference. However the difference 
between groups in SF36 General Health and WSAS scores became significant at the 
0.05 level, which suggests our approach of excluding missing cases was the more 
conservative option.
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Table 6.3. Short Form 36 outcomes at baseline and six months 
 
SF36 Domains 
Intervention Group mean (SD) Control Group mean (SD) Regression coefficient for group, 
baseline as covariate (95% CI) 
Cohen’s d 
BASELINE FOLLOW UP BASELINE FOLLOW UP 
    Physical function 34·8 (23·7) 51·9 (27·2) 23·7 (19·0) 23·2 (21·3) 19·8 (10·2, 29·5) 0·70 
    Physical Role 31·7 (28·9) 47·0 (30·3) 19·4 (21·7) 26·8 (22·5) 13·0 (0·8, 25·2) 0·46 
    Bodily Pain 45·6 (33·5) 47·4 (33·1) 32·1 (25·3) 33·9 (27·4) 3·6 (-8·0, 15·3) 0·12 
    General Health 47·3 (23·9) 54·1 (28·3) 40·7 (23·4) 39·6 (22·6) 9·0 (-0·1, 18·2) 0·34 
    Vitality 32·3 (21·4) 39·2 (27·3) 26·6 (17·6) 28·3 (20·2) 6·2 (-3·6, 15·9) 0·25 
    Social Function 39·7 (33·2) 56·9 (30·2) 34·4 (29·8) 37·0 (25·1) 17·1 (5·0, 29·2) 0·58 
    Role Emotional 70·1 (29·5) 68·7 (34·5) 61·0 (32·6) 62·5 (35·4) 0·1 (-15·1, 15·4) 0·00 
    Mental Health 65·5 (21·1) 67·9 (23·8) 58·4 (23·8) 59·3 (25·2) 3·4 (-6·4, 13·2) 0·14 
Physical Summary score  33·1 (11·1) 38·7 (10·8) 28·7 (7·9) 29·5 (9·2) 5·9 (2·1, 9·7) 0·54 
Mental Summary score 45·2 (13·0) 45·9 (13·6) 42·6 (13·3) 43·3 (14·2) 0·9 (-4·9, 6·8) 0·06 
Higher scores represent better health. Abbreviation: SF36=Short Form 36. Regression coefficients in bold reached statistical significance at 0.05 level. 
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Table 6.4. Continuous outcome measures at baseline and six months 
 Intervention Group mean (SD) Control Group mean (SD) Regression coefficient for group, 
baseline as covariate (95% CI) 
Cohen’s d 
BASELINE FOLLOW UP BASELINE FOLLOW UP 
HADS Anxiety 6·5 (3·8) 6·9 (4·8) 7·7 (4·9) 7·9 (5·6) -0·1 (-2·1, 2·0) -0·02 
HADS Depression 5·4 (4·0) 5·2 (3·9) 8·0 (4·5) 8·4 (5·0) -1·4 (-3·2, 0·5) -0·30 
WSAS 24·7 (7·9) 20·2 (10·5) 27·6 (7·5) 26·9 (10·2) -4·2 (-8·4, 0·1) -0·39 
Berg Balance Scale 39·0 (13·8) 47·7 (13·8) 35·7 (13·2) 37·0 (14·7) 8·0 (2·9, 13·1) 0·53 
10 metre walk time ** 16·8 (10·0) 9·6 (3·8) 24·6 (17·3) 19·0 (10·6) -6·7 (-10·7, -2·8) -0·72 
Functional Mobility Scale 11·7 (4·1) 14·5 (3·5) 10·0 (3·6) 10·0 (3·9) 3·4 (1·9, 5·0) 0·79 
DASH 51·8 (19·6) 39·6 (25·6) 51·2 (15·0) 48·1 (21·4) -9·1 (-17·4, -0·8) -0·38 
S-FMDRS 17.6 (9.0) 10.6 (9.1) 15.6 (7.8) 16.6 (8.6) -7.4 (-11.0, -3.8) -0.79 
B-IPQ total score 50·0 (10·8) 39·4 (16·1) 54·6 (10·6) 51·0 (13·0) -8·0 (-14·4, -1·6) 0·51 
 
**  2 outliers removed from the intervention group (baseline times of 197 and 182 seconds). Removing these outliers decreased the treatment effect by 1.4 
seconds. Higher scores represent better health in the Berg Balance and Functional Mobility Scale. Higher scores represent worse health for HADS, Work and 
Social Adjustment, 10 metre timed walk, DASH and Simplified-PMDRS. Abbreviations: HADS=Hospital Anxiety and Depression Scale; WSAS=Work and Social 
Adjustment Scale; DASH=Disabilities of Arm Shoulder and Hand. Regression coefficients in bold reached statistical significance at 0.05 level.
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Itemised results for the B-IPQ are reported in Appendix 7 (page 240). Figures 6.2 to 
6.10 present mean scores and 95% confidence intervals of continuous clinical 
outcome measures for the intervention group (green line) and control group (blue 
line), at baseline, four weeks and six months.  
 
 
 
 
 
 
 
Figure 6.2. Hospital Anxiety and Depression Scale, Anxiety Score. Adjusted 
difference between groups at six months -0.1 (95% CI -2.1, 2.0). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3. Hospital Anxiety and Depression Scale, Depression Scores. Adjusted 
difference between groups at six months -1.4 (95% CI -3.2, 0.5).  
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Figure 6.4. Work and Social Adjustment Scale. Adjusted difference between groups 
at six months -4.2 (95% CI -8.4, 0.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5. Berg Balance Scale. Adjusted difference between groups at six months 
8.0 (95% CI 2.9, 13.1), d=0.53. 
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Figure 6.6. 10-Metre Timed Walk. Adjusted difference between groups at six 
months -6.7 (95% CI -10.7, -2.8), d=0.72. 
 
 
 
 
 
 
 
 
 
 
Figure 6.7. Functional Mobility Scale. Adjusted difference between groups at six 
months 3.4 (95% CI 1.9, 5.0), d=0.79.  
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Figure 6.8. Disabilities of the Arm Hand and Shoulder (DASH). Adjusted difference 
between groups at six months -9.1 (95% CI -17.4, -0.8), d=0.38. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9. Brief Illness Perception Scale, Total Score. Adjusted difference between 
groups at six months -8.0 (95% CI -14.4, -1.6), d=0.51. 
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Figure 6.10. Simplified Psychogenic Movement Disorders Rating Scale at baseline 
and six months follow up. Adjusted difference between groups at six months -8.6 
(95% CI -12.8, -4.4), d=0.79. 
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6.10 Categorical Clinical Outcomes 
The CGI data are presented in Table 6.5. At six months, 72% of the intervention group 
reported a good outcome, compared to 18% in the control group. Thirty-two per cent 
of the control group felt that their symptoms had got worse from baseline to six 
month follow up, compared to 3% in the intervention group. There appeared to be a 
perceived loss of treatment effect with time, in the intervention group the proportion 
with a good outcome at four weeks (93%), reduced at six month follow up (72%). 
Table 6.5. Clinical Global Impression Scale at four weeks and six months. 
 
CGI Rating 
4 Weeks 6 Months 
Intervention 
Group 
Control 
Group 
Intervention 
Group 
Control 
Group 
Much worse 0   1  (4%) 0  3 (11%) 
Worse 0  7  (28%) 1 (3%) 6 (21%) 
No change 2 (7%) 14  (56%) 7 (24% 14 (50%) 
Improved 12 (41%) 2  (8%) 11 (38%) 5 (18%) 
Much improved 15 (52%) 1  (4%) 10 (35%) 0  
 
Collapsed Scores 
    
Good Outcome 27 (93%) 3 (12%) 21 (72%) 5 (18%) 
Poor Outcome 2 (7%) 22 (88%) 8 (28%) 23 (82%) 
 
Table 6.6 presents outcome at six months by treatment group in a 2x2 contingency 
table. The assumptions of the Chi Squared test were met. Allocation to the 
intervention group was significantly associated with a good outcome (Χ2 (1) =17.09, 
p<0.001), with an odds ratio of 12.08 (95% CI 3.41, 42.75).  
Table 6.6. Contingency table of outcome by intervention at 6 month assessment 
Outcome Intervention Control Total 
Good outcome 21 (72%) 5 (18%) 31 
Poor outcome 8 (28%) 23 (82%) 26 
TOTAL 29 (100%) 28 (100%) 57 
 
There were more cases of anxiety and depression (HADS subscale score ≥ 10) in the 
control group compared to the intervention group at baseline (anxiety: 4 cases in the 
intervention group, 9 in the control group; depression: 6 cases in the intervention 
group, 11 in the control group), see Table 6.7 below. Average HADS scores did not 
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change, see Table 6.4, but there was an increase in the number of cases of anxiety in 
the intervention group only. Cases of depression did not change. 
Table 6.7. Cases of anxiety and depression, as defined by Hospital Anxiety and 
Depression Scale sub scores of 10 or greater 
HADS 
Caseness 
Intervention Group Control Group 
Baseline 4 Weeks 6 Months Baseline 4 Weeks 6 Months 
Anxiety 4 6 10 9 8 9 
Depression 6 3 6 11 9 11 
 
Table 6.8 and Table 6.9 present six month outcome by cases of anxiety and depression 
for the intervention group. The assumptions of the Chi Squared test were not met (cell 
counts less than 5), therefore Fisher’s exact test was performed. Anxiety or depression 
‘caseness’ was not statistically associated with a particular outcome. 
Table 6.8. Contingency table of intervention group outcome at 6 months by anxiety 
caseness at baseline 
Outcome Anxiety case Anxiety non-case Total 
Poor outcome 1 (25%) 7 (28%) 8 
Good outcome 3 (75%) 18 (72%) 21 
TOTAL 4 (100%) 25 (100%) 29 
Χ2 (1) = 0.016, p=1.00, Fisher’s Exact Test = 1.00  
 
Table 6.9. Contingency table of intervention group outcome at 6-months by 
depression caseness at baseline 
Outcome Depression case Depression non-case Total 
Poor outcome 2 (40%) 6 (25%) 8 
Good outcome 3 (60%) 18 (75%) 21 
TOTAL 5 (100%) 24 (100%) 29 
Χ2 (1) = 0.466, p=0.597, Fisher’s Exact Test, p=0.597 
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Further comparisons of baseline characteristics of the intervention group by good 
versus poor outcome is presented in Table 6.10. This comparison is limited by the 
small number of participants with a poor outcome. Differences are not statistically 
significant, except for ‘pain self-rating of severe to extreme’, (Fisher’s exact test 
p=0.0142). 
Table 6.10. Baseline characteristics of the intervention group by outcome 
Baseline Characteristic / Score Good Outcome 
n=21 
Poor Outcome 
n=8 
Intervention 
Group (all) n=30 
% Female 81% 63% 73% 
Age, mean (SD) 41.5 (14.2) 48.4 (10.3) 44 (13.1) 
Graduate or post graduate qualification 57% 50% 53% 
Symptom duration, years, mean (SD) 5.8 (8.8) 6.9 (8.1) 5.9 (8.3) 
Not in work due to ill health 43% 50% 45% 
Number PMH issues listed, mean (SD) 2.4 (1.98) 3.2 (2.8) 2.6 (2.2) 
Pain self rating severe to extreme, n (%) 7 (33.3%)* 7 (87.5%)* 13 (45%) 
Fatigue self rating severe to extreme, n (%) 10 (47.6%) 4 (50.0%) 15 (50%) 
Primary Symptom, n (%)    
 Mixed movement disorder 8 (38.1%) 3 (37.5%) 11 (37%) 
 Gait disturbance 4 (19.0%) 2 (25.0%) 7 (23%) 
 Tremor 4 (19.0%) 3 (37.5%) 7 (24%) 
 Weakness 3 (14.3%) 0 3 (10%) 
 Jerks 2 (9.5%) 0 2 (7%) 
Baseline Clinical Outcome Measure Scores    
 HADS Anxiety Score, mean (SD) 6.2 (3.7) 7.2 (4.4) 6.5 (3.8) 
 HADS Depression Score, mean (SD) 5.2 (4.2) 6.0 (3.8) 5.4 (4.0) 
 BIPQ Threat Score, mean (SD) 48.5 (10.2) 52.9 (12.6) 50.0 (10.8) 
 WSAS, mean (SD) 24.9 (7.0) 24.0 (10.6) 24.7 (7.9) 
 Berg Balance Scale, mean (SD) 37 (14.5) 37.5 (12.5) 39.0 (13.8) 
 10-metre Walk Time 33.9 (40.9) 17.3 (6.9) 16.8 (10.0) 
 DASH 48.9 (17.8) 59.3 (23.5) 51.8 (19.6) 
 Simplified-PMDRS 19.9 (9.5) 19.3 (14.3) 19.6 (10.6) 
Short Form 36  
 Physical Function 33.3 (21.8) 38.8 (29.5) 34.8 (23.7) 
 Physical Role 31.8 (28.9) 31.3 (31.0) 31.7 (28.9) 
 Bodily Pain 51.1 (32.1) 31.1 (34.9) 45.6 (33.5) 
 General Health 51.0 (20.1) 37.4 (31.3) 47.3 (23.9) 
 Vitality 33.6 (21.3) 28.9 (22.6) 32.3 (21.4) 
 Social Function 39.9 (31.8) 39.1 (39.2) 39.7 (33.2) 
 Role Emotional 74.2 (30.1) 59.4 (26.5) 70.1 (29.5) 
 Mental Health  67.6 (21.2) 60.0 (21.4) 65.5 (21.1) 
 Physical Summary Score 33.5 (10.9) 32.1 (12.3) 33.1 (11.1) 
 Mental Summary Score 46.5 (13.3) 41.7 (12.5) 45.2 (13.0) 
* Statistically significant difference (Fisher’s exact test p=0.0142)  
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6.11 Health Economic Analysis: Cost-Utility Analysis 
The mean EQ-5D-5L utility scores at baseline, four weeks, and six months are 
presented in Figure 6.11. Using a linear regression model to adjust for baseline 
differences, the mean QALYs over six months for the intervention group was 0.34 (95% 
CI 0.31, 0.37) and 0.26 (95% CI 0.22, 0.30) for the control group with a mean gain in 
QALYs per patient of 0.08 (95% CI 0.03, 0.13). The cost of the intervention was 
estimated to be £1200 per patient. This took into account the time of the neurologist 
(£105 per hour)182 and physiotherapist NHS band 7 (£49 per hour),182 provision of 
equipment (usually downsizing walking aids and splints for some patients only), day 
hospital admission costs (including meals), and hotel accommodation (required for 
85% of participants). The cost of the control was on average 4.8 sessions per patient 
multiplied by the cost of one hour of an NHS band 7 physiotherapist, or £233 per 
patient. Based on this data, the mean incremental cost per QALY gained was £12,087. 
 
Figure 6.11. Mean EQ-5D-5L utility scores at baseline, 4-weeks and 6-months for the 
intervention and control groups. A utility score of 1.0 represents full health 
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6.12 Health Economic Analysis: Client Service Receipt Inventory 
Table 6-11 displays services used and associated costs for both groups reported at 
baseline and six-month follow up. At baseline, the control group had higher service use 
costs than the intervention group (£719 compared to £579). There was a small 
reduction in total costs for the intervention group at six months compared to baseline 
(from £579 to £441) and an increase in total costs for the control group (from £719 to 
£1104).  
Acute care costs (hospital based service) made up approximately 75% of total costs 
and community care 25% of total costs for both groups at both time points. Hospital 
outpatient appointments and day case procedures/tests were particularly common. 
The control group reported utilising these services more frequently than the 
intervention group. At follow up, 35% of the intervention group had attended a 
hospital outpatient appointment compared to 54% of the control group. Also at follow 
up, 10% of the intervention group had a day hospital admission compared to 36% of 
the control group. Acute care services came with a high cost and accounted for most 
of the difference in costs between the control and intervention groups.  
The questionnaire did not allow for further details on hospital appointments, such as 
procedures performed or specialities under which participants were admitted, 
therefore assumptions based on mean costs were made which may have over- or 
under-estimated the true costs. The questionnaire also did not ask participants what 
they paid when they received private physiotherapy or occupational therapy. Private 
therapy costs were omitted from the total costs calculation as references for these 
costs are not well documented and in this case their impact would have been 
negligible.  
 
Table 6.12 summarises the number of medications taken. At baseline, the mean 
number of medications taken regularly was 3.9 (SD 3.6) for the intervention group and 
4.6 (SD 3.4) for the control group. Approximately 30% of participants took 5 or more 
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medications regularly. There was little change at follow up, although both groups had 
a slight reduction in numbers.  
Days lost through sickness absence were calculated. The average number of sick days 
in the intervention group was 5.4 (SD 16.3) at baseline and 3.4 (SD 13.3) at follow up. 
Average sick days for the control group were 3.5 (SD 11.2) at baseline and 4.8 (SD 16.5) 
at follow up. The CSRI provided insufficient data to calculate sickness absence as a 
proportion of hours worked (a measure that accounts for differences due to part-time 
workers). 
Overall, data completion for the CSRI questionnaire was satisfactory. Yes or No tick-
box questions were rarely missed. When further qualification was required (i.e if yes 
was ticked for “Seen GP at the surgery”, how many times did you see your GP?) data 
was missing in approximately 5-10% of cases. Only 16 participants wrote a response to 
the question “What is your gross income (i.e. before tax) per week?” This equates to 
59% of those who were in paid employment. Most participants were able to 
remember their medications, though some did not know the correct spelling, which 
may have led to inaccurate data. Participants who brought a list of their current 
medication found this exercise easier, and this list was photocopied, anonymised and 
attached to the data collection sheet. In retrospect the headings for the table in 
question 3, in which participants were asked to list their medications were unclear and 
open to different interpretations. These headings were “Duration of use (days)” and 
“Dose/no. per day”. The CSRI questionnaire is presented in Appendix 5 (page 231). 
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Table 6.11. Services used and costs, data from Client Service Receipt Inventory 
Resources utilised BASELINE FOLLOW-UP 
  
Intervention 
n=30 
Control 
n=30 
Intervention 
n=29 
Control 
n=28 
Table  Yes Number of participants utilising the service (%) 
legend Number (if yes) Mean frequency of service utilisation amongst users (SD) 
 Cost (all) Average cost of service use per participant (SD) 
 Missing (count) Participants with missing data 
GP – practice  Yes  22 (73.33%) 22 (73.33%) 24 (83%) 20 (71 %) 
 Number (if yes) 2.95 (2.23) 3.77 (2.81) 2.2 (3.1) 3.5 (1.8) 
 Cost (all) £70 (76) £91 (97) £59 (72) £78 (72) 
 Missing (count) 2 0 2 3 
GP - home Yes 1 (3.33%) 2 (6.67%) 3 (10.34%) 2 (7.14%) 
 Number (if yes) 4 2 (1.4) 1 (0) 3 
 Cost (all) £7.26 (40) £7.26 (31) £3.89 (14) £6.05 (31) 
 Missing (count) 0 0 1 1 
GP - phone Yes 11 (36.67%) 11 (36.67%) 7 (24%) 9 (32%) 
 Number (if yes) 1.63 (1.19) 3.27 (4.20) 1.3 (0.52) 5.3 (9.7) 
 Cost (all) £10 (20) £24 (59) £5.71 (12) £26 (100) 
 Missing (count) 3 0 1 3 
Nurse - practice Yes 9 (30%) 10 (33.3%) 11 (38%) 7 (25%) 
 Number (if yes) 3.88 (6.56) 1.3 (0.48) 1.6 (0.8) 2.2 (1.2) 
 Cost (all) £13 (45) £5 (8) £11.79 (18) £9.15 (20) 
 Missing (count) 1 0 0 1 
Home Help Yes 0 2 (6.67%) 0 1 (3.57%) 
 Number (if yes) 0 5.5 (2.1) 0 84 
 Cost (all) 0 £11 (44) 0 £36 (190) 
 Missing (count) 0 0 0 0 
Social Work Yes 0 2 (6.67%) 0 1 (3.57%) 
 Number (if yes) 0 1.5 (0.7) 0 3 
 Cost (all) 0 £6 (22) 0 £5.89 (31) 
 Missing (count) 0 0 0 0 
Physiotherapist  Yes 7 (23.33%) 13 (43%) 5 (17%) 16 (57%) 
- hospital Number (if yes) 3 (2.1) 4.9 (5.4) 2.8 (2.9) 4.3 (4.1) 
 Cost (all) £24 (54) £64 (139) £16 (53) £82 (127) 
 Missing (count) 0 1 0 1 
Physiotherapist -  Yes 0 2 (6.7%) 0 3 (10.71%) 
home Number (if yes) 0 1.5 (0.7) 0 1 
 Cost (all) 0 £6.7 (27) 0 £2.58 (13) 
 Missing (count) 0 0 0 2 
Physiotherapist  Yes 2 (6.7%) 3 (10%) 1 (3.45%) 2 (7.14%) 
- GP practice or  Number (if yes) 2.5 (2) 2.5 (2) 0 12 
clinic Cost (all) £6 (27) £6.21 (27) 0 £16 (83) 
 Missing (count) 0 1 1 1 
Physiotherapist  Yes 1 (3.3%) 0 0 0 
Private - home Number (if yes) 5 0 0 0 
 Cost (all)     
 Missing (count) 0 0 0 0 
Physiotherapist  Yes 3 (10%) 2 (6.7%) 1 (3.45%) 5 (17.86%) 
Private  Number (if yes) 1.7 (0.6) 11.5 (12) 2 5 (1.4) 
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Resources utilised BASELINE FOLLOW-UP 
  
Intervention 
n=30 
Control 
n=30 
Intervention 
n=29 
Control 
n=28 
Outpatient Cost (all) *    
 Missing (count) 0 0 0 0 
Physiotherapist  Yes 2 (6.7%) 0 0 0 
Private Hospital Number (if yes) 4 (0) 0 0 0 
 Cost (all) *    
 Missing (count) 0 0 0 0 
Occupational  Yes 3 (10%) 1 (3.6%) 0 3 (10.71%) 
Therapist Number (if yes) 1 1 0 2 (0) 
Hospital (NHS) Cost (all) £1 (5.2) £1 (5.2) 0 £6 (18) 
 Missing (count) 2 0 0 0 
Occupational  Yes 1 (3.3%) 3 (10%) 1 (3.45%) 2 (7.14%) 
Therapist Number (if yes) 1 1.5 (0.7) 0 1 (0) 
Home (NHS) Cost (all) £1.30 (7.1) £4.17 (16) 0 £2.79 (10) 
 Missing (count) 0 1 1 0 
Occupational  Yes 0 0 0 0 
Therapist Number (if yes)     
Hospital or Home Cost (all)     
(Private) Missing (count)     
Accident &  Yes 3 (10%) 5 (17%) 3 (10.34%) 4 (14.29%) 
Emmergency Number (if yes) 2 (0) 1.2 (0.4) 1.3 (0.6) 1.8 (1.0) 
 Cost (all) £25 (76) £25 (60) £17 (55) £31 (87) 
 Missing (count) 0 0 0 0 
Elective Yes 1 (3.3%) 2 (6.7%) 0 0 
Overnight  Bed days (if yes) 2 2   
hospital stay Cost (all) £94 (513) 97 (522)   
 Missing (count) 0 1   
Non-Elective Yes 2 (6.7%) 3 (10%) 1 (3.45%)  1 (3.57%) 
Overnight Bed days (if yes) 5 (2.8) 5.5 (6.4) 9 1 
hospital stay Cost (all) £176 (724) £200 (980) £164 (881) £19 (100) 
 Missing (count) 0 1 0 0 
Intensive care or Yes 0 1 (3.3%) 1 (3.45%)  1 (3.57%) 
High dependency Bed days (if yes)  4 4 5 
overnight stay Cost (all) 0 £33 (181) £34 (184) £35 (187) 
 Missing (count) 0 1 0 0 
Outpatient Yes 14 (46.7%) 22 (73.3%) 10 (35%) 15 (54%) 
hospital  Number (if yes) 1.7 (1.3) 2.7 (4.2) 1.4 (0.5) 2.6 (2.2) 
appointment Cost (all) £85 (136) £216 (422) £50 (82) £149 (226) 
 Missing (count) 1 1 0 1 
Day case Yes 1 (3.3%) 6 (20%) 3 (10.34%) 10 (35.71%) 
procedure or test Number (if yes) 4 1.8 (1.3) 1 (0) 2.1 (1.8) 
 Cost (all) £94 (514) £258 (653) £49 (182) £495 (1011) 
 Missing (count) 0 0 0 1 
See next page for totals. 
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Resources utilised BASELINE FOLLOW UP 
  
Intervention 
n=30 
Control 
n=30 
Intervention 
n=29 
Control 
n=28 
 
Community  Average  (SD) £118 (146) £202 (367) £77 (67) £192 (243) 
care cost  Missing no. (%) 2 (6.7%) 1 (3.3%) 3 (10.34%) 4 (14.29%) 
      
 
Acute care cost Average (SD) £449 (1038) £517 (850) £330 (1105) £840 (1227) 
 Missing no. (%) 2 (6.7%) 2 (6.7%) 0 2 (7.14%) 
      
 
Total cost Average (SD) £579 (1056) £719 (905) £441 (1167) £1104(1378) 
 Missing no. (%) 3 (10%) 2 (6.7%) 3 (10.34%) 6 (21%) 
      
Community care costs are those that do not occur in a hospital setting (e.g. GP, practice nurse, 
community physiotherapy and social work). Acute care costs are costs incurred in a hospital 
setting (e.g. inpatient admissions and outpatient hospital appointments). The sum of each 
column does not exactly equal listed total costs due to adjustments for missing data. 
* Costs were not calculated for these items as they are unknown, and were overall negligible 
to the total costs. Future questionnaire ask for private therapy costs. 
 
 
Table 6.12. Number of medications taken 
Number of Regular 
Medications 
BASELINE 6 MONTHS 
Intervention 
n=30 
Control 
n=30 
Intervention 
n=29 
Control 
n=28 
Mean (SD) 3.9 (3.6) 4.6 (3.4) 3.4 (3.7) 3.9 (3.7) 
Median 3 4 2 3 
Min 0 0 0 0 
Max 13 14 13 14 
Taking 5 or more 
medications 
33% 47% 28% 29% 
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Chapter 7 Feasibility Study Discussion 
7.1 Key Findings Related to Feasibility 
A randomised feasibility study of specialist physiotherapy for FMD was conducted, 
with the primary aim of determining the feasibility of conducting a large scale RCT of 
such an intervention. Recruitment rate, enrolment and retention were high and clinical 
outcomes were promising, providing evidence that an appropriately powered RCT is 
feasible, timely and important. 
7.1.1 Recruitment and Retention 
Thirty-two per cent of new patients presenting with FMD to the recruiting neurology 
clinic met the selection criteria, with a 90% enrolment rate and only a 5% drop out rate 
subsequently from the study. Given the high prevalence of such patients in general 
neurology clinics it follows that there should be sufficient patients to run a larger 
version of this trial.4,183  Problems with travel to follow up assessment appointments 
were the most common reason for missing data. A future trial that minimises travel 
requirements should reduce loss. 
7.1.2 Fidelity to the Intervention 
Fidelity to the intervention as gauged by attendance, completion of the intervention 
workbook and participant feedback was high. Fidelity is defined as the degree to which 
the intervention was implemented as intended. Assessing fidelity is an important 
consideration in the design of a large trial, as it  is required in order to make causal 
claims about the intervention and to reduce the chance of type I or II errors.184 The 
treatment workbook provided a useful measure of fidelity as it logged the education, 
movement retraining and self-management components of the intervention. In 
addition, the daily reflections that participants were requested to write provided 
insight into their levels of engagement. In the feedback forms, participants were asked 
to respond to the following statements: The programme helped me understand my 
symptoms; The programme helped me gain more control over my symptoms; The 
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programme has helped me to create a plan to improve my symptoms; and The 
programme included information about thoughts, feelings and psychological 
influences on my symptoms. These statements relate to the key components of the 
intervention, which were: education, movement retraining, enabling self-management 
and considering symptoms within a biopsychosocial framework. These measures of 
fidelity proved to be practical and useful.   
7.1.3 Acceptability of the Intervention 
The high rates of recruitment, retention, and fidelity point to the intervention being 
acceptable. This is supported by the positive ratings in the post intervention feedback 
questionnaire. 
7.1.4 Safety  
There were no reported serious adverse events associated with the intervention in 
either group. Temporary exacerbation of chronic pain and fatigue was not considered 
to be an adverse event. On the contrary, exposing such patients, who may otherwise 
exhibit avoidant behaviour, to activity may have therapeutic value. It is likely that the 
relatively high intensity and short duration is an important therapeutic element of the 
intervention, but this may make it unsuitable for some patients. With this in mind, 
patients were excluded if chronic pain or fatigue was the dominant problem; however 
half the enrolled participants still rated their pain and fatigue as severe to extreme at 
baseline.  
No mental health related adverse events associated with the physiotherapy treatment 
were found. Patients with clinically evident anxiety and depression warranting 
assessment were excluded from the study and referred to more appropriate 
treatment. On average, measures of mental health (HADS and SF36 Mental Health 
domain) did not change in either group.  
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7.1.5 Determining a Primary Outcome for a Future Trial 
An important aim of this research was to test the utility of a range of outcome 
measures and determine which is the most suitable to use in a power calculation for a 
future clinical trial. Measuring outcome in FMD is complicated by the variable nature 
of symptom severity inherent to the diagnosis. For this reason, snapshot measures of 
disability are likely to have problems with test-retest reliability, limiting their 
usefulness. Gait and balance outcome measures are restrictive as they are not 
applicable to patients with upper limb symptoms only. The SF36 Physical Function 
domain was the most promising potential primary outcome. It had a medium to large 
effect size (d=0.70), it was applicable to all participants, and it is not as vulnerable to 
symptom fluctuation as answers are given based on the respondent’s perception of 
the average experience within the set recall period of four weeks. 
7.2 Clinical Outcomes 
To my knowledge, this is the first reported randomised study of physical rehabilitation 
for FMD, with a control period greater than four weeks. With the caveat that this 
research was primarily designed to assess feasibility, the study found a moderate to 
large treatment effect size across a range of measures of physical function, compared 
to a treatment as usual control. In addition, a larger proportion of the intervention 
group rated their symptoms as improved (72%) compared to the control group (18%) 
on the Clinical Global Impression scale (CGI). Also of note, 32% of the control group felt 
their symptoms had worsened over the follow up period, compared to only 3% in the 
intervention group.  
The agreement between the CGI (patient impression of change) and other outcome 
measures in the intervention group, suggests the reported treatment effect most likely 
represents a clinically significant difference. Minimum clinically important difference 
(MCID) values differ between conditions and vary widely between studies. The MCID 
for the SF36 has not been well established. A review of MCID in hip and knee 
orthopaedic surgery found 3 studies reporting MCID for the SF36 Physical Function 
domain; these were 3.2 (95% CI 2.8,3.9), 11.6 (95% CI 6.5-16.7) and 20.4 (95% CI 14.4-
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26.4)142. The difference between groups in the current study for this outcome was 19.8 
(95% CI 10.2, 29.5).  
The improvements reported occurred in a sample of patients with characteristics 
commonly associated with a poor prognosis. The average symptom duration was 5·8 
years (SD 7·3), participants had multiple coexisting symptoms, and high rates of 
unemployment due to ill health. It is possible that if the intervention occurred earlier 
in the course of their disorder, it may have been more effective. 
Subgroup analyses were performed as an exercise in hypothesis generation, 
recognising that there was insufficient power to detect a statistically significant 
association. In the intervention group, there was no association between the presence 
of anxiety or depression (as defined by a HADS anxiety or depression score of 10 or 
greater) and outcome (good outcome or poor outcome as defined by the CGI). When 
the baseline demographic and clinical variables of the intervention group were 
compared between those with good versus poor outcome, there was a significantly 
higher proportion of participants with high pain levels (self-rating of severe to extreme 
pain) in the poor outcome subgroup. This needs further investigation, however it may 
indicate that severe pain is associated with a worse prognosis. If this is the case, it may 
suggest that a different treatment approach is required when patients report severe 
pain; or that a future trial may wish to consider stratifying participants by pain level 
during randomisation. There is no good evidence that a future trial should exclude 
participants based on any of the variables measured in this trial, which suggests the 
study eligibility criteria were appropriate.  
7.2.1 Comparison to Similar Studies 
The effect size of the intervention across the outcome measures assessed is consistent 
with those in similar published studies in FMD. Direct comparison of study outcomes is 
limited by differences in study design, interventions, follow up time frames, and use of 
outcome measures.  
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Jordbru et al (2013)73 reported a larger treatment effect at 12 months in the 
Functional Mobility Scale and Short Form 12 physical score (comparable to the Short 
Form 36 Physical Summary score185) compared to the current study (Functional 
Mobility Scale: 6.9 units compared to 3.4; SF12: 11.7 units compared to 5.4). Some of 
this difference may be explained by the shorter symptom duration in their participants 
(9.5 months compared to 5.8 years) and lower scores at baseline. Other significant 
differences between studies include the nature of the intervention (three week 
multidisciplinary inpatient rehabilitation) and absence of a control comparison beyond 
4 weeks, so regression toward the mean is not accounted for in their 12-month follow-
up measures. 
My previous cohort study of the same intervention, published in 2015,1 reported 
similar outcomes at three months to the current study. The gain in the SF36 Physical 
function domain was greater in the current study (19.8 units compared to 8.9), but 
other outcomes showed a slightly greater treatment effect in the cohort study, 
including SF36 Physical Role, Berg Balance Scale and 10-metre timed walk. An 
interesting difference between these studies was the proportion of the different 
symptom phenotypes. The earlier cohort study had a larger proportion of subjects 
with fixed dystonia (25% compared to 3% in the current study), a condition that shares 
many characteristics with complex regional pain syndrome and is often associated with 
soft tissue contracture.65 As such, fixed dystonia may have physiological limitations on 
recovery rate.  
Czarnecki et al (2012)75 reported a retrospective cohort of 60 patients with FMD who 
received an intensive 5-day physiotherapy and occupational therapy intervention 
following a mechanistic explanation for their symptoms (symptoms due to disconnect 
between brain and body). Outcome was reported as patient perception of change. 
Immediately after treatment, 69% of patients rated their symptoms as markedly 
improved or resolved and 60% at one year postal follow. These results are similar to 
the 72% with a good outcome at six months reported in the present study. 
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7.3 Health Economic Analysis 
7.3.1 Cost Utility Analysis 
The EQ-5D-5L is the preferred instrument for generating Quality Adjusted Life Years 
(QALYs) by the UK organisation the National Institute for Health and Care Excellence 
(NICE).186 The average difference in QALYs between the groups adjusting for baseline 
differences was 0.08 QALYs and the resulting incremental cost effectiveness ratio of 
(ICER) £12,087 suggests the intervention is most likely to be cost effective. In general, 
an ICER below £20,000 is considered cost effective.177 This is without accounting for a 
potential reduction in the costs of health and social care utilisation, reduction in 
disability benefits and return to paid employment. In our sample, we found little 
overall change in employment status over the six month period. In the intervention 
group, one participant was medically retired, another reduced to part time hours and 
one participant moved from unpaid voluntary work to part time paid work. In the 
control group one part time worker stopped work due to ill health.  
ICER’s are reported by a number of large therapy trials for chronic conditions. An 
appropriate comparison to the current study is the PACE trial, which compared 
adaptive pacing, cognitive behavioural therapy (CBT), graded exercise and specialist 
medical care for symptoms of chronic fatigue syndrome at 12 months.187 Compared to 
specialist medical care, the ICER’s were £18,374 for CBT, £23,615 for graded exercise 
and £55,235 for pacing. Studies of therapy for subacute to chronic low back pain 
(including group treatments) have reported more impressive ICER’s ranging from 
£1,786 to £8,700.188 
7.3.2 Health Service Use: CSRI 
The primary purpose for including the CSRI was to inform the design of a version of 
this questionnaire to be used in a future RCT. Overall the CSRI questionnaires had fair 
levels of completeness. Adjustments to the questionnaire may help to reduce missing 
data. Only 59% of eligible employees reported their annual income and participants 
may have been uncomfortable sharing this information. An alternative to consider in a 
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future iteration of the CSRI would be to estimate incomes using standard reference 
figures based on reported occupation and hours worked. There was insufficient 
information in the CSRI to determine sickness absence as a proportion of hours 
worked and the cost impact of improved engagement with employment. An additional 
questionnaire, such as the Work Productivity and Activity Impairment 
Questionnaire,189 may be required for a more robust cost-impact analysis in a future 
trial. Encouraging participants to bring pharmacy medication lists to their appointment 
should help improve the accuracy of medication reporting. 
Acute care costs made up 75% of the total costs and a future version of the CSRI 
should focus more attention on these costs. More information is required in order to 
reduce the number of assumptions made regarding the actual services received and 
the associated costs. Additional information should include the reason for any hospital 
admission, the medical discipline under which the admission was recorded (e.g. 
neurology, endocrinology, etc.), the procedure(s) or interventions performed, the 
length of appointment/admission, and the health professionals/disciplines involved. A 
future CSRI should also ask for costs paid for private services and to improve the 
quality of the data, the questionnaire could be administered rather than self-report. 
Overall, the intervention group reported lower total costs than the control group at six 
months, £441 (SD 1167) compared to £1,104 (SD 1378). All service costs were higher 
for the control group, except for seeing a nurse at the GP practice and elective 
overnight hospital admissions. In addition, the intervention group reported a reduction 
in sickness absence. These results are promising; however, in order to consider if the 
intervention may have contributed to the cost difference found, a larger sample size 
and more information would be required. Given that some service costs for both 
groups reduced at six months (e.g. GP appointments, community physiotherapy, non-
elective hospital admissions), regression to the mean may account for some changes.  
7.4 Mechanism 
The B-IPQ total score is thought to represent the threat value of an illness. The 
intervention was associated with a reduction in the B-IPQ total and there was little 
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change in the control group. It is hypothesised that the intervention helped 
participants to understand their symptoms and improve control over their movement, 
both of which resulted in diminished concerns. This may represent one mechanism by 
which the intervention affects change, although it is noted that in some health 
conditions, the total B-IPQ score as an outcome measure may have problems with 
internal consistency.190  
On average, measures of mental health (HADS anxiety and depression scores and the 
SF36 Mental Health domain) did not change; however an interesting finding was an 
increase in the number of participants reaching levels of  anxiety ‘caseness’ in the 
intervention group. This may be a clinically insignificant chance occurrence. However if 
it represents a true change in these participants, it can be interpreted in a number of 
ways. A superficial interpretation is that the intervention made some participants 
more anxious. An alternative explanation is that the intervention helped some 
participants gain a better insight into their symptoms, leading them to rate their 
anxiety higher; and/or the trust and therapeutic rapport developed over the 
intervention period reduced the participant’s concerns about reporting psychological 
symptoms. These interpretations would provide support for the intervention aim of 
helping the patient to understand their problem within a biopsychosocial framework. 
7.5 Limitations  
There are a number of limitations to this study. It was not specifically designed or 
powered to detect a treatment effect. However, given the absence of controlled trials 
in the literature it was considered appropriate to report the clinical outcomes. At 
baseline, the control group had scores that represented worse health than the 
intervention group. The analysis accounted for baseline differences and there was still 
a large treatment effect with the intervention and little or no change with the control 
condition. A larger, powered study is less likely to have such discrepancies between 
groups; however a future trial could also consider a randomisation procedure that 
involved minimisation to account for baseline severity.  
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Another limitation was that the participants and assessors were not masked to 
treatment allocation, which may have introduced bias. Most outcomes were subjective 
patient reported outcomes, which may be influenced by many factors, including the 
lack of blinding. However the S-FMDRS was scored blindly (by video) and showed the 
largest treatment effect size (d=0.79). 
A potential criticism is that the criterion for excluding patients with anxiety and 
depression was not operationalised. Clinical judgements were made by clinical 
impression based on whether it was felt that levels of anxiety or depression would 
interfere with engagement with the treatment, as we were unable to find an 
assessment tool suitable for this purpose. Other limitations were the lack of 
standardisation of the control condition and that follow up was limited to six months. 
Additional reflections on the trial methodology can be found in Appendix 8 (page 242).  
7.6 Generalisability 
A strength of this study was that the sample was generally representative of the 
population suitable for physiotherapy, thereby increasing generalisability. We did not 
exclude participants on the basis of age, symptom duration, phenotype, and 
availability of medical insurance as other studies have done.73,75 Also, most eligible 
participants elected to take part. We did however exclude participants with a primary 
problem of pain, fatigue or dissociative seizures and those who had significant 
comorbid psychopathology, for which there are specific specialist treatments available 
on the NHS. 
Being a single centre study, it is not known whether these results could be replicated 
outside the study setting; thus, a multicentre RCT is required. Together with the 
previous cohort study,1 this study provides useful  preliminary evidence that other 
physiotherapists can be taught to deliver the intervention. 
7.7 Clinical Implications 
This study adds to a growing body of evidence supporting specialist physiotherapy and 
physical rehabilitation for FMD. The intervention in this research differs from standard 
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physical rehabilitation in a number of key ways. Firstly, and similarly to some 
physiotherapy led interventions for chronic pain,160 there was an emphasis on 
symptom education. Secondly, movement retraining aimed to distract participants’ 
attention away from the body. Rehabilitation for neurological disease often 
encourages the patient to think about movement or attend to their body, which is 
known to exacerbate FMD and therefore such an approach can be counterproductive. 
The different approach required for treatment of FMD compared to other neurological 
symptoms suggests there may be a role for specialist clinicians and highlights a need 
for treatment to be delivered by experienced or well informed clinicians. Another 
potential difference from standard physiotherapy was the high intervention intensity 
and short duration. 
7.8 Future Research 
Aside from support for progressing to a powered RCT, this study highlights some 
directions for future research. Measuring outcome in FMD remains challenging and 
currently available outcome measures do not appear to reflect the true burden of the 
diagnosis. An assessment tool specifically designed for FMD may increase sensitivity, 
validity and reliability of outcome measurement. A specific tool should consider the 
burden from comorbidity (such as pain, fatigue, anxiety, bladder dysfunction, etc.); the 
variable nature of the motor symptoms, and the impact across biopsychosocial 
domains. The intervention could be further developed and refined based on research 
aiming to elucidate the mechanisms by which it is likely to work. There may be several 
factors mediating recovery, possible candidates are: a change in illness belief, reduced 
self-focused attention during movement, acceptance of the diagnosis, understanding 
the diagnosis, reduced threat value of symptoms, a sense of self efficacy, reduced 
avoidance behaviour, reduction in perceived pain level, and increased physical activity. 
Finally, there may be value in exploring common symptom phenotypes (e.g. weakness, 
tremor, dystonia) independently, which may lead to more effective treatments. 
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7.9 Conclusions 
In summary, this study demonstrates the feasibility of performing a larger trial of 
specialist physiotherapy for FMD. A large treatment effect and evidence of cost benefit 
was found in a group of patients that are prevalent, have poor quality of life and have 
a poor prognosis with the current standard treatment. The study data strongly support 
the need for a multicentre randomised trial of this intervention.  
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Chapter 8 Qualitative Study – Introduction and Methods 
A Longitudinal Qualitative Study of Patients with Functional Motor Disorder Selected 
for Specialist Physiotherapy 
8.1 Introduction 
In the previous chapters I have described the development and feasibility assessment 
of trialling a specialist physiotherapy programme for patients with functional motor 
disorder (FMD). Embedded in this research, was a longitudinal qualitative study of the 
subjective experiences of participants receiving the study intervention.  
There is little qualitative data about patients with FMD. Studies of neurologists, 
neuroscience nurses and physiotherapists report that clinicians find these patients 
clinically challenging and often have negative attitudes towards them.145,192,193 
However, we know little about patients’ perspectives, such as their perceptions about 
getting this diagnosis and interactions with health care professionals (HCP), how it 
feels to have FMD and priorities and preferences for treatment. Results from previous 
clinical trials suggest that physical rehabilitation for FMD leads to improved measures 
of disability and quality of life,1,73,75 but these quantitative values provide little insight 
into the real world impact of treatment. Qualitative research methods are an ideal way 
to explore these unknowns, which are important to consider in order to develop an 
intervention that is both effective and acceptable to patients. 
Qualitative research embedded into a clinical trial can provide additional rich 
explanatory data. This includes information about the acceptability of the intervention, 
potential mechanisms involved in the intervention, explanations for why a particular 
outcome occurred, and outcomes that may not be captured with quantitative 
measures. At the feasibility stage, findings from qualitative research can be used to 
optimise the intervention and inform the design and conduct of a definitive clinical 
trial.194  
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The current literature, while limited, provides some data on patient perspectives. 
Nettleton et al (2005)195 explored perspectives of patients with “medically 
unexplained” neurological symptoms with a narrative analysis of in-depth interviews. 
This cohort of 18 patients recruited from neurology clinics was similar to those in the 
current feasibility study in that participants had motor symptoms (spasms and 
paralysis) and/or non-motor symptoms (blurred vision, non-epileptic seizures, pain, 
fatigue, etc.). A difference was that some of the patients in the Nettleton study only 
had non-motor symptoms. A key finding from that study was that participants 
commonly felt that clinicians, family and acquaintances saw them as a fraud, time 
waster, hypochondriac or malingerer and that such perceptions were associated with 
their symptoms being classified as psychological. Patients felt they had been 
marginalised from medicine; the authors used the phrase Medical Orphans to describe 
this. The patients’ narratives were classified as chaotic, without a clear beginning, 
middle and end. This was related to their difficulties in articulating their problem and 
entering a sick role that was legitimised by the system. The authors suggest that the 
practical implications from their findings include the importance of listening to 
patients’ narratives, and acknowledging their symptoms as genuine. They also suggest 
there may be value in the doctor providing explanations that may in part be consistent 
with the patient’s point of view. 
Qualitative research methods have been used more extensively to study patients with 
the related condition of non-epileptic seizures. Non-epileptic seizures, also called 
functional seizures, are usually thought to have a shared aetiology with FMD and 
patients with non-epileptic seizures also commonly experience functional motor 
symptoms. Rawlings and Reuber (2016)196 produced a narrative systematic synthesis of 
qualitative studies investigating patients’ accounts of living with non-epileptic seizures. 
From 21 studies including 220 patients they identified themes relating to the symptom 
(seizure event), diagnosis, treatment, emotional events and the impact of the 
symptoms. In regards to the diagnosis, they found that many patients felt confused 
and often exhibited resistance to psychological attributions being suggested. Patients 
felt isolated, they usually described an inability to work and often felt a sense of loss. 
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The illness beliefs of patients with FMD have been explored using questionnaires. It 
was found that a patient expectation of non-recovery and non-attribution of 
symptoms to psychological factors (believing that psychological factors are not 
relevant) are predictive of poor outcome.153 This study supports the importance of 
considering patients’ beliefs and expectations as part of their treatment, although the 
research was not designed to explore why participants held particular illness beliefs.  
Thus, the existing small body of research shows that patients with FMD often have 
difficulty understanding the diagnosis and often show resistance to psychological 
explanations. There is however little data to suggest why patients may hold these 
particular points of view and how their beliefs and experiences influence their 
interaction with treatment. Confirming or disconfirming these findings and exploring 
other themes in a cohort with an established diagnosis of FMD is of high clinical 
relevance.  
In this qualitative study, I aimed to develop an understanding of the participants’ 
perspectives and experiences of their journey from developing FMD to completing the 
study intervention. In particular, I planned to explore how they interacted with the 
intervention and its impact on their life at six months follow up. To gain a greater 
understanding of the intervention, I planned to explore the data for evidence of how it 
may have helped participants, and the underlying mechanisms for this, or conversely 
why it may have failed to help. 
8.2 Methods 
8.2.1 Ethics Approval and Consent 
Ethics approval for this study was obtained from the National Research Ethics Service 
Committee London – City Road & Hampstead (14/LO/0572). All participants gave 
written informed consent. See Appendix 9 and 10 (page 246 and 249) for patient 
information sheet and consent form. 
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8.2.2 Study Design 
I employed longitudinal semi-structured interviews to explore participants’ beliefs, 
perceptions and experiences. The longitudinal design enabled change associated with 
the intervention to be a key focus of the interviews and analysis, as well as 
investigating the possible causes and consequences of such changes and the 
usefulness or otherwise of the intervention over a longer period.197  
8.2.3 Purposive Sampling 
I selected the qualitative study participants purposively from those allocated to the 
intervention condition of the feasibility study. Purposive sampling is designed to 
achieve symbolic representation of the diversity of the population being studied but 
not necessarily a proportional and statistically representative sample.198 The purposive 
sampling criteria were designed to ensure representation of common symptom 
phenotypes, symptom duration, age and gender. See Table 8.1 for purposive sampling 
criteria. A minimum of eight participants were required to meet these criteria, but I  
planned to recruit a minimum of 10 participants, and up to 20 if I felt that I had not 
approached data saturation.  
Table 8.1. Purposive sampling criteria (participants could be represented in more 
than one box) 
Criteria Aimed minimum number to recruit 
Symptom Tremor 1 
Gait Disturbance 1 
Mixed Movement Disorder 1 
Weakness 1 
Symptom 
duration 
Less than 18 months 2 
18 months to 5 years 2 
More than 5 years 2 
Age bracket 18-29 2 
30-59 2 
60+ 2 
Gender Male 3 
Female 5 
 
I chose these particular purposive sampling criteria as they may influence the lived 
experience of having FMD or be associated with different prognoses. For example, 
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different symptom phenotypes may have greater or lesser association with common 
comorbidities such as pain, fatigue, anxiety or depression; however, research exploring 
subgroups of FMD is scarce. A systematic review of the prognosis of FMD found that a 
shorter duration of symptoms has consistently been found to predict a better 
outcome; whilst younger age predicted a better outcome in some studies but not 
others and no study has found gender to have an effect on outcome.70 I am not aware 
of any studies comparing the outcomes of functional motor symptom phenotypes. As 
baseline interviews were conducted prior to commencing the intervention, it was not 
possible to purposively select participants based on intervention outcome; that is, to 
ensure a mixture of participants rating their symptoms as improved, no change and 
worse. 
Symptom phenotypes were tremor, gait disturbance, weakness and mixed movement 
disorder. Mixed movement disorder represented a mixture of dystonic-type 
movement, tremor and weakness. Symptom duration brackets were chosen to ensure 
inclusion of participants in the ‘relative’ acute phase (less than 18 months); 
participants with chronic symptoms (18 months to 5 years); and those with a long term 
condition (5 years or greater). Age brackets were chosen to represent key phases of 
adulthood: 18-29 = ‘Early’ adulthood, capturing participants prior to having 
dependents/children and an established career; 30-59 = ‘Mid’ adulthood, capturing 
participants who may have dependents and are at working age; and 60+ = ‘Mature’ 
adulthood, capturing participants who may be in or approaching retirement. Nested 
criteria in the form of a sampling matrix (e.g. having a spread of ages across symptom 
type) was not feasible given the proposed sample size. The gender proportion was 
biased toward females, as this reflects epidemiological findings that FMD is more 
common in women by a factor of 2–3:1.20 
8.2.4 Data Collection 
I interviewed participants in the qualitative study at (i) baseline (following initial 
consultation with the study neurologist, but prior to starting the intervention), (ii) 
post-treatment (after the final physiotherapy session), and (iii) at six months follow up. 
Interviews were conducted in outpatient clinic rooms at the National Hospital for 
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Neurology and Neurosurgery. Family, friends and partners were asked to step out of 
the room during interviews. The interviews were semi-structured, following a topic 
guide. The topic guide was prepared and piloted in a practice interview. The topic 
guide was updated throughout the data collection period in an iterative manner to 
explore emerging themes. I recorded Interviews using a digital voice recorder 
(Olympus VN-732PC) and later transcribed them verbatim, with identifying data 
removed to preserve anonymity.  
Where possible, I transcribed interviews on the day they were recorded and aimed to 
complete interview transcription within one week. During transcription, interviews 
were played at reduced speed (50-100%) using Media Player for Windows version 7 
and transcripts were typed into Word, Microsoft Office Professional Plus 2013. 
8.2.5 Data Collection Reflexivity 
I introduced myself to interview participants as a physiotherapist who was part of a 
team researching FMD. The study neurologist may have previously introduced me as a 
specialist physiotherapist in FMD in the clinic where patients were being recruited for 
the study. How the participants responded to the interview questions is likely to have 
been influenced by my perceived status and connection to the treating clinicians. For 
example, some participants may have felt concerned about appearing ignorant when 
discussing their understanding of their disorder or concerned about appearing 
ungrateful when discussing ongoing problems after the intervention. On a few 
occasions, some interviewees avoided answering questions by turning the question 
back on me. I responded by saying that I did not know the correct answer or that there 
were no right or wrong answers. I attempted to distance myself from the clinical team 
and environment by wearing casual clothes, choosing interview rooms with less of a 
clinical feel and providing tea and coffee.   
From the outset of this study, I had a particular understanding or conceptual model for 
FMD that was influenced by my experiences working with this patient group over 
several years. This experience included working within a neuropsychiatry led 
multidisciplinary rehabilitation programme and setting up a specialist physiotherapy 
140 
 
service for FMD. I considered FMD to be a genuine problem that is distinct from 
malingering and to be a heterogeneous biopsychosocial condition that is commonly 
precipitated by physical events. I believed that psychological factors are relevant to 
FMD, but that the relative importance and severity varies between individuals. My 
assumption was that patients with less significant psychopathology were more likely to 
benefit from the study intervention. My particular beliefs may have impacted on my 
line of questioning and the focus of the interviews. 
Prior to this study, I had no experience in qualitative research. As the study 
progressed, through a process of regular supervisory feedback and reflection, my 
interview skills developed leading to better quality data. Transcribing interviews as I 
went along allowed me to receive and act upon supervisory feedback. Personally 
transcribing each interview and by necessity listening and re-listening to each 
interview during transcription gave me the opportunity to reflect on my interview 
technique and get to know my data in depth. 
An early limitation of my interview style was asking clinically orientated questions, 
such as asking for information regarding previous interventions and their outcome. I 
was mindful of avoiding ‘clinical questions’ in subsequent interviews and endeavoured 
to maintain a focus on the participants’ real-life experiences and perceptions. Another 
limitation of my early interviews was that at times I would summarise what people had 
said, potentially imposing my interpretation and meaning on the conversation. Other 
early limitations and potential issues that I noted and was mindful to avoid in 
subsequent interactions were: filling ‘awkward’ silences rather than leaving space for 
the participant to talk; closing topics of conversation too early; leading questions (e.g. 
“Was it difficult when…”); double questions (why and how); and finally on a few 
occasions I prefaced questions with an apology that they were difficult (e.g. “I’m sorry 
this is a difficult question, but can you tell me…”). Improvements that can be seen in 
later interviews include leaving longer silences to give space for participants to speak; 
using probes more effectively to explore topics; and an improvement in the flow of 
interviews, with fewer leading questions.  
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The model with which I conceptualised patients with FMD changed subtly during data 
collection and analysis. Some preconceptions softened, which allowed me to let 
people express their own understanding with less influence from my own beliefs via 
leading questions and specifically focused questions. As an example, I initially made 
the assumption that all participants would be offended by psychological symptom 
explanations, which was not necessarily the case. With a softened stance, I allowed 
participants to tell their own story, rather than shifting the topic of conversation to 
what I perceived to be important. There were incidental consequences of the 
longitudinal research design. The three interviews over six months allowed 
development of rapport and trust. I found that some participants would reveal more 
intimate information in subsequent interviews, such as personal relationship issues, 
mental health history and difficult experiences from their past.  
8.2.6 Analysis 
Data were analysed using inductive thematic analysis. The approach was informed by 
the process described by Braun and Clarke (2006),199 which identifies six phases of 
analysis: (i) familiarisation with the data, (ii) generating initial codes, (iii) searching for 
themes, (iv) reviewing themes, (v) defining and naming themes, and (vi) producing a 
report. Thematic analysis was chosen as the method of analysis for several reasons. 
First, it can be considered a foundation method of analysis, suitable for novice 
qualitative researchers.199 Second, thematic analysis is flexible, in that it is free from 
theoretical commitments, unlike other specific methods of analysis.199 Finally, I wanted 
to perform an inductive analysis, where themes are derived directly from the data, 
rather than from interview questions or my preconceptions.  
Analysis was concurrent with data collection, allowing the interview topic guide to be 
updated iteratively in order to explore emerging themes. Familiarisation with the data 
started during transcription; this allowed time to think about the data and consider 
any changes in the patients’ perspectives across the time points. Each interview 
transcript was then read, re-read, highlighted and annotated in a process of 
familiarisation with the data. Selected interviews were discussed in detail with the 
analysis team (Fiona Stevenson, Medical Sociologist and Marta Buszewicz, Academic 
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GP and Clinical Trialist), which met at regular intervals throughout the data collection 
and analysis period. Topics and themes from each interview were identified and 
discussed.  
After I had transcribed, annotated and highlighted all the interviews, I collated a 
comprehensive list of topics from all the transcripts. This list was refined by consensus 
within the team and then used to create a coding framework (see Appendix 11 page 
250, for the list of codes). Each transcript was then coded according to the coding 
framework with the aid of the computer software, NVIVO for Windows, version 10. 
Data for each code was retrieved and subjected to further analysis. The data was 
considered within cases, where the unit of analysis was the participant, and across 
cases, where the unit of analysis was interview time point. The research team agreed 
that the findings from an across case analysis was the better way to address the 
research questions. Themes and subthemes for each time point (baseline, post-
treatment and follow up) were identified from the coded data. The original transcripts 
were then reviewed to ensure the themes were an authentic representation of the 
data and to seek disconfirming data. Un-coded text was examined for disconfirming 
evidence.  
The first draft of the manuscript was then written, with each time point considered 
separately. The final list of themes at each time point was presented initially without 
quotations in order to develop arguments. This draft was then discussed and refined 
by the research team and quotations to support the arguments were then sought from 
the interview transcripts. This gave an additional check that the themes were 
grounded in the data.  
8.2.7 Evolution of the Topic Guide 
The topic guide was updated iteratively based on emerging themes. Some participants’ 
accounts tended towards the factual, with little in the way of expression of feelings. To 
address this issue I made a note to ask for anecdotes, such as “Can you give me an 
example of…” or “Can you tell me about a time when…”.  
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Participants’ views about being given psychological explanations and attitudes towards 
mental health problems emerged as an important theme early in the data collection 
period. I started to explore these issues in more depth and returned to this topic in the 
follow up interviews to look for any changes in perceptions. I also added questions 
about close relationships, as it became clear that family and friends were an important 
part of the participants’ narrative. Finally, in order to encourage constructive feedback 
I started to ask participants how could we have made the programme more helpful 
and asked what advice they would give others in similar situations. As I became more 
familiar with the topic guide I was less inclined to follow it in a linear fashion. See 
Appendix 1 (page 251) for interview topic guide. 
8.3 Sample Description 
From a pool of 29 participants who had been allocated to the intervention condition of 
the feasibility study, 11 fitting the purposive criteria were invited to participate in the 
qualitative study. All invited participants agreed to take part and there were no 
dropouts or missing data.  
Clinical and demographic characteristics are presented in Table 8.2, where participants 
are identified by assigned pseudonyms. The sample is representative of the larger 
feasibility trial sample and similar to previous descriptions of this population.3 The 
average age was 44 (range 21-67), 82% were female and the average symptom 
duration was 6 years (range 1 to 30 years).  There was a mixture of the most common 
symptom phenotypes. 
Table 8.2. Participant clinical and demographic characteristics  
Pseudonym Sex Age Symptom 
Duration (years) 
Symptom 
Amy F 43 2 Head & upper limb tremor 
Michael M 46 2 Mixed movement disorder 
Julie F 50 6 Upper limb tremor & gait 
Lynn F 56 4 Gait disturbance 
James M 36 1 Mixed movement disorder 
Mary F 67 10 Head tremor 
Nicole F 45 4 Gait disturbance 
Deborah F 58 5 Mixed movement disorder 
Sarah F 21 1 Left sided weakness 
Megan F 22 1 Weakness 
Lisa F 43 30 Weakness 
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Table 8.3 presents target versus actual recruitment for the purposive sampling criteria. 
The recruitment targets for each purposive sampling criterion were met, except for the 
number of males and the age bracket 60+. Two out of a planned three men were 
recruited and there was only one out of a planned two participants in the older age 
bracket of 60+. The failure to meet these sampling criteria related to the limited 
number of males and participants aged over 60 recruited and randomised to the 
intervention group.    
Table 8.3. Purposive Sampling Criteria Targets (participants fulfil multiple criteria). 
Criteria Aimed minimum 
number to recruit 
Actual number of 
subjects recruited 
with criterion 
Symptom Tremor 1 3 
Gait Disturbance 1 3 
Mixed Movement Disorder 1 4 
Weakness 1 1 
Symptom 
duration 
Less than 18 months 2 3 
18 months to 5 years 2 5 
More than 5 years 2 3 
Age bracket 18-29 2 2 
30-59 2 8 
60+ 2 1 
Gender Male 3 2 
Female 5 9 
 
Thirty-three Interviews were conducted and analysed (three per participant), ranging 
in length from 36 to 71 minutes. The findings from each interview time point will be 
explored in three separate chapters, Baseline, Post-Treatment and Follow Up. A 
summary of central themes across all time points is presented at the end of Chapter 
11, after the findings from interviews conducted at six month follow up. Quotations 
supporting the findings were found by reviewing the coded transcripts using the 
software NVivo. When it was relevant to the quotation, the interview question was 
included and prefaced with the label “I:”. The participants’ quotes are prefaced with 
the label “R:” for respondent. I aimed to provide a spread of quotations from all 
participants. Each quote ends with the participant’s pseudonym and age in 
parentheses.   
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Chapter 9 Qualitative Findings: Prior to Treatment 
9.1 Introduction 
This chapter will explore themes from the baseline qualitative interviews, conducted 
prior to commencing the study intervention. Several weeks before the interview, the 
participants had attended an initial consultation with the study neurologist (Mark 
Edwards). During this consultation they were given the diagnosis of FMD which was 
explained according to the study protocol. The explanation emphasised the 
importance of self-focused attention as part of the mechanism driving symptoms and 
described psychological issues as part of the problem for some patients but not 
necessarily everyone. Many of the participants had been diagnosed with FMD prior to 
their initial consultation with the study neurologist, although often a different 
diagnostic label was used, such as Conversion Disorder. 
The key themes that emerged from the baseline interviews stem from the participants’ 
lack of understanding of their problem and their perception that health care 
professionals (HCPs) also did not understand their problem. The themes are explored 
under the following sections: Symptom Onset, Early Interactions with Health Care 
Professionals, Resistance to Psychological Explanations, Feeling Unconvinced by the 
Diagnosis, Conflict and Marginalisation, the Impact of their Symptoms, Relationships, 
Isolation, Symptoms Remain Mysterious and Powerlessness.   
9.2 The onset of FMD 
Seven (of the eleven) study participants associated the onset of their motor symptoms 
with a sudden injury, illness or biological event. This event was often perceived as a 
frightening life threatening emergency.  
Respondent (R): I was just cooking some dinner. Making some scrambled egg and 
I went all sort of tingly and on my tongue and down the side of my face. And my 
hand had gone all like [short pause] tingly. And I sort of panicked because working 
in healthcare I was thinking I was having a stroke or something. And I was really 
panicked about it and my mum called 111, which is the out of hours and they sent 
a paramedic around. And they took me to the hospital. [Sarah, age 21] 
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The remaining four participants described a slower more insidious onset of their 
troubling physical symptoms. Consultations with doctors had led them to believe that 
their motor symptoms were associated with neurological disease; specifically multiple 
sclerosis (Nicole), Parkinson’s disease (Julie), scarring seen on her brain MRI (Mary), 
and some as yet undiagnosed neurological problem (Michael). 
R: So I was dragging my leg. And then from then, it’s just been a series of tests, 
different consultants to get to the point where I was then diagnosed with possible 
MS. Through MRI scans, but the leg slowly got worse. [Nicole, age 45] 
Physical or biological precipitating incidents or an initial causal attribution of 
symptoms to neurological disease were central to all the participants’ illness 
narratives.  
9.3 Early Interactions with Health Care Professionals 
The onset of motor symptoms led the participants to a series of interactions with 
HCPs, often initially in the context of a perceived medical emergency. These contacts 
usually became drawn out over a long period of time, while waiting for investigations 
and waiting to be seen by specialist doctors.  
9.3.1 Nobody knows what’s wrong 
The perception of most of the participants was that their doctors did not know what 
was wrong. This belief was reinforced by the commonly reported experience of 
undergoing multiple investigations that failed to identify the cause for their symptoms 
(negative test results). Rather than being reassuring, negative tests were often 
interpreted as the unhelpful and sometimes frightening news that the cause of their 
symptoms remained unknown.  
R: Because I went for the DAT scan, then I went to see the consultant. And he 
showed me the brain results on his screen and told me what the normal levels 
should be. And said well you don’t have Parkinson’s disease, but I don’t know what 
it is that’s wrong… and it was, and then he said you don’t look very happy. But it 
was plunging at the unknown then as I hadn’t a clue what the diagnosis was. [Julie, 
age 50] 
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Other events that led participants to believe that nobody understood their problem 
were successive referrals to different medical specialists that often did not result in a 
conclusive diagnosis; conflicting information from different doctors; and prescribed 
treatments or advice that were considered in retrospect to be unhelpful or harmful.  
9.3.2 Harmful treatments 
Six out of the 11 participants reported that they had been given inappropriate 
treatment that they believed made their problem worse. These treatments were: 
treatment with anti-Parkinson’s disease medication (Julie, see quote below); advice to 
use alcohol to control a tremor (Mary, see quote below); provision of splints without 
follow up (Lisa, see quote below); prescription of escalating doses of benzodiazepine 
medication (Michael); functional electrical stimulation (FES) to aid gait (Nicole); and 
anti-sickness medication that caused an acute dystonic reaction (Deborah).  
R: I was given Parkinson’s mediation for two years… And then the medication was 
making the symptoms worse… I can only attribute it to the Parkinson’s medication 
because it wasn’t as bad as that. I had a tremor in my hand at the start of it all and 
by the end of taking Parkinson’s medication, I’ve been left with weakness in my 
right side. [Julie, age 50] 
R: Because I was taking, one of the consultants recommended that I took a glass 
of wine every evening. And it did relax me instantly. And even that if I took a glass 
of wine it would stop it, you know, for a while. But of course once you start you 
need more and more. Your body becomes reliant on it and I’m afraid I did become 
an alcoholic. [Mary, age 67] 
R: So they felt that a [splint] would be more appropriate and I was advised not to 
walk without it. And I never questioned it and I think there was supposed to be a 
time where I didn’t use that. But I was never. I never questioned it or pushed it 
and I was never advised not to wear it. I’ve always linked, if I need to walk, I need 
to wear my brace. Um and still, um 10 years down the line, that’s how I still see 
things. So I never really thought about anything else. [Lisa, age 43] 
9.4 Resistance to Psychological Explanations 
Eventually all participants were given a psychological explanation for their symptoms, 
which left them feeling dismissed and disbelieved and some felt ashamed.  There 
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appeared to be several issues associated with the general resistance to or rejection of 
psychological explanations. 
9.4.1 Resistance to psychological explanations was associated with… 
Psychological explanations were at odds with the participants’ physical experiences. 
This included perceived physical precipitating events, associations with neurological 
disease (some had been given diagnoses of multiple sclerosis or Parkinson’s disease 
before being told their problem was functional), and the physical impact of their 
symptoms. 
R: And one doctor sort of just said to me, like, “Oh, it’s all in your head”. And I was 
a bit confused because, well, it’s swollen [my arm], it’s not in my head. I am seeing 
that. I was sort of like, are you seeing that or not? [Sarah, age 21] 
Psychological explanations were often interpreted as meaning that there was nothing 
wrong with them, with the implication that the patient was imagining the problem, 
exaggerating their symptoms or faking it.  
R: Because that’s what it feels like, psychological feels like it should mean, it’s 
literally you are making it up. It’s all in your head, there’s nothing wrong with you 
at all. [Megan, age 22] 
Participants understanding of psychological problems did not fit with their personal 
illness narrative or perception of self. It was common for the participants to associate 
psychological problems with pejorative negative stereotypes. For example: 
psychological problems are trivial and the person would get better if they really 
wanted to; psychological problems are a character flaw and the fault lies with the 
patient; or psychological problems were either trivial or signs of severe mental illness. 
The participants’ accounts often distanced themselves from negative stereotypes. 
R: They said it might be psychological. I thought, well, surely I would have beaten 
it, that, because, you know, I’m determined to get better, you know. [Mary, age 
67] 
R: It makes you feel um that you are a mass murderer. Do you know? When 
someone says psych you think Norman Bates, do you know what I mean? 
Something bad. You’re a bad person because you’ve got a psychiatric problem. … 
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You automatically think they’re a nut-job, they must have bumped their wife off. 
[James, age 36] 
R: Um, well, before all this happened I was like, I’d been on holiday with my 
friends. I’d been to Ibiza, which was really good and… I don’t think there was 
anything really that could of caused any stress really… And I’ve never sort of been 
one to like, I don’t know, stress about things. [Sarah, age 21] 
Some participants implied that their resistance to psychological explanations related to 
the danger and undesirability of the corresponding psychological treatments. One 
participant described a frightening experience of being admitted to a locked psychiatry 
ward. Another described how he was denied active treatment and prescribed 
escalating doses of benzodiazepines. 
R: So then I had investigations in, I self-admitted, well I agreed to an admission 
into a psychiatric unit for 3 days, which scared the living daylights out of me… I 
was called in front of a panel of psychiatrists and after 3 days there were 7 people 
in the room, I was absolutely terrified. I was 17 and I was, err, in with some quite, 
quite dangerous patients, I was with some paranoid schizophrenics, yeah it was 
quite a secure wing. [Lisa, age 43]  
R: Because they have absolutely no experience of my condition at all. All it was, 
was keep on taking medication [diazepam] and we’ll see you in 6 months. That’s 
great, increase my misery for 6 months and do nothing about it. Hopeless. 
[Michael, age 46] 
Finally, there appeared to be resistance to psychological explanations that was 
associated with a perceived negative attitude of HCPs towards problems associated 
with psychological factors. 
R: Yeah, he said you haven’t got a, you haven’t got a brain tumour and you haven’t 
got cancer, I’ve got other patients. Like, he said like, because I didn’t have cancer 
he didn’t want to help me. And he, he literally like rolled me around like a bit of 
meat when he… put the pin up your foot… [Sarah, age 21] 
R: So I was always led to feel almost, ah, I don’t want to, I don’t know embarrassed 
but, quite shamed, in that that was the reason. That’s how I always felt, in that I 
was contributing or a contributory to my condition. Um, without anyone actually 
coming out and saying that, that was kind of how I was always left to feel. [Lisa, 
age 43] 
150 
 
9.4.2 Psychological problems were often considered as separate or secondary 
There was a subgroup of participants, who were resistant to psychological 
explanations for their motor symptoms, but also acknowledged a past medical history 
of psychological problems. These participants generally considered that their 
psychological problems were separate and unrelated, or that problems such as anxiety 
or depression were secondary to the physical impact of FMD. 
R: I’ve seen a psychologist for the pain, because that’s part of the pain 
management. And there are issues, underlying issues, you know from getting over 
my dad’s death and different things like that. But I think that’s separate. I think 
this is something different. [Julie, age 50] 
Often these individuals felt that the doctor had dismissed their physical symptoms due 
to their past medical history of psychological problems, preventing them from 
performing a thorough medical assessment. This left them with little faith in the 
diagnosis.   
R: And I saw another consultant after that who more or less told me it was 
psychological. Um that because I had a history of, a history, I’d had stress and 
depression in the past. And he sort of honed in on that and because of that, it’s 
just psychological your symptoms and we don’t think that there’s anything wrong. 
[Julie, age 50] 
9.5 Feeling Unconvinced by the Diagnosis 
Most of the participants had been given the diagnosis of FMD (some under a different 
name, such as Conversion Disorder) or a probable diagnosis of FMD before being 
referred to the study neurologist. They generally described feeling confused and 
unconvinced when they were first given the diagnosis. This was related to 
psychological explanations as described above, but biological explanations were also 
often met with confusion.  
R: She said it’s like software problem, she said and it’s basically, say you are trying 
to tell that leg to do that, your other leg might go, you’re focusing and it’s not 
going where you need it to. And that was the easiest way she could describe it. 
But to me it sounded alien. It seemed like how could that be me? That can’t be 
right. There’s either something wrong or not. [James, age 36] 
151 
 
Sometimes feeling unconvinced about the diagnosis was related to a perception that 
the diagnosis was reached because no other problem could be found (based on 
negative tests or a diagnosis of exclusion). 
R: Ahh I, I took it as bullshit really. I just thought, you’re putting me in a, you can’t 
find anything specifically wrong with me. My brain MRI is clear. There’s no lesions 
showing on my brain. My spinal MRI is clear. All the other tests, the nerve 
conduction studies are clear. The EMG’s are clear. So it has to be a functional 
neurological disorder. Because we can’t find anything else wrong with you. So it 
has to be this. That was my interpretation. [Michael, age 46] 
9.6 Conflict and Marginalisation 
Anecdotes describing conflict with HCPs and perceived poor treatment featured 
prominently in many participant’s narratives. These experiences had a powerful and 
lasting impact on participants, leaving many with a sense of indignity. It was common 
for participants to describe being left feeling that their problem was not worthy of 
help.  
R: Part of me would love to put a complaint in and say, here just to let you know 
about the treatment I received under Dr so and so, I wouldn’t like this to happen 
to anybody else. [Michael, age 46]    
Participants often felt that they had been abandoned by doctors and let down by the 
health care system. Nettleton et al (2005)195 used the term “medical orphans” to 
describe a similar situation in patients with unexplained neurological symptoms who 
felt they had been marginalised from medicine.  
R: All it was, was keep on taking medication and we’ll see you in 6 months. That’s 
great, increase my misery for 6 months and do nothing about it. Hopeless. …I tried 
chasing him for 3 days. And each time he ignored me. He ignored my phone call 
for help. [Michael, age 46] 
R: So getting that diagnosis was a plus, but then it was also a negative because I 
didn’t know what I was dealing with. Does that make sense? Because there’s not 
enough, like some, if someone had a heart attack for instance, there’s a set of 
actions to do, to help that person. But there didn’t seem anything to sort of help 
me with my situation. [James, age 36] 
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In contrast, one participant described an overall positive experience of interacting with 
HCPs. She reported that everyone had tried their hardest to understand and help her. 
Most participants had encountered at least one clinician who they considered 
praiseworthy. The characteristics commonly associated with these clinicians were 
listening, believing, open mindedness, and being supportive. 
R: I’ve got a very good doctor and he’s been looking it up. And he’s been very 
supportive. [Amy, age 43] 
9.7 Impact of Symptoms 
The negative impact of FMD on participants’ everyday life was significant. A few 
described how they had adapted to minimise the limitations on their lives. More 
commonly however participants described how their symptoms limited their ability to 
work, fulfil their role as a parent, or perform activities of daily living such as washing 
and dressing. The impact described by each participant is summarised in a 
representative quote in Table 9.1. 
Table 9.1. Participant's descriptions of the impact of FMD 
Participant Participant’s description of the impact of FMD 
Amy  
age 43 
“Well it is quite debilitating. Um, it has a complete impact on, on your life. 
You have to, reassess what’s important to you and what’s not. And you 
know, to the point of, um… I’ve had to let people look after my children 
when I am usually primary carer. I’m a very hands on mum, and I’ve had to 
let people take over. So it’s been quite hard to ask people to help.” [Head & 
upper limb tremor] 
Michael 
Age 46 
“I’ve been off [work] for the last 13 months. I’ve been registered disabled. I 
have, it has drastically affected my life over the last, that was January so 
over the last 13-14 months. I’ve lost virtually a year of my life, because of 
my condition.” [Mixed movement disorder with jerks] 
Julie 
Age 50 
“Because of the pain, I’m up most of the night with the pain, at most I have 
2 hours, 2 and half hours of sleep a night. And I wake up and I’m really tired 
and mornings I just feel… I don’t know, poorly is the only way I can describe 
it. As if I could, I could just stay in bed and just sleep. I don’t because I push 
myself to, but I just, I just feel really under the weather, it’s as if I can’t 
function sometimes.” [Tremor and functional gait disorder] 
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Lynn  
age 56 
 
“It’s just that I’m an active person and it’s so frustrating sitting there. I want 
to do it. My brain wants to do it but my body doesn’t want to do it. That’s it 
really, it’s just so frustrating. Just sitting there. It’s gone on for a long time 
now. It’s slowly getting to the stage where I’m accepting that I can’t do it.” 
[Functional gait disorder] 
James 
age 36 
“I just feel like I’m 36 and I’ve got the needs of a 5 year old. Like having to 
have help to do stuff, having to have someone to get me something. Not 
being able to drive. And, and things like that, it just feels like I’m cut off and I 
can’t do nothing about it.” [Mixed movement disorder] 
Mary 
age 67 
“Well, it’s constant. And people say, oh, it’s hardly noticeable. But to me, it’s 
day and night, you know. Even if I wake up in the night it still shakes. And 
um, well, my favourite hobby, reading. And I loved my books and especially 
autobiographies, my favourite author, believe it or not is Charles Dickins. Oh 
yes. And the best book is Barnaby Rudge. Of the lot. And, of course I can’t 
read now, because everything flickers, you know.” [Head tremor] 
Nicole 
Age 45 
“And that’s it and I just ended up, you know, you accept it and get on and 
just focus on the positives. But it is hard. Because, you know, we’re [my 
children and I] at the park and I want to be running around and getting 
involved with them, because I’m quite an active person. I want to play 
rounders with them, or kick a ball. It is hard.” [Functional gait disorder] 
Deborah age 58 “I’ve always been terribly independent and I want to remain that way and I 
want my independence back. And I feel like this is starting to take it away 
from me really. Because I don’t want to be pushed around in a wheelchair 
and have somebody take me on the Ambi-lift and help me here there and 
everywhere else. I just want to get on and do it myself.” [Mixed movement 
disorder]  
Sarah 
age 21 
“I do get annoyed but. I just get frustrated because I, I get angry because 
like, you see other people doing things. Like a simple thing like going in to 
town and having a coffee. There’s so much you have to think about when I 
go into town and I have to make sure I’ve got my crutches, make sure I’ve 
got a bag that I can carry with my crutches. Make sure I haven’t parked too 
far away.” [Functional weakness] 
Megan  
age 22 
“[It affects me] quite a lot and it’s pretty horrible. It stops me doing a lot of 
things. And it does get me down quite a lot, not being able to work.” 
[Functional weakness] 
Lisa  
age 43 
“I think I’ve lived with it for such a long time that I don’t really, I mean, I’ve 
lived with this condition um longer than I’ve not. Um, and you know, I was 
13 when I first started getting it. So I’ve accepted it as part of who I am. I 
don’t really know any different… And I worked quite hard to, not be as 
limited as much as possible. So I don’t feel I’m limited in any. I have a social 
life. A working life that I achieve, in spite of that. So it has limited in lots of 
ways but, yeah, I don’t believe it defines me.” [Functional weakness] 
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The experience of FMD was most commonly described as frustrating. Frustration was 
expressed in relation to an inability to control their movements and the inconvenience 
of having a disability. Other sources of frustration were being misunderstood, lack of 
support from the health service and the lack of answers. Frustration often developed 
into anger and distress. 
R: It’s just that I’m an active person and it’s so frustrating sitting there. I want to 
do it. My brain wants to do it but my body doesn’t want to do it. That’s it really, 
it’s just so frustrating. [Lynn, age 56] 
R: I do get really down about it and I get very frustrated and very angry. And I try 
not to continually to go back to the past. So I try not to, to like say, you know to 
go back to why has this happened. [Julie, age 50]  
In general, the experience of having FMD appeared to have a negative effect on the 
participants’ sense of self-worth. 
R: I just feel a bit useless. I feel sometimes, I just feel like I just want to get up and 
do stuff. And it’s frustrating. It’s frustrating to not be able to do anything about it. 
[Megan, age 22] 
R: And it’s just things like I’m back to being a kid again, do you know what I mean? 
And, that’s how I feel, I feel like I’m a kid. [James, age 36] 
9.7.1 Relationships 
The support of family and friends was considered important in order to cope, although 
many disliked feeling dependent on others and some were concerned about becoming 
a burden. 
R: I worry, well it doesn’t worry me, I feel bad because I’m always asking people 
to do things. Because I can try and do what I can, but sometimes I just can’t do it 
and I don’t like to put loads of pressure on to people. [Sarah, age 21] 
Some reported that their health problems had become a source of tension in their 
relationships.  
R: It’s, it’s made a severe impact on the quality of the relationship I have with my 
wife. She gets very, very impatient at times. She gets, ahh. It’s more annoyed and 
distressed I would say, more than anything else. My 15 year old at times would 
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like me to be able to do more things. …a lot of the times I have to say I’m sorry 
girls I’m just not well enough. I’m just not well enough today, I have to go to bed. 
[Michael, age 46] 
R: Um, yeah I can get really snappy. I never used to be. So I can get really grumpy. 
Which is not very nice. I’m grumpy at my children quite a bit. They will tell you. 
[Amy, age 43] 
Participants often felt that family and friends were unable to understand or relate to 
their experience. They perceived that others questioned whether their problem was 
genuine or that they underestimated the severity and impact of their problem. Some 
related the lack of understanding from others to the invisibility of the pain and fatigue, 
which most experienced in addition to their motor symptoms.  
R: And this is really, really frustrating. Because people, because I look perfectly ok 
and people comment, “Oh you look well” and yeah. I can’t explain to people. I 
can’t do it. And I think they think that I’m telling little porkies. [Lynn, age 56] 
9.7.2 Isolation 
Most participants described feeling socially isolated. This was especially a problem for 
those who had left work or education due to ill health. Isolation was associated with 
difficulty accessing some environments, withdrawing from social activity due to pain or 
fatigue, and avoiding going out in public due to the embarrassment caused by their 
symptoms attracting unwanted attention. Some participants described feeling lonely, 
as they experienced a gradual loss of contact with their friendship network.  
R: Friends, as I’ve said, I’ve cut a lot of them off. Not in a nasty way. I’ve just said 
when I’m feeling better, when I’m feeling better. So as time goes by, out of sight, 
out of mind. So it’s like they think, oh he’ll get in touch when he’s ready, so you 
hear less and less and less from people. Which makes it worse, because you 
normally get a random text and that, and now you get nothing. [James, age 36] 
9.8 Symptoms Remain Mysterious and the Uncertainty is Frightening   
Despite an average FMD duration of five years in this cohort and multiple 
consultations with HCPs, participants generally reported that their symptoms were 
mysterious and the cause unknown. The uncertainty of the diagnosis and prognosis 
was a common source of concern. 
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R: It’s not knowing of whether you’re going to get better or not. It’s, it’s not in the 
back of your mind it’s in the front of your mind. [Michael, age 46] 
Waiting while not knowing what’s wrong was often distressing, leaving many with a 
heightened sense of powerlessness.  
R: [The podiatrist said] A second opinion is what you need. And then it’s back to 
the doctors and back to the doctors and then you’re waiting and waiting and 
waiting and I’m just sitting at home.  
I:  What effect did the waiting have? 
R: Oh dear, very, very, I’m going to get upset now,.. Very depressing [voice breaks] 
it really, really was depressing. Because I can’t do anything. [Lynn, age 56] 
9.9 Powerlessness 
It was common for participants to describe feeling stuck because they did not know 
what was wrong and therefore did not know how to help themselves. This, together 
with feeling abandoned by the health care system, appeared to leave many feeling 
powerless and unable to move forward in their lives.  
I: So what does it feel like to have a bad day? 
R: I just can’t control my head or my hands or my legs at all. I’m trying to tell them 
to stop. They won’t stop. Um, it gives me headaches. I get a lot of pain, I end up 
going to bed early. [Amy, age 43] 
9.10 Summary 
This chapter explored themes arising from an inductive analysis of interviews with 
patients diagnosed with FMD, prior to receiving the study intervention. Participants 
commonly associated the onset of their symptoms with a preceding injury or illness. 
Their problem led them to a series of encounters with medical professionals which 
were usually perceived as having been unproductive. There was a common perception 
that HCPs did not know what was wrong. Virtually all the participants had been given 
psychological explanations for their symptoms which left them feeling disbelieved and 
dismissed. Reports of conflict with HCPs were common. FMD had a significant impact 
on the participants’ lives, causing disability and distress and many felt isolated and 
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abandoned. A perceived lack of understanding from both professionals and their social 
circle left them feeling powerless to help themselves.
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Chapter 10 Qualitative Findings: Post-treatment 
10.1 Introduction 
The previous chapter explored participants’ experiences up until their engagement 
with the study intervention. In this chapter I will explore themes identified in the 
interviews conducted immediately after completing the five day intervention.  
The intervention participants completed 8 sessions of physiotherapy over five 
consecutive days. The first session of the intervention was a joint consultation with the 
study neurologist (Mark Edwards) and treating physiotherapist (Kate Holt). The 
diagnostic explanation previously given during the initial neurology consultation was 
reiterated. The study intervention was introduced to the participant as a specific 
treatment for FMD. Optimism was expressed that the patient would see an 
improvement in their symptoms by the end of the week, but it was stated that the 
main objective was to learn how to manage their symptoms in the long term. All 
subsequent sessions were run by the physiotherapist. The second session elaborated 
on the explanation for FMD. Using the physical biased aetiological model described in 
the previous chapters, the aim was for the participant and physiotherapist to come to 
a shared understanding of the participant’s problem. Education continued during the 
subsequent sessions but the focus shifted towards movement retraining using 
strategies to divert the focus of motor attention. The intervention concluded with 
writing a long-term symptom management plan and completion of the final outcome 
measures.  
Themes from post-treatment interviews are explored under the sections: Physical 
Changes, Ingredients of the Intervention, I Could See It Working, Understanding, Less 
Resistance to Considering Psychological Factors, Work in Progress, Hope, A Positive 
Experience and Outlier. 
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10.2 Physical Changes 
All but one participant felt the intervention had helped their motor symptoms. There 
was considerable variation in the perceived extent of change; some described only 
modest improvements (e.g. James, see quote below) while others described significant 
changes such as no longer requiring walking aids (e.g. Sarah, see quote below) and one 
person reported complete resolution of their symptoms (Michael, see quote below). 
R: I still got the shakes but the leg movement is a lot more advanced, as we’ve 
seen, it’s a lot more advanced as to where it was at the beginning of the week. 
[James, age 36] 
R: My walking is so much better now and I don’t drag my foot along. I’m almost 
walking normal [laugh]. I think that will come with time. I can actually walk up the 
stairs now without lifting, like I had to lift it up with my hand before, whereas I can 
just lift it up now. [Sarah, age 21] 
R: If I’d been told Monday that in the next couple of days, you’re not going to have 
any symptoms, I would have found it hard to believe. But here we are, come 
Friday, I can sit, I can talk. There is normal muscle control. And it’s fabulous. 
[Michael, age 46] 
10.3 Ingredients of the Intervention 
The intervention was highly praised by the participants. There were several elements 
that were commonly considered important ingredients in making the treatment 
effective.  
10.3.1 The Role of the clinician 
The clinicians were perceived as specialist and eminent. This contrasted with the 
participants’ previous experiences, where it was commonly reported that HCPs had 
not been specialised enough and did not know what was wrong or how to help. Most 
participants’ reported that the study clinicians had taken their concerns seriously and 
understood their problem. Some participants commented on the personal attributes 
of the physiotherapist that helped them develop rapport and trust. This included being 
calm, kind, non-judgemental and interested. 
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R: I actually feel that [the treatment team] might not be going through it but they 
actually understand what [I’m] going through because they’ve done the research, 
they’ve done, they’ve had the clinical trials and stuff. [James, age 36] 
R: [The study physiotherapist] was really good to have that relationship [with]. Um 
and she’s such a nice person. And to trust her. You know. And believe that what 
she was telling me really. [Deborah, age 58] 
10.3.2 The Intervention was challenging 
Often the first comment participants made about the intervention related to its 
challenging nature. Most reported feeling challenged physically, cognitively and 
emotionally, generally to a greater degree than had been expected.  
R: Um, The week of physiotherapy was both mentally and physically exhausting. 
Especially mentally exhausting. It’s been quite a journey. [Deborah, age 58] 
R: Um, intense and emotional. Um, it really pushed my boundaries, made me re-
evaluate behaviours… So it’s been very intense but it’s just amazing. [Lisa, age 43] 
For those who found the intervention cognitively demanding, this was related to 
learning and understanding about their symptoms, as well as the concentration 
required during movement retraining. Some noted the apparent paradox of having to 
concentrate to not think about their movement (attend to their body). 
R: …I’m feeling mentally tired, I feel it’s because I’m thinking, thinking more about 
not thinking [laughs]. Does that make sense? My focus is obviously on what is 
going wrong with me and whatever, so I’m trying to retrain myself not to think 
about it so much. …There’s so much to think about when I’m trying to manoeuvre 
around. I think that’s where I am feeling tired. I’m just thinking constantly about 
what I’m doing. [Nicole, age 45] 
The physical challenges usually related to the intensity with which treatment sessions 
were scheduled over five consecutive days. This is discussed below. 
10.3.3 Treatment intensity 
The intensity (frequency) of treatment sessions was considered an important element 
for success by most. Some participants described how consecutive days of treatment 
made progress more noticeable and allowed progression without setbacks. Some 
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contrasted this to their previous experiences of physiotherapy, where sessions had 
been intermittent and considered less helpful. 
R: And it’s been continuous, whereas the physio I’ve had, I have some one week 
and then the next week, or two weeks later by which time you’ve forgotten what 
has happened. But I think it’s because it’s been five days continuous that I can see 
an improvement, whereas before I couldn’t. [Julie, age 50] 
R: I think having it every day really helps. Because I think if I had sort of come for 
one day, then gone home for a month, then come back again, I don’t think that 
would have been beneficial really. I think having it in a short space of time really 
helps. [Sarah, age 21] 
While the high intensity was generally considered useful, some participants also found 
this difficult to cope with.  
R: I think 5 days was a killer. Um, maybe it could be split, the first week is two 
sessions and then the second week three sessions and aim to build. I don’t know. 
I don’t know if that would work. I’m not sure. [James, age 36] 
10.3.4 Coming away from home 
In addition to the high intensity of the intervention, coming away from home was 
reported by several participants to be helpful by preventing interference from normal 
routines. All were provided with hotel accommodation during the five day 
intervention, which may also have impacted on how they perceived the treatment. 
R: I think it was more about, the good thing about coming away from home was 
that I was, and not stay in hospital but I was then able to go out and practice. And 
there wasn’t any normal life like interrupting. [Megan, age 22] 
However, one participant found staying away from home difficult and reported that 
this hindered her ability to engage with the intervention. 
R: That’s the state I was in. I did not want to go through with all this. I just wanted 
to go home. Get back to my um, comfort zone, normal area. I don’t know. [Lynn, 
age 56] 
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10.3.5 Focus on education and learning 
Participants often commented that the study intervention was different from their 
previous experiences with physiotherapy because of the emphasis on learning and 
developing an understanding of their symptoms. Some described how they were 
intellectually engaged in the treatment process, which included learning the 
theoretical rationale behind the treatment strategies. 
I: And how was it different from your previous experiences with physiotherapy? 
R: I had one session and it was very much focused on physical. There was no kind 
of background to it and what was actually happening. And it was all very focussed 
on trying to get that one, that movement to happen. And, whereas this was kind 
of, the link between the kind of theoretical side and then diverting attention a 
little bit, but in a way where you can still work on things. And, and not slip back 
into like old movement patterns. That was completely different. [Megan, age 22] 
10.3.6 Structure and flexibility 
A few participants commented that the intervention was well structured, but 
importantly it also allowed for some flexibility to meet their needs. This structure gave 
James the impression of progress, he noted that structure was missing from previous 
experiences of physiotherapy. 
R: it’s quite well structured, which I weren’t expecting. I was expecting it to be a 
bit hit and miss. It’s not regimental, it’s flexible, but it wasn’t hit and miss.  I was 
expecting it to be hit and miss because of past experiences of how things happen 
in hospitals, like timing and stuff and um, having clear goals each session, where 
in other places it’s been, well we’ve done that today and then you go and repeat 
it again tomorrow and then you repeat it, and it’s not moving forward, it’s just like 
repeating. Whereas this week I’ve found that it’s been quite diverse but also quite 
structured as well, because we go back but not constantly go back. [James, age 
36] 
10.3.7 Potential problems and barriers  
Participants were generally reluctant or unable to provide much criticism of the study 
intervention. As previously discussed, the high intensity of treatment and coming away 
from home to stay in a hotel were considered helpful for most, but a potential barrier 
to progress for a small minority.  
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Awareness that the intervention was part of a clinical trial may have influenced the 
participants’ perception of its value and how they reported their outcome.  
R: The symptom model [was the most helpful part of treatment], you can’t find 
that anywhere else. Of course you can’t because this is a clinical trial. [Michael, 
age 46] 
I: Do you have any other comments or thoughts? 
R: Um, not really, I just, it’s refreshing, that’s the word, it’s refreshing to know that 
there’s, there is a treatment out there. Whether at the moment it is still early days 
and still being trialled, but there is a way out. [James, age 36] 
10.4 I Could See It Working 
It was common for participants to report that the movement retraining strategies had 
an immediate impact on their symptoms.  
R: …now when people give you exercises usually, you think oh gosh, I’ve got to do 
them, I’ve got to do them. But when I started doing them I could feel the 
difference. The physical difference, you know? The head wasn’t shaking so badly. 
[Mary, age 67] 
The use of a video and mirrors during physiotherapy sessions enabled participants to 
see their movement normalise while using the treatment strategies. This appeared to 
help motivate participants to engage with the intervention. 
R: Um, and I get this child like delight when I see the flickers of the muscles working 
and everything going. It’s just, I’m like a kid. [Lisa, age 43] 
The perception that the treatment strategies worked and worked immediately seemed 
to be an important element of the intervention. It challenged participants’ beliefs 
about paralysis or their inability to move normally. This in turn seemed to help them 
learn to trust their body. 
R: Because when I saw, you know I could see in the mirror that there were flickers 
of movement [in the muscles of my ankle]. And I think if I hadn’t had seen that, I 
wouldn’t have trusted. [Lisa, age 43] 
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10.5 Understanding 
Participants reported that the intervention had helped them to understand their 
problem and this was considered the most valuable intervention outcome by many 
participants. The value placed on having some understanding corresponds with the 
participants’ focus on the lack of understanding and distress associated with 
uncertainty that characterised the baseline interviews.  
10.5.1 Understanding was multifactorial, with a biological focus 
The biological or physical events that dominated most participants’ illness narratives in 
baseline interviews remained important in their understanding, but there was a shift 
towards recognising that other factors were part of their problem. 
I: Can you talk to me about what you think caused the problem in the first place. 
R: After this week with [the study physiotherapist], I think there’s a few factors, 
um … [Nicole, age 45] 
In the above quote, Nicole goes on to describe in detail several potential contributing 
factors which included “possible MS” (confirmed by neuroimaging), a situation where 
she was stuck in a car unable to move her leg which was anxiety provoking, and her 
perfectionist personality trait. Another example of a multifactorial formulation is given 
by Julie below. It is less explicitly biopsychosocial in scope, however it is not singularly 
biological or structurally focussed, nor is it characterised by mystery as was the case 
with most participants’ understanding at baseline.  
I: What do you think caused your symptoms in the first place? 
R: After looking at the process this week, I think it’s a combination of the, it started 
when I had the occlusion in my eye, that’s when the first tremor started and then, 
I had quite a bit of illness. Um, and then I was diagnosed with Parkinson’s disease 
and given medication and the symptoms got worse. So I think it’s a culmination of 
all of that. Now having an understanding of functional movement symptoms, um, 
I think it’s just been quite a collective reason um, Illness and just circumstance. 
[Julie, age 50] 
When asked to describe their understanding of their problem, most participants 
articulated that they understood that it was not caused by a structural lesion or a 
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degenerative process and most were able to suggest several factors that could have 
contributed to its development. These changes in conceptualisation could be 
considered as a move towards a biopsychosocial understanding of their illness.202 This 
differed from the baseline interviews where symptoms were generally seen as 
mysterious and potentially sinister, and the onus was on the physician to solve the 
problem.  
10.5.2 Understanding provided legitimacy  
The intervention, learning that FMD was common and having a perceived improved 
understanding of their problem appeared to provide legitimacy, validating the 
participants’ illness experiences.  
R: I’ve learned about the disorder, about the symptoms. I know that they are real 
now. And I know there are other people in the same situation as me. Which I 
didn’t, I thought I was alone in this. So it’s been a real enlightening experience. 
[Julie, age 50] 
10.5.3 Understanding reduced threat value of symptoms 
In the baseline interviews, several participants described feeling unsettled by or fearful 
of the uncertainty of their diagnosis and prognosis. In contrast, in post-treatment 
interviews participants often described feeling relieved and reassured, suggesting the 
experience of their functional symptoms felt less threatening. 
R: Um, I think now I understand it more, I can accept it and it doesn’t feel too bad. 
It’s a bit scary that there’s something sort of not right in your brain, but I think like 
there’s a lot more things that are worse and it’s good because it can get better. 
And it’s not going to like, even though it probably will be quite difficult, but I think 
I’ll be able to manage it more and I know how to deal with it now. [Sarah, age 21] 
I:  Do you think you will be better equipped to deal with a dip? 
R: Yes. I think it’s taking it slower. When the tremor starts or when my speech 
starts, instead of getting into a panic and trying to undo things, it’s to take time to 
think it through... But I think it makes a big difference when you know why 
something is doing what it’s doing. As opposed to being in the dark and now 
knowing why it’s doing that. [Julie, age 50] 
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10.5.4 Understanding allowed improvement  
When asked to comment on why they thought their symptoms had improved, most 
participants attributed changes to their improved understanding of their disorder. 
Participants described how their new understanding gave them more control over 
their symptoms and that it enabled them to become active in their rehabilitation. 
I:  What do you think, do you have a sense of what’s changed to allow these things 
to improve? 
R: I’ve realised I understand it more and I’m giving my body the opportunity. 
[Megan, age 22] 
R: I don’t think it is possible for the muscles to have changed so significantly in a 
couple of days. I think it’s definitely in my understanding in my um, my trust, my 
confidence in my ankle. [Lisa, age 43] 
10.5.5  Understanding was empowering 
Together with the perception of improved understanding, there was an apparent shift 
from the sense of helplessness and powerlessness prevalent in the baseline interviews. 
Some participants described a new sense of self-reliance and an ability to help 
themselves.   
I: What would it mean if the spasms come back? 
R: I work harder trying to beat them. Because I think, being here I have the, I have 
the skills and knowledge, I have the skills base now and the knowledge to 
understand what is going on in your body. And the techniques to, counteract this. 
And get control back. And regain control and maintain control. [Michael, age 46] 
10.6 Less Resistance to Considering Psychological Factors 
In the baseline interviews, there was resistance towards acknowledging a potential 
role for psychological factors as part of the problem. This persisted in some 
participants, but for most there was less expressed resistance to the notion that 
psychological factors were part of the problem. An example of the softening stance in 
considering a role for psychological factors can be seen with Michael. In the baseline 
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interview he stated several times that he did not think that psychological factors were 
relevant to his problem:  
I: How would you describe the relationship between psychology and functional 
symptoms? 
R: There may be a relationship. I can’t see it in my case. [Michael, Baseline 
Interview, age 46] 
Post-treatment, he appeared to be less sure. 
I: So what do you think caused them in the first place? 
R: I don’t know. I don’t know. It may have been just an accumulation of stress at 
work, stress at home. I have 3 kids. Was it an accumulation of stress that set it all 
rolling? It might be. It might have absolutely nothing to do with it at all. It’s hard 
to tell. [Michael, Post-Treatment Interview, age 46] 
Several participants described coming to a new realisation that they often felt anxious 
and that this was part of their problem.  
I: And can you speak a bit about, um, the role of mood or anxiety, how it affects 
symptoms. 
R: Yeah. If I feel stressed, then my symptoms do get a lot worse. Sometimes quite 
uncontrollable. So I, try to become more aware. Um, it’s, this week has been of 
benefit because it has pointed out that. The anxiety. You just don’t think about it 
do you? [Amy, age 43] 
R: Yeah, I’ve definitely learnt a bit this week about it as well, and how I’ve been. 
Um, and it’s around people, like up in the gym we’ve been doing some… good 
walking, but then someone would cross my pathway or I’d be conscious of 
somebody there and it would all go wrong. Because I felt, I hadn’t maybe realised 
it as much before but I was anxious about it. [Nicole, age 45] 
Despite this softening stance, all the participants tended to hold the view that 
psychological factors, if present, were usually secondary to their motor symptoms or a 
separate issue and that they were not the cause of their FMD.  
10.7 A Work In Progress 
Only one participant considered that their movement problem had completely 
resolved, the remainder considered that they had benefited from the intervention but 
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that there was more work to be done. Treatment and rehabilitation was seen as a 
work in progress. They referred to newly acquired knowledge, movement strategies or 
a treatment plan that would enable them to progress their rehabilitation after 
discharge. However, they often reported expecting this to be difficult.  
R: Yeah, it will take time. It’s like everything, with physiotherapy it takes time you 
need to work at it. I didn’t expect a quick fix, I knew I would have to put in a lot of 
work. Um so, I’m prepared to do a lot of work at home. [Amy, age 43] 
10.8 Hope 
The improvement that participants experienced during the intervention appeared to 
give them hope. Most described feeling cautiously optimistic about the future and 
hopeful for further progress. 
R: I still got the shakes but the leg movement is a lot more advanced, as we’ve 
seen, it’s a lot more advanced as to where it was as the beginning of the week. So 
I feel there is hope now, where at the beginning of the week I thought that’s it. 
There’s no hope. [James, age 36] 
R: And so I can just see a light at the end of the tunnel that wasn’t there. You know, 
I just, you know, I believe in it. [Deborah, age 58] 
10.9 A Positive Experience 
The participants considered that the intervention had been worthwhile and was 
generally experienced as positive and uplifting. This seemed to be related to it 
providing legitimacy to their illness experience, introducing a belief and optimism that 
their symptoms could improve in the future and some resolution of the uncertainty 
about their problem, which had weighed heavily on their minds prior to the 
intervention. Their positive experience contrasted sharply with their previous 
interactions with health care professionals, as described in the previous chapter, which 
had been mainly negative and unproductive. 
I: Do you have any thoughts or comments to finish up? 
R: No, just really this week has been brilliant for me. Amazing. Because I really do 
feel, after this week, that’s what’s wrong. You know, and it’s like, yes [deep sigh]. 
[Nicole, age 45] 
169 
 
10.10 Outlier  
There was one clear outlier amongst the participants, who presented an account that 
at times was contradictory. She suggested that the intervention had not made any 
difference to her motor symptoms and that it could not help her because nobody had 
understood the cause of her movement problems. However, like some of the other 
participants, she stated that the intervention had helped her come to the realisation 
that she was anxious. In addition she described renewed confidence that her problem 
with balance and falls would improve with perseverance and practice.  
I: Was there anything about this week that was useful for you? 
R: Understanding. Understanding what’s happening. And understanding, I didn’t 
think I was an anxious person. But I think this balance has made me very anxious. 
And I think that’s when I get really anxious and I don’t want do anything. I just 
don’t feel I can do it. [Lynn, age 56] 
R: But I don’t, at the beginning of this I didn’t know why [this problem started]. 
What, what built up to it? Why? You know? Out of the blue. If I had fallen, broken 
my arm or my leg. Then ok, then you, you’ve broken your leg and it’s going to take 
this long. This has just come out of the blue. That, I find is really strange. Really 
hard. Because it’s just, why? Why did it? Why did it do that? Why? [Lynn, age 56] 
10.11 Summary 
All the participants described having had at least some benefit from the intervention. 
Reported improvements in their motor symptoms ranged from modest changes to 
symptom resolution. They had experienced the intervention as “intense”, challenging 
them physically, cognitively and emotionally, which was unexpected. The participants 
identified several components of the intervention that they considered important and 
these were generally different from their previous experiences of physiotherapy. This 
included that it was delivered by specialist clinicians, the high treatment intensity, the 
focus on education and that movement retraining involved redirecting attention away 
from the body. Another important difference with this experience of treatment was 
that they could see the treatment strategies having an immediate impact on their 
symptoms, which left them feeling motivated and hopeful about the future. The 
participants generally considered the understanding that they had gained from the 
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intervention to be the most valuable intervention outcome and that this had enabled 
them to become active in their treatment. As part of their new understanding, most 
participants were less resistant to the idea that psychological factors were part of their 
problem. Most found the intervention to be an uplifting experience, in that it 
legitimised their illness experience, providing clarity to what was previously their 
‘mysterious illness’. One outlier felt that the intervention had not been helpful, which 
she related to nobody understanding what was wrong.
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Chapter 11 Qualitative Findings: Six Months Follow-up 
11.1 Introduction 
In this chapter I will explore themes from interviews conducted at the six month follow 
up. The themes will be explored under the sections: Impact of the Intervention, 
Putting it into Practice, Perceived Role of Psychological Factors and Feedback. The 
chapter concludes with a table highlighting themes that were central to each interview 
time point (baseline, post treatment and follow up). 
11.2 Impact of the Intervention 
At six months, most of the participants reported that they thought they had benefited 
from the intervention. It appeared to have had a wide and varied impact on the 
participants’ lives, which is discussed in detail below. It was quite difficult to 
disentangle physical, social or psychological changes, as well as the extent to which 
each individual had benefited.  
11.2.1 Understanding 
In the interviews conducted immediately after the intervention, most participants 
regarded the understanding they had gained about their problem to be the most 
valuable intervention outcome. In the six-month follow up interviews, improved 
understanding appeared to remain the most highly regarded outcome, although most 
commented that some things remained unexplained or confusing. 
There was little change in the participants’ conceptualisation of their movement 
problem from post-treatment to six months. In general they remained convinced that 
the diagnosis of FMD was correct. Most presented a belief that multiple factors had 
probably contributed to their problem. This often resembled a biopsychosocial 
formulation, although most considered biological events, such as a viral illness or 
injury, to be of primary relevance. 
I: …what do you think caused the problem in the first place? 
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R: I really believe that, I’d had bronchitis on and off for 2 years. So every 3 months 
it was the steroids or antibiotics. I was really run down. I believe that amalgamated 
in a like a semi-collapse [when] I was out one day with a friend. So I believe the 
two of that together sort of, obviously caused, a reaction in the brain.   [Amy, age 
43] 
11.2.2 Hope  
Participants continued to see their problem as one that could improve in the future. 
The hope and optimism that was prominent immediately post-treatment remained to 
some extent, but was now tempered with a realisation that future progress was likely 
to be slow and that their symptoms would persist for the foreseeable future.  
I: So what are you expecting to happen over the next 6 to 12 months? 
R: Um, if I carry on as I’m on, then hopefully more improvement and more 
improvement in my knee. And that’s, you know, even a small amount. [Nicole, age 
45] 
11.2.3 Reduced threat 
Immediately after the intervention, some participants, having gained a greater 
understanding of their problem, described feeling less concerned by their symptoms. 
This perception of reduced threat continued at six months, with several participants 
describing feeling more at ease with their problem. This change was associated with 
having an acceptable diagnostic label, a greater understanding of their problem and 
some resolution of the uncertainty of their prognosis. Several participants had 
expressed a concern in their baseline interviews that their problem would continue to 
progress causing increasing disability. Most now considered that their problem was 
one that could improve, and that they were better equipped to prevent deterioration. 
R: Oh yes, you know, when you said what it was, it’s a functional tremor, it’s not 
dystonia, it’s not Parkinson’s. The relief! You know, from head to toe, of somebody 
telling me after 12 years of going to every doctor... Just knowing what it was, you 
know, the answer, after all those years. You know. That has made, well made me 
more relaxed. [Mary, age 67] 
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11.2.4 Self-Confidence 
In the six month follow up interviews, positive outcomes were often associated with 
having greater self-confidence, particularly when out in public. Confidence was drawn 
from knowing what was wrong and having strategies to control their symptoms. 
Conversely, participants who had experienced falls or were concerned about falling 
often described a need to rebuild their self-confidence in order to progress. 
I: What sorts of things can you tell me have changed and what things might not 
have changed? 
R: Um, I think it helped, it’s helped me feel a bit more confident, because I 
understand, sort of semi-understand what’s going on now. And it’s not me, you 
know, I’m not intentionally doing these kind of things. So that’s been a real great 
benefit. It’s sort of boosted me. I feel more comfortable in public. [Amy, age 43] 
R: But I had a couple of falls, which knocked my confidence, just because I was 
trying to do things too quickly. So I have to really step back and go slowly, but, 
yeah it’s, it’s um. Yeah it’s been a journey. [Lisa, age 43] 
11.2.5 Physical Changes: Impairment, Activity and Participation 
The actual changes to their motor symptoms and movement problems at six months 
varied considerably amongst participants. No one considered that their problem was 
worse compared to baseline, but one participant reported at six months that their 
problem had relapsed to baseline levels. Participants who reported ongoing benefits 
were generally evenly split between three groups; either reporting some setbacks 
after receiving the intervention but still better than baseline, feeling that their problem 
was stable, or reporting further improvement. As was the case in the post-treatment 
interviews, participants reported gradations of benefit, ranging from subtle changes to 
symptom resolution (one participant only, Michael). 
Many described reduced physical disability, such as less reliance on mobility aids and 
greater ease with mobility and usual activities. One participant reported that he had 
returned to work with reduced hours after a long period of sickness absence, one had 
started paid employment for the first time and one had started a college course.  
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Some participants reported unexpected health benefits from the intervention. Mary 
had previously been told she was unable to have laser cataract surgery due to her 
head tremor, but this was now considered viable.  
R: But my only problem now more than anything is cataracts… But I’m going on 
the 4th of November and they’re going to try and laser that. They couldn’t do it 
before because of the tremor …she said, oh I think we can do it [now]. It only takes 
a few seconds and we’ll try. [Mary, age 67] 
Michael described how, with some difficulty, he was able to stop taking 
benzodiazepine medication, which he considered a significant achievement.  
I: Could you start off by telling me how things have been over the last 6 months? 
R: Since I was here in November, ah, all my spasms have ceased and stopped. At 
that stage I was on 4mg of clonazepam, on returning home I then cut it down by 
1mg per week. Which meant come, I think it was the 20th of December I was drug 
free. No medication whatsoever. I’d say the down side of it all was, of the 
medication side was the symptoms, the withdrawal symptoms of clonazepam 
were horrendous. [Michael, age 46] 
11.2.6 Relationships 
Several participants noted that their overall improvement over the six months had 
been accompanied by positive changes in their relationships. Some described less 
tension and conflict in their family unit. For example, Michael described how his wife 
was less stressed now that he had a better sleeping pattern and was contributing to 
household duties and that he was better able to fulfil his role as a father to his young 
daughters.  
I: My wife was very stressed and rightly so. Understandably so. She was getting 
very tired. I was up most nights, ah, during the day I was going to bed… and my 
wife coming home found very little done in the house. I just wasn’t able to do it… 
It’s, it’s much less stressful now. Every house with 3 children has its associated 
stresses, but not the stress when one of the parents is very unwell. [Michael, age 
46] 
Some participants described how others had noted a change in their character, 
specifically being less irritable. 
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I: What about other people. Have they noticed any differences? 
R: Yes my children have. They’ve noticed that sometimes my movement has better 
control. Um, they said sometimes I’m less grumpy. [laughs]. [Amy, age 43] 
11.2.7 Validation 
Validation of their illness was an important outcome immediately after treatment and 
this remained prominent at six months. Such validation justified dissatisfaction of 
previous interactions with HCPs (e.g. Sarah, see below). It also made one participant 
more willing to accept help from others (Deborah, see below), and helped another feel 
empowered to medically retire (Julie, see below). 
I: Is there anything that everybody should know about functional neurological 
disorder? 
R: Um, that they are real symptoms. Because when I was in [my local hospital] 
some people said to me I was making it up. Because nothing was showing up on 
my scans, which is fair enough, but I wouldn’t make it up. And I think, they are real 
symptoms that people are having. I think people just need to be sort of like, 
educated on it because I think people don’t understand it. [Sarah, age 21] 
R: So it’s always been, you know, I am not disabled. I am not disabled, I will drag 
that suitcase down the corridor, I am not disabled! And now it’s like, it’s just 
somebody helping me as you would help any other person. [Deborah, age 58] 
R: But I think it’s important because for me it was, “am I imagining this?” and 
because I’ve spoken to the likes of yourself and [the study neurologist] and the 
experts at home. I know I’m not imagining that it’s there. [Julie, age 50] 
11.2.8 Self-Reliance 
Immediately after the intervention, it was common for participants to express an 
expectation of being able to manage their health more independently in the future, 
with less reliance on consultations with HCPs. In the follow up interviews, this sense of 
self-reliance continued in many participants. In practical terms, this was related to 
having an answer for what was wrong (so further investigations were unnecessary), 
knowing how to help themselves, and having an expectation of further recovery.  
I:  Do you think you need any other support or help for this to continue to get 
better? 
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R: Well, is there anything else? If I can keep doing these exercises as [the study 
physiotherapist] has taught me. And it is working. Surely if I keep on it will work 
more, you know? 
I:  Is there anything else that you think you might need other than physio? 
R: Well is there anything else? No, I don’t think so. [Mary, age 67]  
This sense of self-reliance did not mean that participants felt they no longer required 
any contact with health services, but that they expected to use them less frequently 
and more efficiently. For example, participants often expressed relief at knowing they 
could contact the study team (neurologist and physiotherapist) should questions or 
new problems arise in the future, as they perceived the team understood their 
problem and could deal with it more effectively than their local services. This 
contrasted with their early difficult experiences of finding support in the NHS, which 
involved long waiting times and multiple consultations with different professionals 
which they generally had not found helpful. 
11.2.9 Moving On 
In the baseline interviews, there had been a prominent theme of feeling stuck and 
powerless to effect change, whilst immediately after the intervention, participants 
described a sense that they would now be able to move on. This continued at the six 
month follow-up interviews, where there was a sense amongst most participants that 
they had moved forward and were getting on with life despite continuing to 
experience symptoms.  
I: Um and any thoughts about the next 6 to 12 months? About what you might 
think will happen? 
R: …I’d like to think that now I’m just going to start getting on with life… I just want 
to get on with life. [Lisa, age 43] 
11.2.10 Outliers 
There were two outliers amongst the participants. Lynn (age 56) was described as an 
outlier in the post-treatment interviews because she considered that the intervention 
had not been particularly helpful for her. At six months follow up, she continued to 
believe this was the case, despite also reporting a significant improvement to her gait 
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and balance problem. She attributed her improvement to the efforts she had made to 
practice walking, build confidence and confront her fear of falling. Her perception that 
the intervention did not help may have been related to an expectation of receiving a 
treatment that would result in an immediate improvement, and therefore she did not 
see the value in education and learning about self-management. 
R: I don’t know why I thought like that but I just thought it would be in a gym…. I 
thought I’d be doing exercises and things in the gym. 
I: And how was it different? 
R: Because I wasn’t doing exercises in a gym, I had to challenge my working. I don’t 
know why I thought it was going to be like that. 
I: So what were you doing instead of exercise? 
R: What do you mean? I thought I was going to be doing exercises, but we didn’t. 
We, we, um, we talked about, how to side track my mind. My mind was thinking 
too much on what my legs are doing… [Lynn, age 56] 
The other outlier, Julie (age 50), was an exceptional case because she was the only 
participant at six months to report that there had been  no improvement in her 
symptoms compared with  baseline. She had reported improvement immediately after 
the intervention but this had relapsed by six months. She attributed the relapse to an 
unfortunate series of health problems that included a fall resulting in a wrist fracture, 
an episode of acute labyrinthitis, exacerbation of long term chronic pain, and low 
mood associated with adjustments to her antidepressant medication. When asked if 
she considered there were any benefits from having had the intervention, she stated 
that she continued to use strategies that helped her balance and she was better at 
pacing her activity to manage fatigue. She also described how the intervention had 
helped her feel more accepting of her limitations. 
I: I was wondering if you didn’t have the labyrinthitis and you didn’t fracture your 
wrist, I wonder how things would have been. 
R: But the pain would have still been there. 
I: So do you think you would have been about the same as you are now? 
R: Probably yes. Yeah. And I think because of, because the thing, um, chopping 
and changing my antidepressants, I don’t think that’s helped my mood through all 
of this, and I’ve just been on a 2 week cruise and I was spending most of the day 
in the cabin, because I didn’t have the energy or the inclination to do anything.  
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I: And um, do you think you got some benefit, do you think you’ve had some 
benefit from the treatment? 
R: Definitely. Because it’s still in my head, what I did with [the study 
physiotherapist]. And I’ve still got the blue book [workbook]. [Julie, age 50] 
11.3 Challenges of Putting it into Practice  
Common to all participants were reports that adjusting to everyday life post-treatment 
and putting symptom management plans into practice was more difficult than they 
had expected. Challenges frequently came with setbacks due to co-existing health 
problems. This included the side effects of withdrawing from benzodiazepine 
medication (Michael); a fall resulting in a fractured wrist, labyrinthitis, and chronic pain 
(Julie); chronic fatigue (Amy, Sarah, Megan); an abdominal mass cancer scare (James); 
and migraine (Megan). 
R: So it just feels like I go 10 steps forward and 10 steps back. And that’s what it’s 
been like, a constant battle. But I know that’s what I got to deal with. [James, age 
36] 
Another challenge frequently described by participants was finding the time to 
implement treatment strategies amongst busy work or family life schedules. Also, for 
some participants, movement strategies that reduced motor symptoms during the 
intervention did not work as well at home, causing frustration. Maintaining motivation 
when progress appeared to plateau was difficult.  
Some participants expressed disappointment that they had not made additional 
progress between discharge and follow up, or that they had failed to meet personal 
rehabilitation goals. 
R: So I haven’t got to where I wanted to be. Um, I wanted to be where I maybe still 
have, like maybe a bit of a limp or, do you know what I mean? But not have no aid. 
That was my goal, was the next I come and see you guys I can go, “Look!” And to 
me I feel like that was another thing I was beating myself up about because I 
wanted to be aid free next time I came to see you. [James, age 36] 
Some participants described how they coped with challenges and setbacks by adapting 
their management plans and resetting their expectations. Participants who displayed 
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this adaptability may have been more likely to feel as if they were on an overall 
trajectory of improvement.  
I: Ok. Um, and so you had a plan of things to do when you left. Were you easily 
able to introduce that into your everyday life when you got home? 
R: Not really, no. I started doing it like [the study physiotherapist] said, which was 
very good, doing a little bit each day at home. So just silly things if I got home and 
I was chopping away or just making a cup a tea and walking around the house and 
doing that. But I found it was too much to think about. So I was trying to, you 
know, bend my knee, heel to toe, it was all too much. …But that is because I’ve 
got children and I’ve got to do school pick up. Drop off and things like that. If I 
didn’t have that and I didn’t have my job then maybe I could have every day, I 
could have set aside more time and done more. So I had to adapt it to my lifestyle. 
[Nicole, age 45] 
11.4 Perceived Role of Psychological Factors 
In their baseline interviews, participants had been generally reluctant to consider that 
psychological factors were relevant to their movement problem. Immediately after the 
intervention, there was less resistance amongst participants to considering that 
psychological factors were relevant and some participants described coming to the 
realisation that they were anxious and that this was part of their problem. In the six 
month follow up interviews, participants remained open to considering that 
psychological factors, specifically anxiety and depression, were related to their 
problem. The level of perceived relevance differed amongst participants. 
I: Do you think psychological things are part of functional movement disorder? 
R: Part of it, I think there’s a chunk of it. I don’t think it’s all because it’s not all. I 
think it’s all, um, because you’ve got the physical effects that go with it. But I think 
that maybe I’d say a chunk of it is. [James, age 36] 
This role of psychological factors was usually perceived to be as a symptom modulator, 
in that anxiety and depression made their physical symptoms worse. Participants 
generally disagreed with the idea their problem was caused by psychological factors. 
This notion was considered either completely wrong or overly simplistic. Some 
participants considered the converse to be true, and that anxiety and depression were 
secondary problems caused by their movement disorder.  
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I: OK and we spoke before about how some people feel that psychological issues 
are generally part of the problem. What are your thoughts on that? 
R: They’re probably a risk factor… I don’t think it’s psychological based. But I think 
[psychological factors] coupled with the physical probably caused the whole main 
thing. But I don’t think it’s just psychological. [Megan, age 22] 
Low mood was a particularly prominent theme in the six-month follow up interviews 
of two participants. Both described how their mood had limited their progress. After 
completing the study intervention, both participants had sought psychological 
treatment. This contact for psychological therapy took place over the telephone for 
both participants and unfortunately both describe a negative experience.  
R: And I’ve spoke to the people on the phone from Friends Life, but they don’t 
know what they’re dealing with.  
I: What do they do? 
R: They just talk to you about it. Talking therapy. It’s about, so how do you feel 
today? And what did you do and how did you make things better. And it’s just, you 
know it’s just text book. They’re reading off a book or off a sheet. They don’t know 
my actual, what I’m going through. They only know… um, trying to… they only 
know the textbook side of stuff. Oh he feels depressed today, ok. Do you know? 
And I feel it’s sometimes a waste of time because I get off the phone feeling worse 
than I did when I got on the phone. Because I feel like they’ve drained all the 
energy out of me talking about my problems. And I feel worse than I actually did 
before they actually called me. [James, age 36] 
I: You told me you saw a CBT therapist recently, what did they say? 
R: Oh no I didn’t see them. No, it was on the telephone. 
I: Tell me about that. 
R: Well I just thought that [it] was weird. Totally weird [laughs]. “Do you want to 
commit suicide?” No! “Do you get anxious when you go out the door? Do you feel 
sick? Do you want to go to the toilet? Do you want to, do you want to kill 
somebody?”  All these stupid questions. Well I say stupid, stupid to me because it, 
no, my brain didn’t think like that. [Lynn, age 56] 
11.5 Feedback from Participants 
The six-month interviews revealed components of the intervention that participants 
considered particularly helpful, and also components that were potentially unhelpful. 
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11.5.1 The Intervention Workbook 
Most participants reported finding the intervention workbook valuable. Some 
described how they referred back to the workbook regularly, while others reread the 
workbook as a reminder before attending their six month follow up appointment. The 
intervention workbook contained personalised information about FMD, strategies that 
helped to normalise movement, and a plan to improve their symptoms in the long 
term. Several participants described finding this information useful and reassuring. It 
was also used by participants to help explain their problem to others and some 
reported that they were able to use it to help local HCPs understand their problem 
(potentially adding legitimacy to their problem).  
R: And when you’re actually flung into normality, it’s quite hard to improve. But 
um, I just kept looking back on the plans that we went through and the study-book 
that we wrote out which, to help me with stuff. So that book that we wrote out 
came quite in useful, cos you look in back on things that you’d done here. [James, 
age 36] 
I: The workbook that you did in physio. Was it useful when you went home? 
R: Yeah. It was really useful to show other people as well. Especially the 
explanation of how FMD can manifest and how it, the whole, how it happens, the 
model. …And going through it with close family and they understand it a lot better. 
[Megan, age 22] 
The workbook also contained a section where participants had been asked to write a 
reflection on each treatment session. One participant described how this had helped 
them build a better understanding of their problem, by being encouraged to reflect on 
the information they had been given and then being given the opportunity to clarify 
questions in the following session.  
R: I thought the writing, the reflective writing [was useful], because sometimes I 
had questions and I could go back and ask [the study physiotherapist] about them 
and we then we would, you know, just talk over things as well. [Deborah, age 58] 
Several participants found that writing and rereading their reflections gave them new 
perspectives on their problem and helped them to see how much progress they had 
made.  
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R: And all the reflections that we did, when I wrote in my [workbook] each night. 
Just for me, it put things into perspective really. That I haven’t got to make life 
quite as difficult for myself as I do sometimes. [Deborah, age 43] 
R: So reading back, I found all the reflective stuff that I was asked to do each night 
that was what fascinated me. Um, because I’m at a completely different stage 
now. [Lisa, age 43] 
11.5.2 Preparing Participants for Discharge 
As part of the intervention, the study physiotherapist routinely warned participants to 
expect setbacks and discussed strategies to cope with difficult periods and to get back 
on track. This was supported in the workbook by a personalised relapse management 
plan. However the rapid improvement that many participants made over the five day 
intervention often left them with high expectations for further progress post 
discharge. 
R: I think, when I was here and the week that I was here, I had such amazing results 
in such a short, almost instantly. That I kind of expected to follow that. So in my 
head, the improvements um and the, the, I guess connections would be in a similar 
linear um, process. [Lisa, age 43] 
The common experience reported at the six-month follow up interviews was that 
maintaining rehabilitation gains and making further progress was more difficult than 
they had expected. Setbacks and periods of symptom exacerbation were common. 
Despite efforts to manage participants’ high expectations, it appeared that some 
participants were disappointed with their lack of further progress.  
I: Do you think, um, we did enough, or do you think there was enough discussion 
from us as a team about what to expect? Do you think we prepared you? 
R: Um, I think [the study physiotherapist] tried. Um, whether or not I would have 
listened if she would have been more explicit, I don’t know. Um, what would have 
been helpful, would have been some follow up. So perhaps some conversation, 
whether it was a phone call, or some sort of… whether it was meeting a local 
physio, just to sort of recap, um, that would have been helpful to kind of amplify 
the angel voices and stop me running away with my own thoughts. But I, yeah, 
because I felt that the first, and I don’t know. I don’t know that the first couple of 
months after being here. I wouldn’t say they were wasted, I needed to go through 
those emotions, there’s no short cut. But whether or not that would have helped 
me, I guess move forward through those stages a bit quicker, um, I don’t know. 
[Lisa, age 43] 
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11.5.3 Earlier follow up 
Several participants (including the example in the above quotation) suggested that a 
follow up sooner than six months would have been helpful. Participants described 
needing some reassurance and wanting an opportunity to practice strategies to 
control their abnormal movements, to talk through difficulties and revise their 
management plans. Participants had been encouraged to telephone the 
physiotherapist if they had any questions or concerns and this was reiterated within 
the workbook. However less than a quarter of participants actually made contact 
between discharge and follow up (7 of the 30 intervention participants). One 
participant described that she wanted to call for advice but was too concerned about 
being considered a treatment failure.  
11.5.4 Patient Interactions 
Several participants were curious to hear the stories of other people with FMD and 
would have liked to have met other trial participants. The desire to meet other 
patients was related to their sense of isolation and the fact that many had been led to 
believe their problem was rare and unusual.   
11.5.5 Intensity 
The high intensity of the study intervention may be an important therapeutic 
ingredient enabling rapid progress; however some participants found the intensity 
very challenging. One participant suggested spreading the treatment sessions out over 
two weeks. 
11.6 Summary 
At six months follow up all but one participant reported that their symptoms had 
improved compared to baseline. The reported impact of the intervention on 
participants’ lives was wide, and varied amongst individuals. It was difficult to 
disentangle physical, psychological and social changes and determine the extent to 
which each individual benefited. A common theme for all the participants, was that 
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putting everything into practice was more difficult than they had expected. Challenges 
came with setbacks due to other health problems, finding the time to implement 
rehabilitation strategies, maintaining motivation when progress plateaued and 
managing fatigue. The optimism and expectation of recovery that was prominent in 
the interviews conducted immediately after the intervention was tempered at six 
months with a realisation that there was no quick-fix to their problems and that                  
further change would be slow.  
In the baseline interviews, participants had described feeling stuck and powerless to 
help themselves. At six months, most continued to experience symptoms, but with a 
sense that they had generally moved forward. This seemed to be associated with 
having a better understanding of their difficulties and thinking that things could 
improve in the future. Many described feeling more accepting of their problem. The 
interviews provided an insight into what participants found helpful about the 
intervention and areas where adjustments may help to improve participant 
experiences and outcomes.  
11.7 Central Themes Across All Three Time Points 
There were three themes that were central to the participants’ narratives and 
common to each interview time point (baseline, post treatment, and follow up). These 
were: (i) the Impact of FMD; (ii) Dissatisfaction with Psychological Explanations for 
Symptoms; and (iii) Understanding.  There were some changes within each theme 
immediately following the intervention and at six month follow up. This is described in 
Table 11. 1 below and discussed further in Chapter 12.
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Table 11.1. Central Themes Across All Three Time Points 
 Prior to Treatment Post Treatment Six Months Follow-up 
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Functional motor disorder had a substantial negative impact, with participants describing both a physical and emotional burden. 
The physical burden of FMD varied amongst the participants, 
however, most described experiencing mobility restrictions 
and/or limitations in completing normal activities of daily 
living, such as washing, dressing, meal preparation, and 
sustaining employment.  
 
The emotional burden of FMD appeared to be of at least equal 
if not greater than the physical burden. The emotional burden 
was expressed as distress associated with frustration related 
to coping with symptoms, not understanding what was wrong, 
the unknown prognosis/future, and difficulty finding support 
from health care professionals. 
 
Isolation was a particularly prominent and distressing 
consequence of living with FMD. This was especially a problem 
for those who had left work or education due to ill health.  
 
Participants commonly described feeling powerless and 
unable to help themselves.  
All but one participant felt the intervention had 
helped their motor symptoms. There was 
considerable variation in the perceived extent 
of change; some described only modest 
improvements while others described 
significant changes such as no longer requiring 
walking aids. 
 
In post-treatment interviews, participants 
often described feeling relieved and reassured, 
suggesting the experience of their functional 
symptoms felt less threatening. This was 
associated with the feeling of having a greater 
understanding of their problem. 
 
The intervention appeared to leave the 
participants feeling hopeful for their future. 
 
Most participants reported ongoing benefit from the 
intervention. Often, improvement in symptoms 
translated to positive changes, such as less reliance 
on mobility aids, return to work, and less tension in 
interpersonal relationships. 
 
It was common for participants to describe feeling 
more at ease with their problem. This change was 
associated with having an acceptable diagnostic label, 
a greater understanding of their problem and some 
resolution of the uncertainty of their prognosis. 
 
The hope and optimism that was prominent 
immediately post-treatment remained to some 
extent, but was now tempered with a realisation that 
future progress was likely to be slow. 
 
The intervention appeared to empower the 
participants, with many feeling able to manage their 
problem more independently. 
Outlier: One participant felt their symptoms had relapsed to baseline levels and they had not sustained any physical benefits from the intervention. However, they 
continued to feel some hope for the future and described feeling less threatened by their symptoms. 
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Most participants were unsatisfied with psychological explanations for their movement problem. After the intervention there was less resistance to the idea that 
psychological factors were part of their problem. 
Most participants felt dissatisfied with psychological 
explanations for their symptoms. 
 
Physical precipitating events or an initial causal attribution 
to neurological disease were central to most participants’ 
illness narrative and psychological explanations were 
generally seen to be at odds with their physical/biological 
experiences.  
 
Those who experienced psychological problems such as 
anxiety or depression, generally felt that these were 
separate issues to their movement problem or reactive to 
their disability.  
 
Psychological explanations were often interpreted as 
meaning there was nothing wrong.  
 
Psychogenic illness was commonly associated with 
pejorative stereotypes, which some participants made 
efforts to distance themselves from (e.g. I’m not that type 
of person). 
Dissatisfaction with psychological explanations 
continued in many participants, but for some 
there was less resistance to the idea that 
psychological factors could be part of their 
problem.  
 
Some participants described a new realisation 
that at times they felt anxious which was part of 
their movement problem.  
 
Despite this softening stance, all the participants 
tended to hold the view that psychological 
factors, if present, were usually secondary to their 
motor symptoms or a separate issue and that they 
were not the cause of their FMD. 
 
 
Those who were less resistant to considering a 
role for psychological factors as part of their 
movement problem post treatment remained 
open to this idea at follow up. 
 
Psychological factors were generally seen as 
symptom modulators, exacerbating the problem 
rather than the cause. 
 
Some participants remained unconvinced that 
psychological factors were part of their 
movement problem.  
 
The explanation for FMD used in the study, which 
can be considered as biopsychosocial in scope 
with a biological emphasis, appeared to resonate 
with most participants. The study explanation for 
FMD appeared to provide validation of the 
participants’ illness experience, in a way that a 
psychologically focused explanation did not. 
There was a tendency for participants to view their problem from a dualistic mind-body perspective. The division between mind and body blurred for some 
participants after the intervention. 
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A central theme relating to the patient’s understanding of their problem ran through the participants’ interviews at all three time points. Understanding had an 
important impact on the lived experience of FMD and appeared to affect the ability to engage with the intervention.  
Most participants reported a lack of understanding 
of their movement problem and symptoms were 
commonly described as mysterious.  
 
Most participants perceived that doctors did not 
understand what was wrong. 
 
It was common for participants to feel unconvinced 
by the diagnosis of FMD. 
 
Lack of understanding meant that the future 
prognosis was uncertain, and for some this was 
frightening to the point of being distressing. 
 
Not knowing what was wrong meant that the 
participants did not know how to help themselves, 
leaving them feeling powerless. 
Most participants reported that the intervention had 
given them a greater understanding of their 
movement problem. 
 
Most reported feeling that the gain in understanding 
was the most valuable treatment outcome.  
 
Most participants described their problem in a way 
that resembled a biopsychosocial formulation of 
FMD. 
 
Several participants attributed improvement in their 
movement problem to having a greater 
understanding. 
 
Understanding appeared to reduce the threat value 
of symptoms and gave many a sense of 
empowerment and a perception that they were 
better equipped to self-manage.  
At follow up, the understanding gained with the 
intervention was still considered the most valuable 
treatment outcome and most were convinced that 
the diagnosis of FMD was correct. 
 
The participants’ understanding of their problem 
could be described as biopsychosocial in nature, with 
an emphasis on the biological. Most continued to 
feel that some things remained unexplained, for 
example why they developed FMD in the first place. 
 
A gain in understanding appeared to be associated 
with a number of positive treatment outcomes. This 
included reduced threat value of symptoms, hope for 
the future, and validation of their illness experience. 
 
 
Outlier: Confusion at baseline was common to all, but only one participant felt that her problem remained a complete mystery after the intervention. She described 
how the intervention could not help because nobody knew what was wrong.  
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Chapter 12 Qualitative Study Discussion 
This qualitative study involved interviews with a selection of participants from a 
feasibility trial, who received a specialist physiotherapy intervention for FMD. The 
participants were interviewed at baseline, after treatment and at six months follow up. 
Interviews were transcribed and analysed across cases at each time point. The findings 
from the baseline interviews provided insights into how the participants experienced 
the onset of FMD, their interactions with the health care system and the impact of 
FMD on their lives. The interviews conducted immediately after treatment provided 
insights into how the participants experienced and interacted with the intervention. 
The six month follow up interviews provided insights into the impact that the 
intervention had on the participants’ lives. The data from all three time points are 
discussed here and considered in relation to the usefulness and further development 
of the specialist physiotherapy intervention. This chapter concludes with a discussion 
of the limitations of the qualitative study and directions for future research.  
12.1 The Impact of FMD 
Participants’ accounts demonstrated the significant negative impact that FMD had had 
on their life. It was reported that physical disability due to FMD had a wide ranging 
impact, including limiting the ability to complete normal activities of daily living such as 
washing and dressing, fulfilling their roles as a parent and sustaining paid employment. 
This in turn put significant strain on their inter-personal relationships. Perhaps of equal 
or greater significance to the physical impact was the distress associated with FMD. 
Participants used emotive language to describe this impact, for example “I’ve lost 
virtually a year of my life, because of my condition” [Michael, age 46, table 2]. Distress 
was associated with not knowing what was wrong, the uncertainty of their prognosis, 
difficult finding support from health care professionals (HCP) and social isolation.  
Other studies of patients with FMD have previously reported high levels of disability 
and distress. Carson et al (2011)6 found that patients with functional neurological 
symptoms (n=1144) scored higher on measures of disability (SF12) and distress (HADS) 
than patients whose symptoms were explained by disease (n=2637), in the cohort of 
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patients taking part in the Scottish Neurological Symptoms Study. Anderson et al 
(2007)203 compared patients diagnosed with “psychogenic movement disorder” to 
those diagnosed with Parkinson’s disease and found equivalent levels of disability and 
impaired quality of life, while those with psychogenic movement disorder had more 
anxiety and depression.  
12.2 Resistance to psychological explanations 
In the baseline interviews, participants were generally resistant to psychological 
explanations for their symptoms. Even those who acknowledged a history of 
psychological problems felt that this was unrelated to their physical symptoms. Such a  
rejection of psychological explanations by patients is widely reported in the literature, 
backed by evidence from qualitative studies,195,196 illness belief questionnaires,204 and 
anecdotal evidence from neurologists.205 The current study offers data which may help 
to understand some of the reasons why patients may reject these psychological 
explanations.  
First, most of the participants associated the onset of their symptoms with a physical 
event, usually an injury or illness that appeared to precipitate their motor symptoms. 
In addition, they described the impact of FMD in terms of physical disability which they 
perceived (or reported) to be the cause of secondary distress. Psychological 
explanations felt at odds with their physical experiences and left them unconvinced by 
a psychogenic diagnosis. This mismatch in participant experience and diagnostic 
explanation can be considered in relation to the issue of mind-body dualism. The 
participants’ conceptualisation of illness appeared to be dominated by a biomedical 
model, where it is assumed that illness is fully accounted for by deviations from the 
norm of measurable biological variables.202 Consequently, whatever is not capable of 
being explained in this way is necessarily excluded from the category of disease. The 
problem of mind-body dualism was likely reinforced by monothematic psychological 
explanations given by HCPs, leaving an explanatory gap between the (physical) 
experience and (psychological) diagnosis that left participants feeling misunderstood 
and dismissed. The issue of mind-body dualism may also help to explain previous 
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reports of patients diagnosed with “conversion disorder” holding onto beliefs of having 
an underlying and as yet undiagnosed neurological disease.204 
Second, psychological explanations were interpreted by many participants as meaning 
that the doctor did not believe they had a real or significant problem. Some even felt 
that HCPs thought that they were faking their symptoms. These interpretations of 
psychological explanations were associated with pejorative stereotyped beliefs about 
mental health issues; which included that they are trivial problems that could be 
overcome if the person wanted to get better, that the patient is at fault and that 
mental illness is a character flaw. Participants either endorsed such views or projected 
them onto others. The implication was that psychological problems are generally not 
considered a legitimate cause of illness.  
Third, psychological explanations felt dangerous for some participants. Several 
potential sources of perceived danger were identified, such as the danger that the 
neurologist had honed into their past history of psychological problems, preventing 
them from performing a thorough assessment and therefore potentially missing 
underlying disease. There was reported danger of being subjected to unhelpful and 
undesirable treatment (reported experiences included the frightening experience of 
being locked in a psychiatric hospital ward and the prescription of unhelpful sedating 
and addictive medications). Finally, there was a perceived danger of being excluded 
from active treatment (such as physiotherapy and botulinum toxin). 
The attitude and behaviour of clinicians may also have played a role in the participants’ 
resistance to psychological accounts of FMD. Mental health problems notoriously lack 
equality with physical health problems. This point is made vividly by Sarah, who 
reports being told by a doctor “you haven’t got a brain tumour and you haven’t got 
cancer, I’ve got other patients.” Whether or not this is an accurate representation of 
the consultation between Sarah and her doctor, this was the message she took from it 
and the inequality and undesirability of problems related to psychological factors is 
made clear. In support of the possibility that patients may pick up on negative 
attitudes that are held by clinicians is a survey of neuroscience nurses.193 One in six did 
not think that functional motor symptoms were real and one in 10 thought that 
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patients with FMD wasted doctors’ and nurses’ time and were not deserving of the 
same level of care as patients with organic disease. Also, in a survey of 349 British 
neurologists,205 it was found that many harbour a belief or concern that patients with 
FMD are feigning their symptoms. Only 44% felt that conversion disorder was 
completely distinct from feigning, the remaining 56% felt there was an overlap 
between the two or that one was a subset of the other. The attitudes and prejudices of 
both patients and clinicians help to explain the reluctance of patients to consider 
psychological factors as part of their problem. 
12.2.1 A change in perspective post-treatment 
A novel finding of this study was that there was less resistance to considering a role for 
psychological factors amongst some participants after receiving the study intervention. 
There may be several explanations for this finding. First, some participants described 
how the intervention had helped them to come to a new realisation that they felt 
anxious and that this was part of their problem. Their previous lack of recognition of 
feelings of anxiety may be explained by the psychological construct of alexithymia, 
which is defined as an inability to accurately recognise one’s own emotions.206 Patients 
with FMD have been found to score higher on scales of alexithymia compared to the 
general population.37,207 However, this does not appear to account for the change in 
perception of all participants. Another potential explanation is that some participants 
felt “safer” disclosing experiences of psychological symptoms, having had their primary 
concern, that is, their physical symptoms, taken seriously and that they would not be 
dismissed. Patient recognition of psychological factors may be an important part of 
successful treatment. In an epidemiological study of 716 patients with neurological 
symptoms that were “not at all” or “only somewhat” explained by disease, non-
attribution of symptoms to psychological factors by patients was found to be a strong 
independent predictor of poor outcome, with an odds ratio of 2.0.153 
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12.3 The importance of understanding 
Understanding of their problem was a central theme in each participant’s narrative. 
The role and relevance of this understanding changed in the post treatment and follow 
up interviews. 
12.3.1 Understanding at baseline 
In the baseline interviews, participants considered their problem to be mysterious and 
they generally perceived that doctors had not understood what was wrong. This 
perception was reinforced when participants felt their diagnosis had been made based 
on negative investigations. Other experiences that undermined the participants’ 
confidence in HCPs included receiving conflicting information from different specialists 
and prescription of treatment that they felt had caused them harm. Some saw 
psychological explanations for their symptoms as further evidence that the doctor did 
not understand their problem, whilst others who had received more biological 
explanations, such as the “software not hardware” analogy, were left feeling confused 
about what was wrong. Difficulty understanding the diagnosis amongst patients with 
functional neurological symptoms is well reported in the literature.195,196 
There were significant negative consequences associated with this perceived lack of 
understanding. Several participants described how not knowing what was wrong and 
the uncertainty about their prognosis was frightening. Not knowing while waiting for 
appointments, investigations and a diagnosis was a particularly distressing experience 
for some. A lack of understanding was also associated with powerlessness. Participants 
described that, as they did not know what was wrong, they were unable to help 
themselves and therefore they were stuck in their distressing situation. 
12.3.2 Understanding after treatment 
Most participants reported that the intervention had helped them to develop an 
understanding of their problem. The understanding reported by participants was not a 
complete picture of FMD, however most recognised that the aetiology was 
multifactorial and included factors other than structural disease. This may be 
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considered a move from a biomedical model of illness towards a biopsychosocial 
conceptualisation of their problem. Improved understanding was usually considered 
the most valuable treatment outcome, which emphasises the negative effect that not 
knowing had had prior to treatment. When interviewed at six months, improved 
understanding remained the most highly regarded treatment outcome. 
12.3.3 The study explanation for FMD 
The study explanation for FMD appeared to resonate with the participants. A potential 
reason is that the explanation did not attempt to challenge pre-existing beliefs held by 
participants about their problem by enforcing a psychological explanation. Instead, the 
explanation aimed to build on their existing beliefs and develop a broader 
biopsychosocial understanding of their problem. This was achieved by formulating the 
participant’s experiences into a coherent (evidence based) biopsychosocial model, 
thereby providing an explanation that was perceived as relevant, legitimate, personally 
acceptable and amenable to treatment. A key element of the explanation was that the 
physical events that, at baseline, most participants perceived to have precipitated their 
problem, became central to the personalised explanation. Psychological factors were 
included in the explanation, usually described as “fight or flight” reactions, which may 
be considered a biological ‘spin’ on psychological processes. The extent to which 
psychological factors were included in any participant’s personalised formulation was 
dependent on the extent to which they considered them relevant to their problem.  
These findings are similar to those reported by Karterud et al (2015).208 They 
conducted semi-structured interviews with 11 adolescent and young adult inpatients 
who had been diagnosed with non-epileptic (functional) seizures. They found that the 
use of a multifactorial biopsychosocial model helped patients to accept the diagnosis 
by providing a recognisable reflection of their lives. In addition, they reported that the 
biopsychosocial model preserved self-esteem, in a way that psychologically heavy 
explanations and associations with mental illness did not.  
Another potentially important factor in the acceptability of the explanation is that the 
aetiological model on which it was based was connected to a corresponding 
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treatment. This may have alleviated the participants’ previous concerns of feeling 
marginalised and abandoned by the NHS, and also a perception reported by some 
participants that there are no available effective treatment for psychogenic problems.  
12.3.4 The impact of the perception of having a greater understanding 
The perception of having a greater understanding of their problem was associated 
with several positive consequences: feeling reassured, feeling empowered, feeling 
hopeful and increased self-confidence.  
Most participants described how understanding their problem left them feeling 
reassured. This related to the fear associated with the unknown that was reported in 
the baseline interviews. In the post treatment and follow up interviews it was common 
for participants to describe feeling less threatened by their symptoms, which may be 
an important mechanism by which the intervention worked. Studies of mediators of 
change in patients undergoing treatment for chronic pain and chronic fatigue (both of 
which may be aetiologically related to FMD), have found that a perception of reduced 
threat of their symptoms mediated improvement.209,210   
Understanding was perceived by many participants to be the reason that they 
improved with the intervention. This relates to the perception in the baseline 
interviews of being stuck and unable to help themselves due to not knowing what was 
wrong. Post-treatment, participants described a sense of self-reliance in managing 
their health problem. In this way, understanding was empowering. This finding may 
also be related to the role of illness belief as an aetiological mechanism that causes 
FMD, whereas a change in understanding may be associated with a positive change in 
problematic illness beliefs and expectations.  
12.4 Legitimisation and Validation 
The intervention appeared to give validation and legitimacy to the participant’s illness 
experience. This is likely to be an important factor in making the intervention 
acceptable and helpful.  
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The sociological concept of the “sickness role”, first described by Talcott Parsons in 
1951, is an influential theory of illness behaviour that may help to understand the 
significance of having illness validated.211 Parsons described how the sick role provides 
an exemption from normal social roles and obligations. The sick role comes with an 
assumption that the person requires specialist help to get better and that access to the 
sick role requires legitimisation of the illness from a doctor. An argument can be made 
that previous interactions with HCPs had not resulted in a diagnosis that the 
participant or society had considered a legitimate reason for entering a sick role. 
Exclusion from the sick role may then have prevented the commencement of 
convalescence and recovery or adaptation. Instead, the participant is left searching for 
a diagnosis that validates their illness experience and grants them access to the sick 
role. The concept of the sick role has been criticised over the years for being a 
simplistic representation of behaviour that does not necessarily represent all cultural, 
ethnic and socioeconomic groups.211 However, it remains an influential concept, which 
may help to understand conflict between patients with FMD and clinicians.   
12.5 From passivity to becoming active participants in rehabilitation 
In the baseline interviews, participants were generally passive in their illness role. They 
described feeling stuck and unable to move forward with their problem. This changed 
in the post treatment and follow up interviews. Participants described a sense of self-
reliance in managing their health and many reported an expectation of future 
improvement in their FMD symptoms following self-management. In this way, they can 
be described as active participants in their rehabilitation. Ingredients that appeared to 
be important in empowering participants to become active in their own rehabilitation 
were; receiving an acceptable diagnosis, having an understanding of their problem, 
validation and support from clinicians whom they trusted and they considered to 
understand their problem, having strategies that they believed improved their motor 
symptoms and having hope for the future.   
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12.6 The impact of the intervention 
The longitudinal design of this study provided insights into how the participants were 
able to use the intervention. In general, all participants described having had at least 
some benefit.  
Perhaps unexpectedly for a physiotherapy delivered intervention, “non-physical” 
benefits appeared to be more prominent than physical benefits in the participants’ 
accounts. As discussed above, most reported that the greatest value of the 
intervention was gaining a greater understanding of their problem. In many cases, this 
appeared to be associated with other benefits including resolution of the distress of 
uncertainty, hope for the future, and empowerment of the individual. Some 
participants also described improvement in their inter-personal relationships, which 
had been negatively affected by FMD. The non-physical benefits that participants 
attributed to the intervention appeared to reduce the general distress associated with 
FMD and may account for the new sense of feeling at peace with their diagnosis 
described by several participants.   
Other studies have reported similar findings. Sharpe et al (2011),77 in a RCT of guided 
self-help for functional neurological symptoms, based on Cognitive Behavioural 
Therapy principles, found that the intervention was associated with reduced health 
anxiety (as measured by the Whiteley Index). Also, Demartini et al (2014),71 in a cohort 
study of 66 patients with mixed functional neurological symptoms, reported that 
multidisciplinary rehabilitation led to a statistically significant improvement in the 
Illness Perceptions Questionnaire subscales of illness coherence (understanding) and 
emotional representation (distress caused by symptoms). 
Participants also reported physical benefits from the intervention. Immediately after 
treatment all participants reported an improvement to their physical symptoms. At six 
months, all but one continued to report physical benefit. Some considered that their 
symptoms continued to improve after treatment ceased, while others reported 
maintaining the benefits gained with treatment but felt there had been little further 
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progress, and some reported improvement from baseline but with some loss of the 
treatment effect.  
There were also reports of broader health benefits from the intervention; this included 
qualifying for cataract surgery when previously a head tremor precluded treatment 
and coming off benzodiazepine medication. 
In the post-treatment and follow-up interviews, there was a sense amongst many 
participants that they had become more self-reliant in managing their symptoms. This 
was associated with feeling as if they understood their problem, knowing how to 
manage it, as well as knowing there was backup support from the study clinicians if 
needed in the future. An implication of a new sense of self-reliance is the potential for 
a reduction in future use of health resources and therefore future cost savings. The 
reports of returning to work and coming off medication also suggest the potential for 
cost-benefit.  
12.7 Barriers to recovery and limitations of the intervention 
Participants’ accounts of the intervention and how they fared in the period between 
treatment and follow-up revealed potential barriers to recovery and limitations of the 
intervention.  
Comorbidity was commonly reported as a cause of symptom relapse or ongoing 
disability. Reported comorbidities that were associated with ongoing problems were 
fatigue, persistent pain, recurrent migraine, transient illness, low mood and a cancer 
scare (abdominal mass found and biopsied). Most patients with FMD have 
comorbidities, such as neurological disease, hypermobility syndromes, anxiety, 
depression and other “medically unexplained” symptoms such as persistent pain and 
fatigue. Comorbidity can be formulated into the biopsychosocial understanding of 
FMD, contextualised as predisposing, precipitating and perpetuating factors.13 The 
clinical implication is that addressing comorbidity is an important part of treatment of 
FMD. The presence of comorbidity may influence the suitability of a patient to a 
particular treatment option. Therefore, patients with, for example, significant 
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comorbid anxiety, depression and pain may benefit from a more multidisciplinary 
approach to treatment. Comorbidity may also influence long term prognosis and 
outcome with treatment.  
A potential limitation of the intervention relates to the finding that many participants 
found that implementing their self-management plan was more difficult than they had 
anticipated, leading to frustration and declining motivation. Participants were warned 
to expect “ups and downs” after treatment and that progress might not be as rapid as 
during the five days of the intervention. However, it appeared that many continued to 
have very high expectations in regard to their recovery which went unmet. This may 
indicate a need to re-evaluate how we prepare patients to cope post treatment. An 
alternative view about this issue is that high expectations of recovery may be helpful. 
This would be predicted by the underpinning aetiological model for FMD, in which 
expectation is considered a mechanism that drives abnormal movement. Supporting 
the aetiological role of expectation in FMD is the finding that expectations of non-
recovery predict a poor outcome.153 It may follow that high expectations of recovery 
predict a good treatment outcome and therefore expectations of recovery are 
therapeutic. In this case, some disappointment at lack of symptom resolution or the 
slowness of improvement may be a necessary inevitability.  
12.8 Clinical and Research Implications 
The findings from this research have several implications for clinical practice. 
12.8.1 The importance of understanding the diagnosis 
The participants in this study considered that developing an understanding of their 
problem was important for them to improve. This highlights the importance of 
providing a diagnostic explanation that patients find acceptable and relevant. In the 
current study, explaining the diagnosis started with the neurology consultation at the 
time of potential recruitment to the study and was backed up during the specialist 
physiotherapy intervention.  
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12.8.2 Vulnerability and risk of iatrogenic harm 
Reports of receiving previous treatments that participants perceived had caused them 
harm were alarmingly common (6 out of 11 participants). This highlights the 
vulnerability of this patient group to iatrogenic harm. It is probable that the 
marginalisation of these patients from mainstream medicine, as  perceived by this 
cohort and as has been reported in previous studies,195 contributes to this 
vulnerability. The availability of specialist services for patients with FMD, where they 
can receive an early diagnosis and be directed towards a range of evidence based 
treatments that reflect the heterogeneity of this group may help limit iatrogenic harm. 
12.8.3 Who is suitable? 
Most of the participants described having had some benefit from the study 
intervention, but there was little data from the feasibility trial or qualitative study 
which would help determine in the future who is most suitable for this type of 
treatment. This may be a reflection of the limited sample size and participant selection 
bias in the qualitative study. Alternatively it may indicate that the study eligibility 
criteria were appropriate.  
12.8.4 Discussing psychological factors with patients 
Several participants described having had particularly negative experiences with 
previous experiences with HCPs that left them feeling ashamed of their problem. 
These experiences were usually related to a perceived implication that their symptoms 
were psychological and not real. Others studies have found that explanations for 
functional neurological symptoms that imply mental illness can be an affront to self-
esteem.208 The explanation given to participants in the current study was based on the 
clinical observation of neurologists Jon Stone and Mark Edwards, that patients are 
more accepting of the diagnosis when it is explained in terms of the physical diagnostic 
signs displayed by the patient.154 They suggest that the explanation should note that 
psychological factors are an important part of the problem for many people, but that 
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the initial consultation is not usually an appropriate time to open up a dialogue about 
the sensitive issue of mental health and past traumatic experiences. 
The study data supports the clinical approach described above. In the baseline 
interviews, participants were resistant to the idea that their problem was related to 
psychological factors. However, it was found that this resistance to psychological 
explanations often softened in post treatment and follow up interviews. The 
intervention helped participants to develop a broader biopsychosocial understanding 
of their problem, which allowed a role for psychological factors which was not 
necessarily causal. Other factors that may be important for the softening stance 
against psychological factors are that they had secured a diagnosis, granting them 
access to the sick role (i.e. validating and legitimising their illness), and knowing that 
they would not be dismissed as was their reported previous experience (for example, 
Lynn’s experience of being told “we think it’s psychological and there is nothing wrong 
with you”). The intervention may also have helped participants to recognise the 
presence and impact of anxiety.  
The clinical implication is that there may be value in “going in easy” with psychological 
explanations in the early stage of diagnosis, in order to engage the patient. 
Commencing physiotherapy may for some patients be an important precursor to 
psychological therapy. It should be noted that the resistance to psychological 
explanations may be particular to certain populations, such as patients seeking support 
in tertiary neurology clinics, and there may be patients with FMD who actively seek 
psychological support, who are not represented in the current study.  
12.8.5 Measuring change in clinical and research settings 
Typically, when assessing the impact of a physiotherapy intervention, the focus is on 
measuring physical impairment and disability; non-physical changes may be an 
afterthought or even ignored. The findings from this research suggest that non-
physical changes make up a substantial part of the positive impact of the intervention 
on participants’ lives and therefore this should be considered in outcome 
measurement. Specific non-physical changes found in the qualitative data that were 
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associated with the intervention were: (i) a perception of increased understanding of 
the problem; (ii) an expectation of recovery; (iii) reduced distress from the lack of 
understanding of FMD, the uncertain prognosis and lack of support from HCPs; (iv) 
reduced threat value of symptoms; (v) a perception of self-efficacy; and (vi) improved 
interpersonal relationships. These findings require further validation and assessment. 
Choosing outcome measures that reflect the impact of treatment and are sensitive to 
change in patients with FMD is problematic. For example, patients with FMD are 
recognised as having high levels of distress, which may improve with effective 
treatment. A prominent source of distress found in the baseline interviews of this 
study was the perception of being abandoned by the health care system. This source 
of distress will not necessarily be captured by generic anxiety or depression scales, nor 
by commonly used measures for illness distress, such as the Illness Perception 
Questionnaire, where none of the 87 items appear to take this specific issue into 
account.212 
12.8.6 Important elements of the intervention 
Elements of the intervention that participants valued and which may be important 
therapeutic ingredients were: (i) the focus on explaining the diagnosis; (ii) the specific 
symptom-explanatory model; (iii) the focus on self-management; (iv) consecutive days 
of treatment (although some participants found the intensity challenging); (v) staying 
in accommodation away from home; and (vi) the intervention workbook. 
It was common for participants to comment after treatment that they held the study 
clinicians in high regard. Higher levels of therapeutic alliance have consistently been 
shown to be associated with better outcomes in both medicine and psychology, and 
there is some evidence for this effect in physiotherapy for chronic low back pain.213 It 
is therefore highly likely that the therapeutic alliance may have been an important 
therapeutic ingredient in the intervention.  
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12.8.7 Refining the intervention 
Based on feedback given by participants during their interviews, some elements of the 
intervention could be refined to improve the patient experience, and possibly improve 
the intervention outcome. The most commonly made suggestion was that the follow 
up appointments should be scheduled earlier than six months. The six months interval 
was chosen in the feasibility study in order for this appointment to coincide with the 
final outcome measurement. In clinical practice, a follow up interval of around four to 
six weeks may be more appropriate. The participant suggestion of a scheduled 
telephone call at one or two weeks may have additional therapeutic benefits. Other 
suggestions for the intervention that warrant investigation and assessment are the 
inclusion of group sessions and flexibility to reduce the intensity of scheduled sessions 
(e.g. delivery of the intervention over two weeks).  
12.9 Limitations 
There are several limitations to this study that should be acknowledged.  
The findings reported represent the views of a relatively small sample with some 
limitations in diversity. A purposive sampling plan was predefined in an effort to 
recruit a representative sample of patients. This planned representation was to some 
extent achieved in that no predefined characteristic went unrepresented in the final 
cohort. However, there were only two men and one person over the age of 60. The 
sample also had limited representation of patients with poor treatment outcomes, in 
that only one of the 11 participants reported at six months that their symptoms had 
not been improved with the intervention and all participants reported getting at least 
some benefit from the intervention. The longitudinal study design with interviews 
commencing prior to treatment meant that it was not possible to purposively select 
participants based on poor treatment outcome. Therefore there was limited data 
available for an exploration of themes associated with poor outcome.  
The study design was confined to exploring the views of participants receiving the 
study intervention. There would have been value in also exploring the views of 
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participants in the control group who received standard physiotherapy, patients who 
were unaccepting of the diagnosis and those that refused to participate in the study.  
My identity as a specialist physiotherapist and perceived connection to the study 
clinicians is a potential limitation. This may have influenced the way participants 
answered questions. For example, participants may have felt obliged to be more 
complementary about the intervention and less inclined to disclose information that 
may suggest poor outcome. In addition, my background as a physiotherapist with 
experience in FMD will have influenced the way I interacted with participants, the way 
I led the interview and interpreted the responses.  
My connection with the study intervention is a potential conflict of interest and source 
of bias. This bias was minimised by the qualitative analysis team consisting of two 
additional researchers who were independent of the intervention. 
An important limitation is the transferability of the findings. Extrapolating the findings 
beyond the highly selected participants of this study should be done with caution. The 
particular characteristics of this cohort are patients attending a tertiary movement 
disorder clinic specialising in FMD, who met the eligibility criteria of the feasibility 
study. Therefore, the findings may not apply to patients who are only seen in 
psychiatric settings or primary and secondary care, those with high levels of comorbid 
pain, fatigue or psychopathology, and those who have more significant disability (i.e. 
disability to the extent that assistance is required for toileting). A final limitation was 
the relatively short follow-up interval of six months.  
12.10 Future Research 
Future studies should seek to explore the views of a greater diversity of patients, with 
consideration of age, gender, ethnicity, and socioeconomic class. Studies exploring 
characteristics and views that may account for good and poor treatment outcomes 
would be a valuable avenue of future research, with implications for refining 
interventions and helping to direct patients towards the most suitable treatment 
option. Data from patients who receive standard (non-specialist) physiotherapy 
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treatment may provide insights into the additional benefits of the study intervention 
or indeed, absence of additional benefit.  The views of physiotherapists treating 
patients with FMD would be important to understand if the intervention were to be 
rolled out across the NHS.  
The non-physical positive impacts of the intervention found in this study, such as 
reduced threat from symptoms, could be validated in future research and used to 
inform the creation of outcome measures specifically for FMD. 
12.11 Conclusion  
The participants in this study reported high levels of disability and distress associated 
with having FMD. They had had multiple previous interactions with HCPs, which they 
generally regarded as unsatisfactory and which was usually associated with receiving 
psychological explanations for their symptoms. Participants rejected such 
psychological explanations for a number of reasons. Firstly, they were unable to 
reconcile their physical experiences with a psychological explanation. Secondly, many 
interpreted psychological explanations as meaning the doctor had not believed that 
they had a real problem. This was related to various pejorative stereotypes of mental 
illness. Thirdly, some felt that “going down the psychological route” was fraught with 
danger and was unlikely to lead to recovery. And finally, a perceived negative attitude 
of clinicians towards problems associated with psychological factors left some 
participants feeling unworthy and ashamed. A novel finding of this study was that 
there was less resistance to considering a role for psychological factors as part of FMD 
after the participants had completed the intervention. This appeared to be related to 
the participants gaining a broader biopsychosocial understanding of their problem, 
where psychological factors could be considered as part of their problem, but not 
necessarily the cause. 
The study intervention was highly praised by the participants and was associated with 
reports of improvement to their physical symptoms. Perhaps somewhat unexpectedly, 
most participants considered having an improved understanding of their problem was 
the most valuable treatment outcome. This perception was associated with feeling less 
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distressed by their problem, a sense of self-reliance and feeling hopeful for the future. 
The specific biopsychosocial explanation for their symptoms that was part of the study 
intervention appeared to resonate with the participants.  The explanation appeared to 
give legitimacy to the participants’ illness experiences, which may have been 
important for engaging them in the specialist physiotherapy intervention and future 
self-management.  
Only one participant reported a complete resolution of their motor symptoms, the 
remaining participants reported gradations of improvement from no change to near-
resolution. A prominent barrier to recovery was the presence of comorbid symptoms, 
which included fatigue, pain, migraine and other illness.  
The clinical implications from this study include the importance of providing a 
diagnostic explanation for symptoms which patients are able to reconcile with their 
problem. In this instance, this meant focusing on physical and biological factors, with 
secondary reference to psychological factors. The study intervention was found to 
have a positive impact on the participants’ lives at six months; in particular participants 
felt less concerned and more in control of their health problem. An implication for 
future research concerns measuring treatment outcome in terms of non-physical 
changes, such as levels of understanding of the problem and changes in illness-
associated distress.
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Chapter 13 Final Thesis Discussion and Conclusions 
13.1 Introduction 
In this thesis, I have explored a specialist physiotherapy-based intervention for FMD 
using a mixed methods research approach. A randomised feasibility study was 
conducted with the primary aim of determining the feasibility of testing the 
intervention in an RCT. A longitudinal qualitative study of patients receiving the 
intervention was embedded into the feasibility study, providing insights into how the 
intervention worked, as well as the lived experience of FMD and its clinical 
implications. Feasibility was demonstrated with high rates of participant recruitment, 
retention and intervention acceptability. The clinical outcomes were promising, 
suggesting that an appropriately powered RCT has a good chance of demonstrating 
clinical and heath-economic effectiveness. This chapter will draw together the 
research findings with a synthesis of the quantitative and qualitative data. 
13.2 Summary of Findings by Chapter 
The topic of FMD was introduced in Chapter 1. FMD was described as a multifactorial 
problem affecting movement that is best understood with a biopsychosocial 
framework. It was argued that the awareness and understanding of FMD was 
surprisingly limited when it is seen in the context of the frequency with which patients 
present and the burden of symptoms to the patient and society. 
In Chapter 2, I argued that the historical context to some extent explains the low levels 
of understanding, interest and status of FMD within the health care system. FMD was 
embraced by neurology, under the influence of the French neurologist Charcot in the 
late 1800’s, before moving towards psychiatry under the influence of Sigmund Freud 
and his contemporaries. However, since the “heyday of hysteria” in the late 1800’s, 
both neurologists and psychiatrists have been notoriously uninterested in FMD, 
leaving patients in a no-mans-land.104 Concerns over malingering and the risk of 
missing organic disease are thought to have led to a virtual disappearance of the 
diagnosis of FMD from medicine. A resurgence of scientific interest started in the mid 
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1990’s, bolstered by findings from functional imaging studies. Today, the scientific 
literature appears to be increasing exponentially, as if making up for lost time. This 
surge of scientific interest may appear as if history is repeating itself, echoing the late 
19th century. Hopefully this time around we will learn from the past and avoid the 
neurology-psychiatry all-or-nothing divide, which I have argued, stunted the 
development of physiotherapy for FMD and the holistic treatment of FMD in general. 
There is reason to be hopeful, multidisciplinary research and treatment teams for FMD 
are starting to become the norm. This has led to fruitful collaborations between 
neurology, psychiatry and rehabilitation specialists, producing outputs such as the 
Stepped Care approach to the treatment of functional neurological symptoms, 
published by NHS Scotland,214 and consensus recommendations for physiotherapy 
practice.41 
Chapter 3 is a systematic review of the literature for physical rehabilitation for FMD. 
Only 35 studies inclusive of physical rehabilitation were found representing treatment 
of 564 people; of whom 79% were women, the average age was 35, and the average 
symptom duration was 3 years. Overall the quality of the evidence for physical 
rehabilitation was considered low due to the limitations in the study methodologies. 
However, the reported results were encouraging. There is controlled evidence from 
one study that physical based rehabilitation can provide at least short term 
improvement for patients with functional gait disorders with a symptom duration less 
than 5 years. There is also uncontrolled evidence from several large cohort studies that 
treatment involving physical rehabilitation is beneficial for the majority (55-72%) of 
patients with mixed FMD symptoms selected for treatment, and treatment effects 
have been reported to last up to two years. However, it appears that most patients 
remain symptomatic to some extent after rehabilitation and return to work is rare. 
Measures of physical function tended to show medium effect sizes, while measures of 
mental health tend not to change. In summary, the major limitation of the literature is 
the absence of controlled evidence for rehabilitation beyond four weeks. There are 
multiple unanswered questions including: What are the most important ingredients of 
rehabilitation? Which are the most suitable outcome measures? What are the most 
suitable treatment parameters in regards to setting, duration and intensity? And, how 
generalisable is the literature to the NHS? 
208 
 
The important first stages of developing and evaluating a complex intervention, 
according to the MRC, is to ensure the intervention has a coherent theoretical basis 
that it is described in full and is implementable in a clinical environment. This is the 
focus of Chapter 4. A theoretical, evidence based model for FMD which is amenable to 
physiotherapy is described. The model is biopsychosocial in design, but emphasises the 
biological sphere, which provides a specific rationale for physiotherapy. The key 
mechanisms by which physiotherapy intervention are proposed to affect change are: a 
reduction of self-focused attention during movement; and a change in the patient’s 
belief and expectation that their movement will be abnormal.  
The randomised feasibility study of the specialist physiotherapy intervention is 
reported in Chapters 5 to 7 (methods, results and discussion). In short, 60 consecutive 
patients with FMD who met the selection criteria were randomised to receive either 
the study intervention or a control consisting of a referral to community neuro-
physiotherapy. The feasibility of conducting a trial was demonstrated by high rates of 
recruitment, retention and the acceptability of the intervention, with no reported 
serious adverse events. The clinical and economic outcomes were promising, in that 
the intervention was associated with a moderate to large treatment effect size across 
a range of physical and quality of life outcome measures. Together with demonstrated 
feasibility, the positive trial outcomes further support the progression to a large scale, 
definitive trial.  
The feasibility study provides a template for the design of a definitive trial. The 
inclusion criteria appeared to work well. While only 32% of patients with FMD seen in 
the neurology movement disorders clinic where recruitment took place met the 
eligibility criteria, recruitment was completed in nine months, which reflects the high 
volume of patients suitable for physiotherapy treatment and meeting eligibility. The 
high rate of intervention-patients reporting improvement at six months (72%), 
suggests that patients unsuited to physiotherapy were appropriately excluded. The 
most suitable primary outcome measure for a large RCT of the intervention was found 
to be the SF36 Physical Function and the study provides data for an RCT sample size 
calculation. The CSRI was found to have limitations, in that there was insufficient data 
to accurately estimate service use costs and changes in engagement with employment. 
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These issues should be addressed by adapting the CSRI in any future studies. An 
employment specific questionnaire, such as the Work Productivity and Activity 
Impairment Questionnaire may be a valuable addition for health economic analysis.189 
Based on the experience of uneven rates of recruitment between the intervention and 
control groups, a future study should also consider block randomisation.   
The qualitative study methods, findings and discussion are reported in Chapters 8 to 
12. Data from interviews conducted prior to treatment provided insights into the 
qualitative study participants’ views and experiences of developing FMD and accessing 
the health care service. Common themes emerged around a lack of understanding of 
what was wrong and resistance to psychological explanations for their symptoms. Data 
from interviews conducted after treatment and at six months provide insights into 
how the participants engaged with the study intervention and the impact that the 
intervention had had on their lives. A central theme related to gaining understanding 
of their problem ran through the interviews at all three time points. The lack of such 
understanding was implicated in the participants’ ongoing problems prior to 
treatment. Post-treatment, most participants felt they had gained an understanding of 
their problem, which they perceived to be the most valuable outcome of treatment, 
despite most also reporting improvement to their motor symptoms. At six months 
follow-up this understanding remained the most important outcome and was 
associated with positive changes, such as a perception of greater self-reliance in 
managing their movement problem, reduced concern over their movement problem 
and hope for the future. The study findings could help to refine the intervention, for 
example, providing greater support during the transition from treatment to discharge 
with earlier follow up and bolstering self-management skills. How this is best achieved 
would be a valuable focus for future research.  
13.2.1 Limitations of the Research 
The limitations of both the feasibility and qualitative study are discussed in detail in 
the relevant chapters. A limitation that warrants repeating is that the clinical trial was 
designed to assess feasibility; therefore interpreting clinical outcomes as controlled 
evidence for effectiveness would be extrapolating the data beyond its value. The 
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limiting factors include that the study was not powered to detect a treatment effect, a 
primary outcome measure was not predefined and assessment was not blinded. 
However, given the lack of clinical trials in FMD, the feasibility study outcome data 
make a significant contribution to the evidence base that supports the use of specialist 
physiotherapy for FMD. The findings should, however, be interpreted with caution as 
generalisability is not assured, due to the single recruiting centre, and the neurologist 
and physiotherapist had a special interest in FMD, which may not always be the case if 
the intervention were to be rolled out across the NHS. 
13.3 Synthesis of Quantitative and Qualitative Data 
13.3.1 Outcome Measurement 
An important aim of the research projects included in this thesis was to identify a 
suitable primary outcome measure for a RCT of physiotherapy for FMD. The SF36 
Physical Function domain was found to be the most suitable candidate from the 
measures assessed in the study. It showed a large effect size, which appeared to be a 
clinically important change; it had the advantage of being a self-report measure, which 
is less likely to be affected by the variable nature of FMD severity over short periods of 
time (associated with self-focused attention); and was applicable to patients 
independent of symptom location (i.e. symptoms affecting gait, upper limb function or 
posture). Measures of gait impairment had a larger effect size but were not necessarily 
applicable to patients with only upper limb or head and neck symptoms. The 
qualitative data supports the relevance of the SF36 Physical Function to the impact of 
FMD on patients and change with treatment. The SF36 Physical Function domain 
considers mobility and activities of daily living requiring upper limb dexterity (bathing 
and dressing, vacuum cleaning and carrying groceries). In the qualitative interviews, 
the participants reported that physical symptoms were the primary problem, causing 
disability which resulted in secondary distress. In post-treatment interviews, the 
qualitative study participants often described their improvement in terms of their 
ability to walk and access their environment.   
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In the qualitative interviews, it was common for participants to report that the most 
valuable outcome of the intervention was having a greater understanding of their 
problem. This perception of greater understanding was also found in some of the 
outcomes from the feasibility study. The “Coherence” dimension of the B-IPQ asks, 
“How well do you feel you understand your illness?” with answers ranging from 0 
(don’t understand at all) to 10 (understand very clearly). The intervention group mean 
scores were 6.2 (SD 2.6) at baseline, 8.8 (SD 1.6) post-treatment and 7.8 (SD 1.9) at six 
months, with little change in the control group 4.9 (SD 3.1), 5.7 (SD 3.5), 5.9 (SD 3.1) 
(see Appendix 7, page 240). Given the thesis finding that understanding of the problem 
appears to be important in improvement of FMD, an assessment of patients’ 
understanding should be considered in future interventional studies.  
 The qualitative data may help to explain the feasibility study finding of an increase in 
the number of cases of anxiety in the intervention group (and not the control group) at 
six months (n=4 at baseline, n=10 at six months). The increase appeared 
counterintuitive, given that the intervention group reported significant improvement 
on measures of physical disability and a change in the total B-IPQ score suggestive of a 
reduction in the perceived threat posed by illness. Possible explanations for the 
increased cases of anxiety are that it is a chance occurrence in the data, that some 
participants became more anxious, or that the intervention helped some participants 
develop insight into their problem and possible links to anxiety. The qualitative data 
support this last explanation. Several interview participants reported in post-treatment 
interviews, that they had come to a realisation that they were anxious or that anxiety 
was part of their problem. This realisation may have led them to score themselves 
higher on the HADS. Recognition of the role of anxiety may be a helpful outcome of 
the physiotherapy intervention. It may help some patients with FMD to more correctly 
attribute sensations and involuntary movement to the sensorimotor consequences of 
anxiety, rather than symptoms of disease. It may also help some patients who could 
benefit from a psychological intervention engage with treatment when they are 
initially reluctant to do so. These hypotheses are consistent with data from a large 
cohort study that found that non-attribution of the symptoms of FMD to psychological 
factors predicts poor outcome, with an odds ratio of two.153  
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Both the feasibility study and qualitative study found that the intervention was 
associated with decreased distress associated with symptoms (reduction in B-IPQ total 
score and interview reports of feeling at more at ease with ongoing symptoms). The 
qualitative data provided possible reasons for this finding. This included the perception 
of knowing what was wrong, knowing how to manage the problem, resolution of the 
uncertainty of the prognosis, and resolution of the perception of feeling abandoned by 
the NHS, despite having a problem that was debilitating and at times frightening.  
The health economic analysis found that the incremental cost per QALY gained with 
the intervention was £12,087, significantly less than the £20,000 upper limit of cost 
effectiveness suggested by NICE.177 The qualitative data gave weight to the probability 
of cost effectiveness. The interview participants commonly reported acceptance of the 
diagnosis and a sense of self-reliance which included an expectation of less 
dependence on HCPs. This suggests the potential for a reduction in health service 
utilisation, such as seeking further investigations, second opinions, and alternative 
treatments.  
13.3.2 How did the intervention work? 
Seventy-two percent of the intervention group participants reported improvement in 
their symptoms at six months. This corresponded with significant improvement in 
measures of physical function (e.g. SF36 Physical Function domain and measures of 
balance, mobility and upper limb function). Data from both the feasibility study and 
qualitative study provide clues as to how the changes may have come about.  
In the feasibility study discussion, I suggested that the reduction in B-IPQ total score in 
the intervention group may indicate a reduced threat of symptoms and that this may 
be an important mediator of change. The qualitative data supported the suggestion of 
reduced threat from symptoms. These findings are consistent with intervention-
mechanism studies of chronic fatigue syndrome and persistent pain treatments.209,210  
Data from the feasibility and qualitative study suggest that a perception of having an 
increased understanding of the problem may be an important mediator of 
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improvement and may help by reducing the threat of symptoms. Such understanding 
appeared to be associated with self-efficacy and hopefulness, which may also be 
important factors that mediate improvement with this intervention.  
Given the association of FMD with psychological disturbance, it would be reasonable 
to hypothesise that changes in mental health scores may mediate improvement. 
However, this was not found in the data. Measures of mental health did not change 
with treatment. However, this may be related to the subclinical levels reported at 
baseline or reflect limitations with the assessments.  
13.3.3 What Constitutes a Good Treatment Outcome? 
The feasibility and quantitative studies raise the question: what constitutes a good 
treatment outcome? Standard definitions of FMD usually highlight that symptoms are 
not related to structural damage or disease and therefore there is a potential for 
complete symptom resolution. This may lead to unrealistic expectations, and a 
perception that lack of symptom resolution is a treatment failure. In the current 
studies, symptom resolution at six month follow-up was rare. This is also the case for 
other interventional studies.75 However, the current study found improvements in 
physical function, perceived understanding, distress and measures of cost-utility. 
These findings emphasise the importance of using sensitive outcome measures and 
measuring multiple domains of health.  
The challenge for physiotherapists treating patients with FMD may be in recognising 
the value of non-physical treatment outcomes, such as reduced illness distress and 
cost-benefit, in situations where there has been no change in disability. The 
expectation that patients should get completely better and that failure to do so 
constitutes failure, is unrealistic and arguably suggests an underlying uncertainty 
regarding the genuine nature of functional disorders.  
13.4 Thesis Conclusions 
FMD is a common cause of disability and distress, for which there are few treatment 
options available. The findings from the studies described in this thesis support the use 
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of a specialised physiotherapy-led intervention for FMD and add to the body of 
evidence for specialist physiotherapy for FMD. The key components of the 
intervention were education about the diagnosis (provided in neurology and 
physiotherapy sessions), demonstrating to the patient how they can move normally 
when distracted, using distraction to develop strategies that normalise movement, and 
developing a long term personalised symptom management plan.  
The explanation given to patients about the diagnosis was the important first step in 
treatment. The explanation was biopsychosocial in scope, but emphasis was placed on 
the biological domain. The explanation resonated with most of the study participants 
and appeared to be important in helping them to accept the diagnosis and engage 
with treatment and self-management. The finding that many participants were less 
resistant to acknowledging a role for psychological factors in their problem after 
treatment may be significant in the intervention success and may have clinical 
implications for designing multidisciplinary treatment pathways (with recognition that 
generalisability beyond patients attending tertiary neurology clinics is not assured). 
The research identified several factors that may mediate a good treatment outcome. 
These were: (i) a change in illness belief; (ii) a perception of improved understanding of 
their movement problem; (iii) reduced threat value of symptoms; (iv) a perception of 
increased self-efficacy; and (v) hopefulness. These potential mediators of change could 
be targeted in future interventions; however confirmation of their role in mediating 
change with further research is needed. Consecutive days of treatment and high 
intensity treatment appeared to be an important element of the intervention that 
warrants further exploration. 
The intervention cohort improved despite an average symptom duration of 5 years. 
Given the substantial evidence that symptom chronicity is associated with a poor 
prognosis,70 it is possible that if the intervention was delivered earlier in the course of 
the participants disorder, it may have been more effective.  
This thesis has explored a specific physiotherapy intervention. Physiotherapy is only 
one of a number of different treatment approaches that may be effective for patients 
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with FMD. Other potentially effective treatments available in the NHS include specific 
types of psychological therapy, occupational therapy and multidisciplinary 
rehabilitation. In addition, there may be other interventions that are not available on 
the NHS and cultural specific treatments that may also prove to be effective. Given the 
heterogeneity of patients with FMD, it follows that a variety of different treatments 
are necessary to suit the needs and preferences of people with this diagnosis. A key 
priority therefore in future work is to identify criteria that predict which patients are 
most likely to benefit from each of these different interventions, to improve the 
effective triage of patients into treatment.  
13.4.1 Progression to a definitive trial 
The findings of this thesis support the progression from the feasibility study to a 
pragmatic multicentre RCT. Additionally, the findings should inform the design of this 
trial. See Appendix 8: Reflections on the Methodology (page 242), for a list of 
methodological considerations for a future trial.  
Refining, standardising and documenting the intervention so that it is both 
implementable and reproducible in a clinical trial will be a challenging but necessary 
step. A useful approach to achieve this objective is Intervention Mapping 215,216. 
Intervention Mapping is a systematic approach to intervention development that 
enables integration of theory, research evidence and practical implementation issues. 
Additionally, Intervention Mapping aims to link intervention components to theoretical 
mechanisms of change, which may help to understand the intervention and improve 
outcomes. Utilisation of Intervention Mapping is likely to make the scaling up of the 
single-site-intervention described here to a multicentre trial intervention more 
successful.    
Given the high satisfaction ratings and positive treatment outcomes, a future trial 
should aim to reproduce as closely as possible the conditions of the study intervention. 
An addition that may improve the intervention is a six week physiotherapy follow up 
session.  
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The SF36 Physical Function domain was found to be the most suitable primary 
outcome measure. The adjusted difference between groups for this measure was 19.8 
(95% CI 10.2, 29.5). When calculating a sample size for a future pragmatic trial, a more 
conservative group difference should be selected, for example a difference of 10 
points.  
Finally, a future study design could consider a secondary mediation analysis to explore 
potential treatment mechanisms. Potential mediators that could be investigated using 
standardised questionnaires include: expectation of recovery, perceived level of 
understanding of the health problem, distress caused by symptoms, and perceived 
level of threat posed by symptoms. Reproducing the study intervention in a pragmatic 
multicentre trial will be challenging. However, my experiences over the past three 
years with inspiring mentors, collaborators and patients have left me feeling confident 
that it is possible and motivated to try.
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Appendix 1 Quality Appraisal of Studies with Subject Numbers of 10 or More 
 
Quality Appraisal Checklist for Case-Series Studies217 
 
(The authors of this tool state that empirical evidence does not support defining quality by a 
cut-off score. Additionally the validity of scoring each criterion with equal weighting is yet to 
be determined) D
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1. Was the hypothesis/aim/objective of the study clearly stated? 1 1 1 1 1 1 1 1 1 1 0 1 1 1 
2. Was the study conducted prospectively? 1 1 0 1 1 1 1 0 0 0 1 1 1 0 
3. Were the cases collected in more than one centre? 0 0 0 0 1 0 0 1 0 0 0 0 0 0 
4. Were patients recruited consecutively? 1 1 1 1 1 1 1 1 1 1 0 1 0 1 
5. Were the characteristics of the patients included in the study described? 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
6. Were the eligibility criteria for entry into the study clearly stated? 0 1 1 1 1 0 0 1 1 0 1 0 0 1 
7. Did patients enter the study at a similar point in the disease? 0 0 0 0 0 0 0 1 0 0 0 0 0 0 
8. Was the intervention of interest clearly described?* 1 1 1 1 1 1 1 0 1 1 1 1 1 1 
9. Were additional interventions clearly described?               
10. Were relevant outcome measures established a priori? 1 1 0 1 1 0 1 0 1 1 1 1 1 1 
11. Were outcomes assessors blinded to the intervention that patients received? 0 0 0 0 1 0 0 0 0 0 1 1 1 0 
12. Were the relevant outcomes measured using appropriate objective/subjective methods? 1 1 0 1 1 0 1 0 1 1 1 1 1 1 
13. Were the relevant outcome measures made before and after the intervention? 1 1 0 1 1 0 1 0 1 1 1 1 1 1 
14. Were the statistical tests used to assess the relevant outcomes appropriate? 1 1 1 1 1 0 1 0 1 0 1 1 1 1 
15. Was follow-up long enough for important events and outcomes to occur? 1 1 1 0 0 0 0 0 0 0 0 0 0 0 
16. Were losses to follow-up reported? 1 1 0 1 0 0 0 0 0 0 1 1 0 0 
17. Did the study provide estimates of random variability in the data analysis of relevant 
outcomes? 
0 1 0 1 0 0 0 0 1 0 0 1 1 1 
18. Were the adverse events reported? 0 0 0 1 0 0 0 0 0 0 1 1 0 0 
19. Were the conclusions of the study supported by the results? 1 1 1 1 1 1 1 1 0 1 1 1 1 1 
20. Were both competing interests and sources of support reported? 1 0 1 1 0 0 1 0 1 0 0 1 1 0 
TOTAL 13 14 9 15 13 6 11 7 11 8 12 15 12 11 
* Clarity of description of the interventions was considered within the scope of the trial report. However, this level of information is generally insufficient to reproduce complex interventions such as 
those described in these studies.  
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Appendix 2 Treatment Protocol 
Assessment 
A thorough subjective history and physical assessment is important to understand the 
patient’s problems; to recognise predisposing, precipitating (triggering), and 
perpetuating factors; to identify factors that may be amendable to physiotherapy; and 
to create an individualised explanation of the diagnosis for the patient. Important 
elements include: 
1. Explore the onset of symptoms and potential precipitating factors which may 
help to facilitate the patient’s understanding of the diagnosis.  
2. Compile a comprehensive list of symptoms and health related problems. For 
each problem, details about frequency, severity, exacerbating factors and 
easing factors are sought. 
3. Develop an impression of the impact of symptoms on daily life by charting a 
typical 24 hour routine. 
4. Enquire about previous experiences with treatment and health care 
professionals. 
5. Explore beliefs and understanding of symptoms. 
6. Observe the impact of symptoms on posture, movement, tasks and activities. 
This includes sitting, standing, transfers, gait and upper limb tasks.  
7. Explore the nature of symptoms, note variations in severity with distraction, 
and any manoeuvres that dampen or exacerbate symptoms. 
Education 
Helping the patient develop an understanding and insight into their symptoms is an 
important first step to prepare them for treatment. This starts with a comprehensive 
explanation of the diagnosis by the neurologist,154 which is built on during 
physiotherapy sessions. The educational components of treatment have four key 
objectives: 
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1. To address unhelpful illness beliefs that may form part of the mechanism 
driving symptoms. 
2. Develop an understanding that symptoms are not caused by structural damage 
or a degenerative process, thereby potentially lowering the threat value of 
symptoms and highlighting reversibility.  
3. To prepare the patient for a symptom management approach to treatment 
according to a biopsychosocial model of illness.202 This is where the patient 
assumes the responsibility for understanding the diagnosis and “administering 
the treatment”. As opposed to a traditional biomedical model where the 
patient is the passive recipient of treatment.  
4. To equip the patient with the knowledge and skills necessary to manage their 
symptoms in the longer term.  
During treatment, the patient and physiotherapist should come to a shared 
understanding of the problem in order to collaborate on a management approach. The 
symptom model (see Figure 1, below) is used to explain how triggering events lead to 
abnormal self-focussed attention and expectations which drives symptoms; and that 
secondary changes occur which perpetuate the problem. A thorough individualised 
symptom formulation is collaboratively built around the framework of the symptom 
model. The formulation is used to explain the rationale for the treatment. This 
explanation forms most of the first physiotherapy session, and is reviewed and 
expanded in subsequent sessions. The patient should be given daily opportunities to 
ask questions and should feel safe to express concerns or doubt about the diagnosis. 
The patient may start to feel more confident in the diagnosis as treatment progresses
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Figure 1. Developing a personalised symptom formulation. Reproduced from Nielsen et al 20151 
 
1.  Most people (but not all) can identify an event that triggered their symptoms, such as injury, 
illness, reaction to medication, panic attack etc. It is different for everybody. 
2. This event results in “novel data” or salient sensory and motor phenomena or symptoms. These 
may include pain, pins and needles, numbness, muscle twitching/ spasm/ cramping/ give-way, 
etc. Sometimes people experience these symptoms without an obvious trigger. 
3. Due to the context of the triggering event or the unexpected appearance of the symptoms this is 
usually associated with a (normal) fight or flight (survival) response. For example shock caused by 
a sudden fall resulting in pain and pins and needles. Background stress or anxiety, the type that 
everybody experiences from time to time may also be present at this particular time and be a 
significant triggering factor. For example a very busy period at work, social conflict or stress from 
physical illness. 
4. The fight or flight response changes the way the brain processes sensory and motor information. 
5. The brain’s attention is turned towards the symptom and the body part in a very intense way, as 
if looking/ scanning for the danger. 
6. Attention to the body impairs our control of movement. Movement should occur automatically 
without our conscious attention, but when we think too much about movement (or the body), it 
is no longer automatic and it starts to go wrong. This is the same as “choking in sport” when 
under pressure or when actors might “freeze” on stage. 
7. The brain starts to expect movement to go wrong and effectively new unwanted movement 
patterns are subconsciously programmed and learnt by the brain. 
8. Self-focus and ‘brain-expectation’ drive the symptoms. 
9. Due to the symptoms, we change what we do and how we do things. For example we may 
become dependent on a wheelchair to get around, we may avoid certain activities or positions 
due to pain, we may sleep more due to fatigue. 
10.  Over time secondary changes occur due to the symptoms and changes in our behaviour, for 
example - secondary weakness, muscle contracture, sensitisation of pain and exacerbation of 
fatigue. 
11. The end result is increasing disability. 
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Movement retraining 
Movement retraining aims to restore normal movement patterns, primarily by: 
1. Altering unhelpful beliefs and expectations about movement. 
2. Reducing abnormal self-focus during movement and restoring “automatically” 
generated movement. 
3. Changing maladaptive compensatory habitual postures, movement patterns 
and behaviours. 
Movement retraining addresses unhelpful beliefs by demonstrating to the patient that 
normal movement can occur. This is also a powerful way to help the patient 
understand the diagnosis and convince them that it is correct. This starts in the 
neurology consultation by showing the patient their clinical signs of FMD, with an 
explanation that clinical signs such as Hoover’s sign and tremor entrainment 
demonstrate intact “wiring”.154 In the physiotherapy gym, normal movement can be 
produced in the context of meaningful activity. The key to normalise movement is to 
redirect the patient’s focus of motor attention. For example a functional gait 
disturbance often normalises when the patient is asked to walk backwards, or to slide 
feet along the floor when stepping forward. Tasks that normalise movement usually 
involve novel or unfamiliar movements and re-direction of attention is required to 
achieve the task. A list of other strategies that may be helpful to normalise movement 
for different symptoms (and form part of movement retraining) can be found in Table 
1, below. Normal movement is demonstrated to the patient with the aid of mirrors 
and video.  
Movement retraining usually involves a sequential approach, where elementary 
symptom free components of movement are established, and built on in successive 
stages to gradually reshape normal movement patterns.75,128 Asking the patient to 
watch themselves in the mirror as they move may help to redirect attention away from 
their body, to their reflection. The mirror provides feedback to help shape movement 
and provides evidence of normal movement to the patient (which may influence 
beliefs and expectations). Movement retraining occurs in the context of functional 
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tasks, such as standing from a chair and transferring to a bed (as opposed to hip and 
knee flexion-extension exercises) may provide a more implicit approach to motor 
learning, where the movement is more automatic and the patient is less aware of the 
“mechanics” of movement with focus directed towards the goal of movement. 
Retraining the sit-to-stand and stand-to-sit movement pattern is often an appropriate 
starting point. Strategies that normalise movement are developed during 
physiotherapy sessions and practiced.  The patient is encouraged to use strategies that 
normalises their movement during their usual routine. This is in preference to setting 
aside time at home to practice physiotherapy exercises. Consolidation and 
generalisation of movement retraining is achieved by gradually increasing the difficulty 
of tasks, changing the environment (e.g. outdoors, busy environments), varying speeds 
and multitasking. The Figure 2 shows examples of movement retraining in action.  
 
Figure 2. Examples of movement retraining  
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Table 1. Movement retraining strategies for different motor symptoms 
Leg weakness  Early weight bearing to trigger automatic muscle recruitment.  
 Side to side weight shifting in a safe environment (e.g. parallel bars/ raised 
plinths on either side) with attentional focus towards the rhythmical 
movement of centre of mass (rather than towards the legs).  
 Crawling in 4-point/ 2-point kneeling. 
 Treadmill walking with or without body weight support harness and 
feedback from a mirror.  
Ankle weakness  Anterior-posterior weight shifting often triggers dorsiflexor activity via the 
body’s automatic ankle strategy. It is useful for the patient to see this in the 
mirror.  
 Walking backwards, or sliding feet along the floor often elicits dorsiflexors 
activity. 
 Electrical stimulation can be useful to provide the patient with the 
experience of muscle activation.   
Upper limb 
weakness 
 Weight bearing in sitting, against a wall, or in 4-point kneeling can help to 
switch on muscles. Crawling can also be very effective. 
 Stimulate automatic upper limb postural responses, for example sitting on 
an unstable surface such as a therapy ball resting upper limbs on a 
supporting surface.  
 Minimise habitual non-use by using the weak upper limb to stabilise 
objects during tasks or assist the other hand.  
 Practice bilateral hand tasks that are familiar or important to the patient 
that may not be associated with their symptoms e.g. use of mobile phone 
or computer tablet.  
Gait disturbance 
 
 
 
 
 
 
 Build up a normal gait from simple achievable components that 
progressively approximate normal walking. For example, side to side 
weight shift, continue this weight shift motion to allowing feet to 
‘automatically’ advance forwards small amounts, progressively increase the 
step length with the focus on maintaining rhythmical weight-shift, rather 
than the conscious action of stepping.  
 Try novel movement such as walking backwards, sideways, sliding feet as if 
skiing.  
 Treadmill walking with or without a body weight support harness and 
feedback from a mirror. 
 Increase walking speed can help to ‘bypass attentional focus’ and tap into 
more automatic muscle recruitment (in some cases this may worsen 
walking pattern).  
Upper limb tremor  Training in front of a mirror seems to aid a sense of agency and control 
over the tremor. It can also shift attentional focus away from the internal 
sensory experience of the tremor.  
 Change habitual ‘coping strategies’ that often paradoxically just increase 
muscle tension and worsen a tremor, such as sitting on the hand or overly 
tensing the limb in an attempt to keep it still.  
 Make the movement ‘voluntary’ by asking the patient to actively do the 
tremor, then change the movement to larger amplitude and slower 
frequency. From here the patient can try and slow the movement down 
towards stillness. 
 Performing competing movements that require re-direction of motor 
attention can be useful.  Shoulder rolling, smooth running of palms of 
hands over thighs, clapping to a rhythm or moving the symptomatic arm as 
in large fluid movements as if conducting an orchestra.  
 Teach the patient to find ways to relax and switch of muscles. EMG 
biofeedback can aid this.  Actively contracting and relaxing muscles with 
progressive relaxation can be useful, as can breathing relaxation exercises.  
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Lower limb tremor  Side to side or anterior-posterior weight shift. When the tremor has 
reduced, slow the weight shift to stillness. 
 Competing movements in siting, such as toe tapping or gently sliding feet 
forwards and backwards on the floor.  
 Ensure even weight distribution when standing. This can be helped using 
weighing scales or a mirror for feedback.  
 Changing problematic habitual postures. For example patients with a 
‘bouncing knee tremor’ often sit with only the toes in contact with the floor 
(which drives the tremor via the clonus reflex). Encouraging full foot 
contact with the floor usually reduces or resolves this type of tremor.   
Fixed Functional 
Dystonia 
 Change habitual sitting and standing postures to prevent prolonged periods 
in end of range joint positions and promote postures with good alignment.  
 Teach positioning strategies to turn down overactive muscles in sitting and 
lying e.g. a limb ‘hanging’ in mid air is much more likely to be active than if 
in contact with a supporting surface. Cushions or folded towels may be 
needed to bring the supporting surface up and bridge gaps.  
 Normalise movement patterns (e.g. sit to stand, transfers, walking) with an 
external or altered focus of attention (i.e. not the dystonic limb).  
 Gentle weight-bearing (as tolerated) though the fixed limb can often help 
to normalise muscle activity around a joint. Sometimes gentle ‘on-off’ 
weight-bearing motions can help turn down dystonic muscles, probably via 
reciprocal inhibition when antagonist muscles are activated.  
 Discourage unhelpful protective avoidance behaviours and encourage 
normal sensory experiences (e.g. wearing shoes and socks, weightbearing 
as tolerated, not having their arm in a ‘protected’ posture across their lap). 
 Consider examination under anaesthetic/ sedation, especially if completely 
fixed or concerned about contractures.  
 Electrical muscle stimulation to the antagonist muscles can sometimes be 
helpful in achieving improved limb posture during therapy.  
Jerks/ Myoclonus 
 
 Address habitual postures that might be feeding into tense/ overactive 
muscle groups e.g. a patient with an upper limb jerk, might tend to hold 
the shoulder in a protracted posture causing overactive/ shortened 
pectoral muscles.  
 Practicing opposing movements that interfere with the abnormal 
movement pattern. E.g. if a patient has abdominal  ‘up and down’ jerks, 
then performing little trunk rotations, or deep thoracic expansion 
breathing might interfere with the jerk.  
 Desensitise and lengthen overactive/shortened muscles through 
therapeutic resting postures (rather than direct stretching) e.g. a patient 
with functional cervical dystonia towards the left, might be able to achieve 
therapeutic lengthening of the dystonic muscles in right sided lying.  
 Relaxation and sensory grounding can be useful, especially if the patient 
can identify warning signs or certain situations that bring on their 
symptoms. 
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Self-management & the Treatment Workbook 
The self-management approach to treatment recognises that FMDs are often chronic 
conditions with multiple contributing factors that can require ongoing attention in 
order to sustain improvement and make further progress. Self-management ensures 
the patient is empowered to put knowledge and skills into practice to improve their 
health and wellbeing. It is an ideological shift away from the biomedical model of 
illness, where patients are passive recipients of treatment to patients being active 
partners in the effective management of their health.218 
The Treatment workbook is designed to support self-management. The patient and 
physiotherapist collaboratively complete the workbook throughout the five days of 
treatment. The contents of the workbook include: 
1. An explanation of the diagnosis using the physical-biased symptom explanatory 
model, with reference to the patient’s personal experience. 
2. Goals for physiotherapy. 
3. Space for the patient to reflect on treatment sessions, noting what was 
covered, things that were easy, things that were difficult and new insights. 
4. A list of symptom management strategies that were developed and practiced 
during the physiotherapy programme. 
5. Explanation and management plan for chronic pain (if relevant). 
6. Explanation and management plan for fatigue (if relevant). 
7. Understanding difficulties with memory, concentration and attention. 
8. Markers of progress, such as achieved goals and scores on outcome measures. 
9. A symptom management plan that aims to sustain and progress improvements 
made with treatment. This may include a list of therapeutic activities and 
behaviours; un-therapeutic behaviours to avoid; when and how to use specific 
symptom management strategies; activity-pacing plan with progressions; a 
plan to return to usual activities; etc.  
10. What to do on difficult days and setbacks. 
11. An end-of-treatment summary, including the most relevant information and 
management strategies, and a list of achievements. 
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Figure 3. Examples of the workbook
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Appendix 3 Patient Information Sheet: Feasibility Study 
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Appendix 4 Consent Form: Feasibility Study 
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Appendix 5 Client Services Receipt Inventory (version used in this study) 
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Appendix 6 Feedback Questionnaire and Results 
1. How likely are you to recommend this programme to family and friends if they need 
similar treatment?  
  Extremely likely 27 (93%) 
  Likely 2 (7%) 
  Neither likely or unlikely 0 
  Unlikely 0 
  Extremely unlikely 0 
  Don’t know 0 
 
2 Please can you tell us the main reason for the score you have given? 
  See below 
 
3. How did you find the intensity of the programme? 
  Too intense 2 (7%) 
  Very intense, but manageable 14 (48%) 
  About right 11 (38%) 
  Ok, but not very intense 1 (3%) 
  Not intense enough 1 (3%) 
 
4. Overall, how satisfied were you with the physiotherapy programme? 
  Completely satisfied 25 (86%) 
  Satisfied 4 (14%) 
  Neither satisfied or dissatisfied 0 
  Dissatisfied 0 
  Completely dissatisfied 0 
 
5.  To what extent do you agree with the 
following statements: 
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 The programme helped me to better 
understand my symptoms 
0 0 0 2 
(7%) 
27 
(93%) 
 The programme helped me gain more control 
over my symptoms 
0 0 2 
(7%) 
3 
(10%) 
24 
(83%) 
 The programme has helped me create a plan 
to improve my symptoms 
0 0 0 3 
(10%) 
26 
(90%) 
 The programme included information about 
thoughts, feelings and psychological 
influences on my symptoms 
0 0 1 
(3%) 
3 
(11%) 
24 
(86%) 
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6.  How easy did you find completing the questionnaires? 
  Very Easy 17 (59%) 
  Easy 7 (24%) 
  Ok 3 (10%) 
  Difficult 1 (3%) 
  Very difficult 1 (3%) 
 
7. Do you have any comments about the questionnaires? 
  See below 
 
8. Do you have any other comments or suggestions? 
  See below 
 
Answers to Open Ended Questions 
 
Question 2. Please can you tell us the main reason for the score you have given? 
(How likely are you to recommend this programme to family and friends if they need 
similar treatment?) 
 Gain an understanding concerning FND through medical information give, 
physio and how to try to improve this 
 This has given me back control of my muscles and given me techniques and 
strategies on how to gain control over future episodes. I have been given a 
symptom model to explain my condition 
 Very informative about diagnosis, staff know what they are talking about. 
Excellent explanation, motivational, assist with unaided walking 
 Great one to one support from the whole team 
 The improvement in my mobility this week has been beyond my wildest 
dreams. I still have to pinch myself to realise that I arrived in a wheelchair 
completely unable to maintain an upright posture and now I'm walking upright 
freely and on our way home the wheelchair will carry our luggage! 
 Found it very helpful and didn’t know that help like this was out there.  If it has 
helped me, I'd like to think it can help other people 
 Everything was explained clearly and it wasn't a pressured environment. Not 
once have I felt I was forced, I got on very well with my physio and that 
DEFINITELY helped 
 It helped my problem so much more than I imagined possible in such a short 
period of time. 
 Think once I get home I could answer this better 
 I have learnt techniques that I can employ in my everyday life all of the time 
which will not impact on my day to day life but enhance it 
 This programme is well thought out. It helps with physical symptoms as well as 
the mental thinking process. I feel more than able to cope with the instructions 
given 
 This has shown that I can be helped with the support given. It has given me the 
tools to help myself get better or certainly improve my daily life 
 I found it very educational and useful in every way. Even if it will make a slight 
difference in managing my condition, I would recommend this programme. 
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 Because I have found some things very helpful. And I can put into place when 
having a mild XXX (?) 
 I have found all the information and tools given extremely helpful and already 
they are having a huge impact on my symptoms 
 The information given on this issue has been amazing! I feel so empowered to 
deal with this. Kate has been amazing, I would recommend anyone with this 
condition to see her. She has helped me so much in understanding the 
condition 
 I have made so much improvement this week, to the point I am not tremoring. 
For 2 reasons, 1. Strategies to cope with the tremors, 2. educational aspects 
 team understand you, make you normal 
 Well explained reasons for condition and good advice and help 
 Explained fully, treated with understanding and explanation. Everything that 
was told worked. Expertise of staff 
 I have learnt a lot during the 5 day physio programme. I am more educated 
about my illness and have a very very good plan to take away with me for 
further rehab 
 Patient centred completely and explain all the theory behind the practice. 
Excellent and patient approach to treatment. Feel so much more empowered 
myself 
 I feel so relieved and relaxed. This was exactly what I needed, very informative 
and useful week. 
 The week has helped me understand the reasons why I walk like I do. it has 
given me strategies to use if things became too awkward. It has given me hope 
that I can reverse this movement problem. I have been able to talk through my 
anxieties about it 
 I feel that now I have a great understanding of my condition and what has 
caused it. Very important to me. I understand how and why I have got it. I 
understand that over focus is part of the problem 
 Treatment has really helped me improve and everything was explained and 
organised really well. Kate was really nice 
 It has improved my symptoms so quickly and has taught me how to carry on 
using the techniques to carry on the improvements 
 Miraculous. Compassionate. Patient. You have helped me push my comfort 
zones, think and work outside the box and results are incredible. Outstanding 
 Because it's worked when I thought there was no help for change at all 
 
Question 7. Do you have any comments about the questionnaires? 
 Very useful in helping to concentrate on specific issues 
 Some of the questions are not clear enough 
 I found it difficult to mark myself due to the fact that some days my symptoms 
are much worse than others 
 It is difficult to answer the past week due to being in hospital and staying at the 
hotel. I would suggest a new one for patients who have stayed in hotels with 
questions more adapted to this environment 
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Question 8. Do you have any other comments or suggestions? 
 Keeping a record over the next few weeks/months will feel important. 
Everything has improved so quickly it will be necessary to consolidate the 
whole learning process, both in terms of actual walking and fully taking on bard 
all the changes that have happened and will go on happening over a period of 
time. I guess many adjustments will be needed both in practice and perception. 
 Would be good to have a chance to feedback about the physio themselves. I 
cannot praise or thank Kate enough for help this past week. She was amazing. 
 An excellent programme that has given a good understanding of the condition 
 thank you for the support 
 I just wanted to say THANK YOU to all the team members that put an effort in 
inspiring and changing the way I manage my condition 
 Thank you! 
 I would have enjoyed more literature to go away with and read. Kate was 
brilliant and did email me some, but I would like more. 
 follow up within 3 months as outpatient or optional day case 
 worked well, going forward will be a real boom 
 if possible it might be nice to meet other participants on the programme to see 
how they got on and what they got out of it 
 I was worried hotel experience would compromise treatment. Admissions team 
could have helped by providing better logistics and hotel could have been loser 
- had to move room 3 times last night. Would not recommend the hotel. If 
treatment had not been so good, got off to a v rocky start due to the hotel 
being such a bad experience. And a welcome pack or phone call the week 
before would have helped to reduce anxiety. 
 Keep up the good work helping people with these symptoms and difficulties. 
Thank you so much :) 
 thank you for the opportunity, support, motivation and understanding 
 Keep doing what you do please! 
 Just thank you 
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Appendix 7 Brief Illness Perception Questionnaire Results 
Brief Illness Perception Questionnaire, dimensions 
 
 
 
The dimensions are derived from the following questions. Each question is rated on a scale of 
0 to 10. 
 
1. Consequences:   How much does your illness affect your life? 
2. Timeline: How long do you think your illness will continue? 
3. Personal Control:  How much control do you feel you have over your illness? 
4. Treatment Control: How much do you think your treatment can help your illness? 
5. Identity: How much do you experience symptoms from your illness? 
6. Concern: How concerned are you about your illness? 
7. Coherence: How well do you feel you understand your illness? 
8. Emotional Response: How much does your illness affect you emotionally? (e.g. does it 
make you angry, scared, upset or depressed?). 
 
In general a higher score represents greater threat, except for Items 3, 4 and 7 where lower 
scores represent greater threat. 
  
 Dimension Group BASELINE 
Mean (SD) 
4 WEEK  
Mean (SD) 
6 MONTH 
Mean (SD) 
1 Consequences Intervention 7.9 (2.1) 6.2 (2.5) 6.2 (2.9) 
  Control 8.3 (2.1) 7.9 (2.2) 7.8 (2.3) 
2 Timeline Intervention 6.5 (2.2) 4.8 (2.4) 5.8 (2.9) 
  Control 7.1 (2.3) 7.5 (2.2) 7.3 (2.3) 
3 Personal control Intervention 3.3 (2.8) 6.0 (2.4) 5.3 (2.9) 
  Control 2.0 (2.1) 3.4 (2.5) 2.9 (2.2) 
4 Treatment control Intervention 6.9 (2.3) 9.0 (1.6) 7.4 (1.9) 
  Control 6.3 (2.4) 6.2 (2.6) 6.1 (2.5) 
5 Identity Intervention 7.9 (2.0) 6.0 (2.7) 6.4 (2.4) 
  Control 7.9 (1.5) 7.8 (1.8) 7.6 (2.3) 
6 Concern Intervention 7.9 (2.0) 5.3 (2.8) 5.5 (3.0) 
  Control 7.7 (2.5) 7.4 (3.0) 7.2 (3.2) 
7 Coherence Intervention 6.2 (2.6) 8.8 (1.6) 7.8 (1.9) 
  Control 4.9 (3.1) 5.7 (3.5) 5.9 (3.1) 
8 Emotional Response Intervention 6.1 (2.9) 5.0 (3.0) 5.8 (3.4) 
  Control 6.8 (3.2) 6.5 (3.1) 6.3 (3.3) 
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Table. Brief Illness Perception Questionnaire items. Mean baseline and follow up scores are 
presented for control and intervention groups. The regression coefficient represents the 
difference between groups adjusted for baseline scores. 
 
 
 Intervention Group 
mean (SD) 
Control Group mean 
(SD) 
Regression coefficient for 
group, 
baseline as covariate  
(95% CI) 
Cohen’s 
d 
BASELINE FOLLOW 
UP 
BASELINE FOLLOW 
UP 
Consequences 7.9 (2.1) 6.2 (2.9) 8.3 (2.1) 7.8 (2.3) -1.3 (-2.4, -0.1), p=0.034 0.48 
Timeline 6.5 (2.2) 5.8 (2.9) 7.1 (2.3) 7.3 (2.3) -1.1 (-2.3, 0.3), p=0.055 0.40 
Personal 
Control 
3.3 (2.8) 5.3 (2.9) 2.0 (2.1) 2.9 (2.2) 2.0 (0.7, 3.3), p=0.004 
0.71 
Treatment 
Control 
6.9 (2.3) 7.4 (1.9) 6.3 (2.4) 6.1 (2.5) 1.2 (0.1, 2.3), p=0.038 
0.52 
Identity 7.9 (2.0) 6.4 (2.4) 7.9 (1.5) 7.6 (2.3) -1.2 (-2.3, -0.1), p=0.031 0.49 
Concern 7.9 (2.0) 5.5 (3.0) 7.7 (2.5) 7.2 (3.2) -1.8 (-3.1, -0.5), p=0.007 0.57 
Coherence 6.2 (2.6) 7.8 (1.9) 4.9 (3.1) 5.9 (3.1) 1.5 (0.2, 2.7), p=0.025 0.55 
Emotional 
Response 
6.1 (2.9) 5.8 (3.4) 6.8 (3.2) 6.3 (3.3) 0.4 (-1.3, 1.4), p=0.958 0.12 
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Appendix 8 Reflections on the Methodology 
 
Randomisation 
There was an issue with online the randomisation application. Participants were 
allocated to the control group at a faster rate than the intervention group. This is 
illustrated in the figure below. The company providing the randomisiation application 
was contacted twice with these concerns, but they assured us that it was working 
correctly and that these differences were due to chance. 
 
Figure 1.  Recruitment rate for control and intervention groups 
 
The result was that the control group was fully recruited (n=30) one month prior to the 
intervention group. Therefore the final 10 participants recruited to the study were 
allocated to the intervention group, which opens a possibility of participant selection 
bias. This issue could have been avoided using block randomisation, and this is an 
important consideration for a future trial. 
  
0
5
10
15
20
25
30
Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15
N
u
m
b
er
Month of Recuitment
Recruitment Rate for Control & Intervention
CONTROL
INTERVENTION
243 
 
Selection Criteria 
The selection criteria appeared to work well and there were no obvious examples of 
participants for whom the intervention was inappropriate.  
Excluding patients that score in range of “caseness” for anxiety and depression HADS is 
not supported by the data. Caseness of anxiety or depression was not statistically 
associated with outcome according to the CGI. Additionally, there was no data to 
support the need to exclude patients on the basis of long symptom duration or age. 
There was a higher proportion of participants with “severe to extreme” self-rated pain 
in those that had a poor outcome compared to good (87% vs 33%). The eligibility 
criteria excluded patients for whom pain was the dominant symptom, but still 47% of 
the participants rated their pain as severe to extreme at baseline. Therefore, excluding 
patients with high levels of pain from a future study may limit the generalisability of 
the findings. In a clinical setting, the decision to exclude patients from specialist 
physiotherapy for FMD based on pain may depend on the availability of more suitable 
alternative treatments.  
We excluded participants with significant comorbid psychopathology contributing to 
their symptoms. This was because inpatient multidisciplinary rehabilitation is more 
appropriate and this treatment is available from two London Hospitals.71,72 The 
exclusion criterion was left as a clinical decision rather than operationalised as a cut-
off score, as no outcome measure has been identified as suitable for this purpose. The 
decision to exclude based on psychopathology takes into account multiple factors such 
as a level of anxiety/depression, and other psychiatric conditions such as personality 
disorder, post-traumatic stress disorder, obsessive compulsive disorder, etc. We could 
have been more explicit and transparent in what we considered to be significant 
psychopathology, for example excluding “incapacitating anxiety”, self-harming 
behaviour and recent suicidal ideation. 
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The Intervention 
Given the high satisfaction ratings and positive treatment outcomes, a future trial 
should aim to reproduce the conditions of the study intervention. However, in a 
pragmatic multicentre trial some compromise will be necessary. For example, other 
NHS centres may not be able to deliver a physiotherapy intervention over five 
consecutive days and the intervention may need to be adapted to be delivered over 
several weeks. However, given the qualitative study finding that most participants felt 
that the high intensity of treatment was helpful, it would be wise to keep the study 
intervention higher than what would normally delivered in standard physiotherapy.  
A future iteration of the intervention should consider scheduling a follow up session 
approximately four to six weeks after completion of the programme, with the aim of 
addressing the qualitative study finding that putting management plans into practice 
post discharge was difficult.  
Follow up 
Several participants in the qualitative study found that the six month follow up period 
was too long and would have liked to have been seen earlier. A future trial should 
consider a physiotherapy follow up appointment at four to six weeks after completion 
of the physiotherapy programme. The benefit of telephone follow up could be 
explored as a potential time and cost saving measure.  
The trial design could have benefited from included a 12 month telephone assessment 
to extend the follow up period.  
An additional avenue of exploration could have been to assess how participants coped 
in the weeks following discharge from physiotherapy. Data collection could have 
included information on setbacks and symptom relapses. This data may have revealed 
issues that could be addressed in future iterations of the intervention to improve 
outcome. Collection of this data could have taken the form of post cards that are sent 
weekly by the participant or scheduled telephone calls.  
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Addressing Psychological Problems 
The qualitative study found that some patients, following receiving the study 
intervention, came to a realisation that anxiety was part of their problem. Additionally, 
several participants were less resistant to considering a role for psychological factors 
as part of their problem after treatment. Therefore, adding information about 
treatment and self-help for psychological problems to the workbook may be useful. 
This could include internet resources for more information and treatment options 
available in the NHS.  
Safety Reporting 
Safety issues and adverse events were discussed in detail during six month follow up 
appointments, and more informally in telephone contact to arrange appointments. No 
adverse incidents were reported. However the trial design would have benefited from 
a systematic and formal method for identifying adverse events throughout the trial 
period. A future trial should build regular formal assessment of adverse events into the 
trial design. 
The Client Services Receipt Inventory (CSRI) 
A future iteration of the CSRI should aim to address the following issues: missing data 
regarding employment earnings; insufficient data regarding hours of sickness absence 
from work; and insufficient data regarding the type (and therefore cost) of hospital 
treatment received.  Specific issues relating to the CSRI were outlined in the discussion 
section of the feasibility study. 
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Appendix 9 Qualitative Study Patient Information Sheet 
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Appendix 10 Qualitative Study Consent Form 
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Appendix 11 Coding Framework 
1. Acceptance of the problem  
2. Awareness of own role in symptoms  
3. Barriers to recovery & ongoing issues  
4. Being part of a trial  
5. Control 
6. Critical incidents 
7. Dealing with symptoms coping adapting 
8. Decreasted threat value 
9. Employment  
10. Engagement with clinicians and the system 
a. Worthiness and the system 
b. Waiting and diagnostic limbo 
c. Nobody is listening 
11. Expectation, Hope & Future  
12. Explanation, understanding & knowledge 
13. Explaining to others  
14. Externalisation 
15. Fatigue  
16. Fear of falling  
17. Feeling relief  
18. Good to know I'm not alone  
19. How it feels and impact  
20. Invisible illness  
21. Isolation  
22. Mystery  
23. Non-physical outcomes  
24. Pain  
25. Relationships and roles  
26. Perceived mechanism of change  
27. Physical or biological cause  
28. Physical outcomes  
29. Presentation of self  
30. Psychological factors  
a. Anxiety and panic  
b. Depression and low mood  
c. Psychological means...  
31. Self reliance & self efficacy  
32. Shame  
33. Trust 
34. About the treatment  
a. About the physiotherapist  
b. Differences from previous physio 
c. Difficulties  
d. Emotional response to treatment 
e. Expectation going into treatment 
f. Helpful components of treatment 
g. It was full on  
h. Mirror, video and visual  
i. Praise and general comments  
j. Suggestions & criticism  
k. The workbook 
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Appendix 12 Qualitative Interview Topic Guide 
PATIENT INTERVIEW TOPIC GUIDE 
Patient Experiences of diagnosis and treatment of FMD 
Interviewer: Glenn Nielsen 
Version 2, 8/03/2014 
 
 
INTERVIEW ONE: PRE-TREATMENT 
 
[Introductory Script] 
Thank you for your time and agreeing to talk to me about your experiences and for me to 
record this interview. I’m part of a research team investigating functional motor symptoms.  
We would like to learn about how it feels to be diagnosed with FMD, how they affect your life 
and what experiences you have had with treatment – specifically physiotherapy. We are 
interested in both positive and negative experiences. All information you provide me will 
remain anonymous. I have to let you know that if you disclose information about risk of harm 
to yourself or others, I am obliged to let the relevant authority know. If you would like to 
pause the interview at any stage, let me know and if you would like to stop the interview at 
any stage, that is fine. 
 
1. Patient Narrative 
 
a) Could you start by telling me your story 
b) When did you first become unwell 
c) How was your health before these symptoms started 
 
2. Illness Experience 
 
a) What are the different symptoms that you experience 
b) How do they affect your every day life 
 What do you need help with 
 Sleeping 
 Work 
 Looking after yourself and others 
 What would you like to be able to  do 
c) Which are the most disabling symptoms 
d) Do you have any control or influence over your symptoms? 
 
3. Receiving the diagnosis 
 
a) Tell me about receiving the diagnosis of FMD 
b) How did they come to the conclusion that your diagnosis was FMD 
c) How did they explain the diagnosis 
d) Was any treatment offered? 
e) What do you think is causing your symptoms? 
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4. Treatment 
 
a) Tell me about what treatments you have had prior to this programme 
b) What has been helpful so far,  
c) What has been unhelpful 
d) What do you think you need to get better? 
e) What are your expectations about this physiotherapy programme? 
 
5. Recovery 
 
a) What would getting better look like to you? 
b) What is realistic to expect – from this programme? With recovery in general? 
c) What would you like to change / be able to do? 
d) Who is important in your recovery? 
 
6. Psychological & Emotional factors 
 
a) How does it make you feel to have FMD 
b) Were these feelings present prior to experiencing symptoms 
c) Some people believe that psychological factors such as low mood or anxiety have a 
part to play in this diagnosis. How do psychological factors relate to your symptoms? 
 
7. Free comments 
 
Do you have anything you would like to say about your experiences? 
 
 
INTERVIEW TWO – POST-TREATMENT 
 
[Introduction] 
 
1. Experience of the physiotherapy programme 
 
a) Tell me about your experience of the physiotherapy programme 
b) What did you do during the week 
c) What was most helpful 
d) What was least helpful 
e) What was different from previous experiences of physiotherapy 
 
2. Illness Experience 
 
a) Has the physiotherapy programme had any impact on your symptoms 
b) What, if anything could have made the programme more effective 
c) What do you expect to happen over the next few weeks? Months? 
 
3. Mechanism 
 
a) What do you think caused your symptoms 
b) What do you think is responsible for any change? (mechanism of change) 
c) What else can be done / what else do you need? 
 
4. Recovery & The future 
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a) Do you have any goals for the future 
b) How do you think you will be in 6 months? – symptom change, ability, occupations, 
dependence 
c) What would recovery mean / how would you be different if you improved 
 
5. Psychological and Emotional Factors 
 
a) How does it feel to have FMD 
b) Are psychological factors such as low mood or anxiety relevant to your symptoms 
c) Do you have any control over your symptoms? 
 
6. Free comments 
 
 
INTERVIEW THREE – 6 MONTH FOLLOW UP 
 
[Introduction] 
 
1. Illness experience 
 
a) How have you been since completing the programme? 
b) What has changed? - ability 
c) How did you feel on initially going home 
d) Were you able to maintain improvement made, why/why not 
e) Was this what you expected? 
 
2. Illness experience & Mechanism of change 
 
a) How are your symptoms now compared to before treatment 
b) Why do you think they are better / same / worse 
c) What is caused / causes your symptoms 
 
3. Recovery & The future 
 
a) What help or support do you need now for your symptoms? 
b) What do you expect to happen to your symptoms over the next 6 – 12 months… and 
beyond 
 
4. Physiotherapy programme 
 
a) Tell me about your experience of the physiotherapy programme 
b) Who do you think would most benefit from this programme 
 
5. Free comments 
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